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CHAPTER 1.  GENERAL INTRODUCTION 
 
1.1 Probiotics, Prebiotics, and Microbiota: Historical Background 
1.1.1 Probiotics 
 
     Probiotics are defined as “live microorganisms, which when administered in adequate 
amounts to the host confer health benefits (WHO, 2001)”. The term probiotics originates 
from the Greek language “pro-bios” means “for life” (Scherzenmeheir and de Verse, 2001).  
     Use of probiotics to treat humans ailments emerged early in human history. In the era 
before Jesus Christ, Pilinus, a Roman historian, described the use of fermented milk to treat 
digestive system inflammations (Caramaia and Silvi, 2011). Genesis 18:1-8 in a Persian 
version of the Old Testament stated that “Abraham owed his longevity to the consumption of 
the sour milk” (Schrezenmeir and de Verse, 2001). Ancient Indian, Egyptian, and Sumerian 
civilizations believed that fermented milk can cure infection with Tuberculosis. Thus, they 
used fermented milk as “a broad-spectrum therapeutic” to rid blood of pathogens and toxins 
and even as “sleep aid” that prevents insomnia and induces hypnosis (Caramaia and Silvi, 
2011; Malago et al., 2011). 
      The recent history of probiotics, however, started in the early 1900s. Metchnikoff (1845-
1916) made the elegant observation that the shepherds of Caucasus and Bulgaria had longer 
average life than the Americans (87 vs. 48 years) (Malago et al., 2011; Caramaia and Silvi, 
2011). Metchnikoff attributed shepherds’ longevity to the consumption of fermented milk, a 
valuable source of antiputrefactive microorganisms. He believed that certain colonic-
inhabitant microbiota putrefy foods resulting in the production of toxic metabolites in the gut 
(Malago et al., 2011; Caramaia and Silvi, 2011).  
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     In 1906, the French Society “Le Fermente” produced the first nutraceutical probiotics-
enriched yoghurt named “Lactobacilline” that contained Lactobacillus delbruekii subspecies 
bulgaricus and was intended as a therapy for childrens’ diarrhea (Malago et al, 2009).  
     The therapeutic value of Lactobacilline as a treatment for childrens’ diarrhea gained more 
credit after Metchnikoff published his book “The Prolongation of Life: Optimistic Studies” in 
1907 in which he emphasized the health benefit of some members of the digestive system 
microbiota.  The rationale for manufacturing Lactobacilline is based on the assumption that 
the type of diet consumed determines the microbial composition of the digestive system 
microbiota. Thus, the digestive system microbiota can be transformed in a noteworthy 
manner to replace the harmful bacterial species by adopting specific dietary measures 
(Metchnikoff, 1908; Caramia and Silvi, 2011). 
 
Figure 1. Streptococcus thermophilus and Lactobacillus bulgaricus from yogurt matrix at 
scanning electron microscope. Adopted from M. Benevelli-Dept. “Scienze degli alimenti”, 
Bologna University, Italy). With permission number 2754390218981 from Springer on 
9/22/2011. 
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     Complete transformation of human fecal microbiota was efficiently achieved by daily 
feeding of 500 -1000 mL of Lactobacillus acidophilus milk (Cheplin and Rettger, 1920b). Of 
special interest to note, attempts to implant Bacillus bulgaricus in the gut of rodents and 
humans did not succeed. These results lend themselves to the conclusion that only bacteria of 
intestinal origin can be implanted in the human intestine (Cheplin and Rettgeer,  
1920a and b).  
     To date, one popular mechanism via which Lactobacillus acidophilus is believed to alter 
the bacterial constituents of the intestinal microbiota is through production of lactic acid and 
hydrogen peroxide that kill other nonlactic acid-producing/utilizing commensals and 
pathogens (Attasi and Servin, 2010). Earlier reports by Cheplin and Rettger (1920a, and b), 
however, indicated that, in humans and rodents, dominance of the Lactobacillus acidophilus 
in the fecal microbiota was not necessarily accompanied by alteration of the hydrogen ion 
concentration.  
1.1.1.1 Invention of the term “probiotics” 
     It was not until 1965 when Lilly and Stillwell used the term probiotics for the first time to 
describe a factor produced by the protozoan Colpidium campylum and stimulates growth of 
Tetrahymena pyrofomis. In their report, Lilly and Stillwell (1965) contrasted the stimulatory 
and growth-promoting effect of “probiotics” factor to the growth-inhibitory effect of the 
antibiotics.  
     By the advent of 1989, Fuller revised the definition of the term probiotics to depict “the 
live microbial additives that exert beneficial effect on the host by improving its 
intestinal microbial balance”. It was this definition coupled with the early perception of the 
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significance of transformation of the intestinal microbiota that ignited more interest in 
elucidating the role of the intestinal microbiota in promoting health or inciting diseases.    
1.1.2 Prebiotics and their use to transform digestive system microbiota  
     As early as the beginning of the 20th century, interest in transforming the gut microbiota 
was increased (Cheplin and Rettger, 1920). The daily addition of 1 g of either lactose or 
dextrin to a basal diet of albino rats composed of bread and meat induced a transformation of 
the intestinal microbiota within about 4 days, and enhanced the development of Lactobacillus 
acidophilus to displace almost 50% of most common bacterial species that constitute the 
intestinal microbiota (Cheplin and Rettger, 1920). Interestingly, feeding more than 2 grams 
daily of lactose stimulated the proliferation of Bifidobacterium bifidum to such extent that it 
dominated the intestinal microbiota and displaced even L. acidophilus (Cheplin and Rettger, 
1920a).   
1.1.3 Microbiota 
     Our knowledge of the precise microbiota role in shaping the gut morphology remains to 
be fully unraveled. The current molecular biology techniques are appreciably enhancing our 
understanding of their mechanism of action and therapeutic potential for animal and human 
digestive system ailments (Patel and Lin, 2010).  
     Because probiotics are defined as live microorganisms that when administered in adequate 
amount induce health benefit to the host (FAO/WHO, 2001), distinct commensals inhabiting 
the digestive tract can be considered probiotics as well (walker, 2008).  
       After birth, the sterile fetal gut starts acquiring an enormously varied commensal 
microbiota. Eventually, commensal bacteria proliferate to outnumber the host cells by ten-
fold (Hooper et al., 2001; Bakhed and ley, 2005). The established symbiotic relationship 
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between the commensal microbiota and host furnishes the microbiota with a nutrient-rich and 
temperature-favorable niche. In return, the host commensal microbiota facilitates nutrient 
assimilation (Bakhed et al., 2005), protection against injury (Hooper et al., 2001), intestinal 
homeostasis (Rakoff-Nahoum et al., 2004), and development of GALT immunity (Rhee et 
al., 2004; Spencer et al., 2009).   Density of microbiota increases from 103 cells·g-1 in the 
stomach and duodenum to 108 cells·g-1 in the jejunum and ileum. The greatest density of 
microbiota, however, occurs in the colon where it reaches 1011 cells·g-1 and contains highly 
diverse species (Neish, 2009).      
     The preliminary acquisition of commensal microbiota is dependent on parturition 
methodology. Initially, the fetus acquires microbiota from species dominate the maternal 
vagina and colon, such as Enterobacteriae, Enterococci and Staphylococci (Patel and Lin, 
2010). Subsequent milk feeding provides newborns with commensal microbiota inhabiting 
the mammary gland and its skin. After weaning, newborn gut microbiota is further altered 
and expanded in accordance with the diet consumed (Patel and Lin, 2010). 
1.1.3.1 Microbiota dysbiosis thwarts host resistance to diseases  
     By the mid of 1950s, Finger and Wood (1955) and Miller et al (1957) pioneered studies to 
explore the effects of the antibiotic-induced perturbation and thus dysbiosis of the intestinal 
microbiota on susceptibility of mice to acquire Salmonella enteritidis infection. These 
pioneering studies grew out of the curiosity about the secondary bacterial infections that are 
associated with antibiotic administration.  
     Secondary bacterial infections that are associated with antibiotic therapy are mostly 
caused by avirulent species, such as Pseudomonas or yeast-like fungi and occasionally are 
initiated by virulent Staphylococci (Miller et al, 1957). Because these microorganisms are 
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normal inhabitants of the digestive tract, their contribution to infection during antibiotic 
treatment raised concern about the role that the digestive tract microbiota plays in disease 
prevention (Miller et al., 1957).  
     Intriguingly, whereas 1 × 101 CFU of streptomycin-resistant Salmonella enteritidis were 
sufficient to infect more than 50% of the streptomycin-treated mice, as much as 1 × 106 CFU 
of Salmonella were required to induce Salmonella infection in the non-streptomycin-treated 
control mice (Miler et al., 1957).  
 
Figure 2. Modification of the microbiota and its effect on intestinal immunobiology. 
Effect of antibiotic administration on composition and function of digestive system 
microbiota. Adopted from Preidis and Versalovic (2009) with permission from Elsevier 
on 6/9/11 
 
     Of significance, fecal culture from the streptomycin-treated mice showed the 
disappearance of the Gram-negative bacilli (Coliforms, Proteus, Aerobacterium aerogenes, 
and Bacteroides) from the intestinal microbiota. In contrast, the Gram-positive bacterial 
populations were not altered by streptomycin treatment (Miler et al., 1957; Bohnoff et al., 
1964).  
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     The reestablishment of the aforementioned gram-negative bacilli in the mice intestine, 
however, did not restore the intact resistance to Salmonella infection. In contrast, feces from 
control mice inoculated into the streptomycin-treated mice were able to restore resistance to 
Salmonella.  
     Further investigations of the fecal matter characteristics of normal mice led the authors to 
suggest that streptomycin-sensitive, unculturable, anaerobic strains contribute the resistance 
to Salmonella enteritidis infection in mice (Miller et al., 1957) through yet-to-be elucidated 
mechanisms.  
     Later, Bohnoff and colleagues (1964) elegantly unraveled the inhibitory mechanism via 
which these Gram-negative anaerobes inhibit the growth of Salmonella enteritidis infection 
in mice.  They showed that these anaerobes produce butyric, acetic, and lactic acids that 
directly antagonize the growth of pathogenic bacteria.  
     Following streptomycin oral administration, the pH in colon increased and the 
concentrations of the short-chain fatty acids (SCFA) decreased. These alterations were 
accompanied by a concurrent exacerbated susceptibility to Salmonella enteritidis infection. 
On day three after streptomycin administration, SCFA concentrations and pH were restored 
to normal values; however, the elevated lactic acid concentration abolished the ability of the 
SCFA to inhibit the growth of Salmonella, favoring increased susceptibility of mice to 
infection (Bohnoff et al., 1964).   
     Findings of Bohnoff and colleagues (1964) suggested that in addition to these anaerobes, 
lactic acid-utilizing species were eliminated by the streptomycin administration. Note 
worthy, the intestinal microbiota is composed of highly intricate populations of archea, fungi, 
and bacteria that exceed 1013 microorganisms (Bailey et al., 2010; Sekirov et al., 2010). It is 
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now well established that these different bacterial species that constitute the digestive system 
microbiota are critical for the development of the gut-associated lymphoid tissues (GALT) 
and their microbiome contribution to metabolizing macronutrients exceeds that of the human 
genome (Gill et al., 2006).  
     It has been suggested that the co-evolution of the digestive system and microbiota 
determines brain development and programming and dictates the type of motor control and 
anxiety-related behavior (Heijtz et al., 2011). In support of this hypothesis, specific 
pathogen-free mice colonized with normal gut flora displayed decreased motor activity and 
increased anxiety in comparison with germ-free mice (Heijtz et al., 2011).  
     Besides contributing to gut inflammation, dysbiosis induces central nervous system 
disorders as well (Bercik et al., 2011). To induce dysbiosis, specific pathogen-free Balb/c 
mice treated or not with sub-diaphragmatic vagotomy or chemical sympathectomy and germ-
free mice were administered with antibiotic mixture in the drinking water for one week 
(Bercik et al., 2011). The oral antibiotic mixture temporarily altered their microbiota 
composition (Figure 2) and enhanced their exploratory attitude and increased expression of 
the brain-derived nuclear factor (BDNF) in the hippocampus.   
     In contrast, colonization of the germ-free Balb/c mice with microbiota from NIH Swiss 
mice enhanced their exploratory activities and the concentrations of BDNF. On the other 
hand, colonization of germ-free NIH Swiss mice with microbiota from Balb/c retarded the 
exploratory activities by NIH Swiss mice (Bercik et al., 2011).  
     Taken together, the findings derive considerable evidence that dysbiosis contribute to 
induction of certain behavioral pattern through modulating brain biochemistry. Interestingly, 
dysbiosis-induced modulation of brain biochemistry was not associated with intestinal 
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inflammation, digestive system neurotransmitters function, or induction of sympathetic 
nervous system stimuli (Bercik et al., 2011). 
1.1.4 Taxonomy and significance of Mycobacterium avium subspecies paratuberculosis, 
the causative agent of Johne’s disease      
     The murine and bovine microbiome compromises major phyla of Firmicutes and 
Bacteroides that make up about 90-98% of the total microbiota. The remaining portion of the 
microbiota (2-10%) is made up from the phyla of Actinobacteria, Proteobacteria, 
Cynobacteria, and Verrucomicrobia (Ley et al., 2005; Bailey et al., 2010).  
     The phylum Actinobacterium is known to comprise the order Actinomycetales that 
contains the family Mycobacteriacea, the genus Mycobacterium, the species avium, and the 
subspecies paratuberculosis. Mycobacterium avium subspecies paratuberculosis (MAP) is 
recognized as the etiologic agent of Johne’s disease (JD), a major disease of ruminants. Since 
1985, JD continues to have significant welfare and economic impact (Ott et al., 1999; 
NAHMS, 2008) on livestock worldwide. JD is characterized by slowly developing chronic 
granulomatous enterocolitis and digestive system lymphadenitis and lymphangitis (Dennis et 
al., 2008). Collectively, these inflammatory conditions induce significant mucosal injury and 
protein malabsorption (Johnson et al., 2011), chronic intermittent diarrhea (Clarke and Little, 
1996), and progressive weight loss (Radostits et al., 1994).  
     To date, there is no effective chemotherapeutic treatment for JD. Following infection, 
mycobacteria becomes dormant and resistant to chemotherapeutic agents (Deb et al., 2009).  
In humans, MAP is prevalent in blood and tissues of 40% of healthy individuals and in 80% 
of individuals affected with Crohn’s disease (Bull et al., 2003). Recent investigations have 
shown that probiotic microorganisms have the potential to enhance the host innate immunity 
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and increase expression of genes associated with host defense against pathogens as well as 
genes that control energy homeostasis (Nerstedt et al., 2007; Ibnou-Zekri et al. 2003; Wei et 
al., 2007).  
    In these studies, we investigated the immunological mechanisms of prevention of JD 
progression in a mouse model and explored efficacy of probiotics to transform the intricate 
microbiome of a dairy cow rumen and its subsequent effect on nutrient digestibility, energy 
harvest, and immunity.  
DISSERTATION ORGANIZATION 
This dissertation is presented as four complete papers with abstracts, introductions, 
materials and methods, results, discussions, conclusions, acknowledgements, and references 
for submission to the Journal of Immunobiology and Journal of Dairy Science. The first 
article is entitled “Tolerance of specific pathogen-free Balb/c mice to varying concentrations 
of Lactobacillus acidophilus strain NP51”. The second article is entitled “Probiotic 
Lactobacillus acidophilus strain NP51 curtails progression of Mycobacterium avium 
subspecies paratuberculosis (MAP) infection in Blab/c mice”.  The third article is entitled 
“Lactobacillus acidophilus strain NP51 restricts progression of Mycobacterium avium 
subspecies paratuberculosis through activating the CD8α+ immune cell-mediated immunity.” 
The fourth paper is entitled “Transformation of lactating dairy cow digestive system 
microbiome by feeding Bovamine®: Effects on productivity and immune responses).  
The dissertation has been prepared from original research conducted to partly fulfill the 
requirements for a Doctor of Philosophy degree from the Department of Animal Science and 
the Interdepartmental Program of Immunobiology at Iowa State University, Ames, IA. The 
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novel findings of this research indicate that probiotic feeding of Lactobacillus acidophilus 
strain NP51 to Balb/c mice infected with Mycobacterium avium subspecies paratuberculosis 
(MAP), the causative agent of JD in ruminant animals, conclusively prevented the 
development of Johne’s disease.  
Also, feeding probiotic Bovamine® (Lactobacillus acidophilus strain NP51 plus 
Probionibacterium freudenreichii strain NP24) to dairy cattle transformed their digestive 
system microbiome and improved ruminal feed digestibility. Because the probiotics NP51 
and NP24 are safe commensal microorganisms that their feeding to dairy cows does not 
entail condemnation of milk and meat, their inclusion in the dairy cattle diet will enhance the 
profitability to the dairy farmers around the globe. A literature review and associated 
references list precede the articles, general discussion, and recommendations for future 
research. The acknowledge section concludes the dissertation. 
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CHAPTER 2.  LITERATURE REVIEW 
 
2.1 Probiotics 
     Probiotics have numerous beneficial effects on animal and human health including 
modification of the aberrant immune responses through balancing of Th1 and Th2 responses 
(Moreau et al., 1988) and preventing of intestinal disorders via production of antimicrobial 
peptides, competitive exclusion of enteric pathogens, and enhancement of gut barrier 
function (Boesten and de Vos, 2008). Probiotics also decrease risk of cancer by lowering ß-
glucuronidase and carcinogens concentrations in the intestine (Bezirtzoglou and 
Stavropoulou, 2011).  
     The co-evolution of the microbiota with the mammalian host digestive system has ensured 
tolerance to the multitude of the bacterial species that comprise the microbiota (Gill et al., 
2006). Nevertheless, certain members of microbiota can acquire virulence ability and 
proliferate causing anomalous autoimmune and intestinal disorders (Willing et al., 2010). 
Such conditions are predominantly accompanied with microbiota dysbiosis (Willing et al., 
2010; Tarasova et al., 2010). Probiotics administration also has potential to normalize the 
dysbiosis and resolve the aberrant autoimmune response (Tarasova et al., 2010). 
2.1.1 Characteristics of probiotics 
     Scientists from the Food and Agriculture Organization (FAO) and World Health 
Organization (WHO) defined probiotics as being “live microorganisms which, when 
administered in a adequate amounts, confer health benefits on the host” (FAO/WHO, 2001).   
     It is widely agreed that substances produced by probiotic microorganisms, however, are 
not probiotics themselves (Guarner et al., 2010). Thus, the conserved and unique 
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extracellular molecules on the outer microbial envelope, such as peptidoglycans, cell wall 
associated polysaccharides, and lipoteichoic acid that are known as pathogen-associated 
molecular patterns (PAMPs) are not per se probiotics (Guarner et al., 2010).  
     Because also the heat-killed and gamma-irradiated probiotics are widely used and have 
shown potential to positively alter the host immune responses, it appears that the definition 
set forth by (Fuller, 1989; FAO/WHO, 2001) is relatively invalid. To include the effect of 
heat-killed probiotics, Salminen and colleagues (1999) revised the definition of probiotics to 
read as “probiotics are microbial cell preparations or components of microbial cells that 
have beneficial effects on the health and well-being of the host.”   
     The World Gastroenterology Organization Practice Guidelines on Probiotics and 
Prebiotics (2008) defined potential probiotic bacteria as microorganisms that are: 
1. Normal inhabitant (intrinsic) of the human or animal gastrointestinal tract. 
2. Resistant to antibiotics because of genomic DNA mutations. 
3. Able to resist the acidic gastric and pancreatic juices, intestinal enzymes, and bile 
salts and colonize the digestive tract when administered at a minimal dose of 107 
CFU·day-1. Laboratory procedures used to evaluate potential probiotics that are able 
to survive transiting and colonizing the gastrointestinal tract include exposing the 
bacteria at 109 CFU·mL-1 to 3 g·L-1 pepsin in sterile phosphate buffered saline (PBS) 
at pH 2.0 (adjusted with HCL) followed by exposure to pancreatin at 1 g·L-1. To test 
the ability of potential probiotics to survive the toxic action of bile, the bacteria are 
exposed to 0.5% (w/v) Ox-gall in sterile PBS at 37o C. Following incubation, 
bacterial cells are withdrawn at different time points and viability is determined by 
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plate count on de Man, Rogosa, and Sharp (MRS) media (Collado and Sanz, 2007; 
Pan et al., 2010). 
4. Able to adhere to the enterocytes via interaction of the surface proteins on the 
probiotics plasma membrane with the mucosal cells. This interaction coupled with 
probiotics secreted proteins should cause immune response. 
5. Able to modify advantageously the intestinal metabolic function to improve the 
animal and human health and antagonize pathogens proliferation by secreting 
bactriocin and enhance secretion of defensin peptides.    
6. Safe immunologically to animals and humans. 
7.  Stable properties during storage time. 
8. Cost-effective when administered in adequate dose.  
2.1.1.1   Resistance to gastric juice 
     The harsh acidic environment of the stomach and the bile salts secreted into the 
duodenum are substantial impediments to the survival of ingested bacteria. Potential 
probiotic microorganisms must be able to transit through the gastric juice of the stomach 
(Hendriksson et al., 1999; Nagata et al., 2009) prior to reaching the small and large intestines.  
     Marteau et al (1993) demonstrated that microbial colonization of the digestive system was 
enhanced by gastrectomy. Similarly, the use of the proton pump inhibitors decreased the 
stomach acidity and induced microbial colonization of the stomach. To isolate and determine 
probiotic ability of Lactobacilli isolated from human ileum, Dunne et al (2001) mixed gastric 
juice obtained from healthy individuals with MRS media. Subsequently, the modified MRS 
media was inoculated with the Lactobacilli of interest to determine its ability to survive the 
acidic environment of the stomach.     
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     The carbon source for probiotics also can affect transit of probiotics through the stomach. 
Incubation of Lactobacillus plantarum at simulated gastric media that either contained 
glucose or fructose as a carbon source was examined (Nagata et al., 2009). Viability of L. 
plantarum remained high at pH 3.5, regardless of the carbon source. When the pH was 
decreased to 3.0, the viability of L. plantarum incubated in the fructose-supplemented 
medium decreased after two hours, whereas incubation in the glucose-supplemented medium 
did not affect the L. plantarum growth. Noteworthy, decreasing the pH to 2.5 decreased L. 
plantarum viability, regardless of the carbon source within an hour of incubation (Nagata et 
al., 2009). 
     These findings clearly demonstrated the effect of the carbon source prevalent in the 
gastrointestinal tract on modulating the resistance of the probiotics to the gastric acidity. 
Thus, when formulating synbiotics, prior assessment of the effect of prebiotics and the 
prevalent carbohydrate in the prebiotic or the diet on the viability of the probiotics is 
warranted.  
     Indeed, ability of probiotics to resist the high acidity of stomach can be enhanced. Collado 
and Sanz (2007) incubated six acid-sensitive strains belonging to the species Bifidobacterium 
longum and Bifidobacterium catenulatum at pH 2.0 for extended periods of time. Following 
the acid incubation, the metabolic and phenotypic profiles of these strains were significantly 
enhanced. It was found that the acid-incubated strains showed better ability to grow in the 
presence of bile salt (1-3%) and NaCl (6-10%). Also, they developed higher resistance to 
elevated temperatures of 60-70o C for 10 min compared with the parental strains.  
     Additionally, the acid-incubated strains exhibited higher fermentative ability and 
enhanced enzymatic activities. Intriguingly, the acid-incubated strains also demonstrated 
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elevated susceptibility to variety of antibiotics compared with the nonacid-incubated parental 
strains (Collado and Sanz, 2007). 
2.1.1.2   Resistance to pancreatic juice  
     Resistance to pancreatic secretion is essential for probiotics to colonize the intestinal tract. 
To examine the ability of probiotic Lactobacilli and Bifidobacteria strains to resist action of 
pancreatic juice, Del Piano and coworkers (2008) measured the viability of lactobacilli 
inoculated in media supplemented with human pancreatic juice obtained from subjects during 
an endoscopic cholangiopancreatography procedure or with standard artificial pancreatic 
juice. After one hour of contact with the artificial or human pancreatic secretion, the viability 
of lactobacilli strains was decreased by 19.7 and 28.6%, respectively. Similarly, the viability 
of Bifidobacteria strains was decreased by 42.2 and 44.4%, respectively (Del Piano et al., 
2008).  Thus, high tolerance of probiotics to standard artificial pancreatic juice (1.0 g/L 
pancreatin) is essential to screening potential probiotics.   
2.1.1.3 Resistance to bile     
     Bile tolerance is a critical attribute that determines the ability of bacteria to survive in the 
small intestine, and, consequently, tolerance to bile is considered a critical criterion in 
selecting probiotics (FAO/WHO, 2001; Hamon et al., 2011). Hamon and colleagues (2011) 
used comparative proteomic analyses to examine differences in protein expression by  
L. plantarum 299 V (bile-resistant), L. plantarum LC 804 (relatively bile-resistant), and L. 
plantarum LC 56 (bile-sensitive) when challenged by bile salts. Proteins that dictate the 
resistance of L. plantarum to bile salt were characterized as being a two glutathione 
reductases that are involved in protection against the bile salts-induced oxidative damage, a 
cyclopropane-fatty-acyl-phospholipid synthase required for cell membrane integrity, a bile 
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salt hydrolase, an ATP-Bound Cassette (ABC) transporter, and a F0F1-ATP synthase that 
pumps out intracellular bile-related stress molecules (Hamon et al., 2011).  
2.1.2 Mechanisms of probiotic modulation of immune system 
2.1.2.1 Secretion of soluble bioactive proteins 
     Probiotics synthesize its extracellular proteins and transport it unfolded to the plasma 
membrane via the Sec channel (Sutcliffe and Harrington, 2002, von Heijne, 1989). 
Alternatively, probiotics may secret its extracellular proteins folded through specific ABC 
transporters (Jongbloed et al., 2006). 
     Screening of Lactobacillus reuteri DSM 20016 cell wall revealed that this probiotic 
bacterium express about 52 novel genes encoding extracellular proteins that are critical for 
host/microbial interactions, transport of molecules, and regulation of sensor molecules. Also, 
some of these genes encoded for enzymes, conserved hypothetical proteins, or unconserved 
hypothetical proteins (Wall et al., 2003). 
     Soluble extracellular proteins secreted by probiotics include the pentapeptide (CHWPR) 
that is secreted by Bifidobacterium animalis subspecies lactis strain BB-12 and has been 
implicated with promoting interleukin (IL)-6 and c-myc genes expression in the HL-60 cell 
line (Mitsuma et al., 2008). Whereas IL-6 is critical for switching the innate immunity into 
adaptive immunity (Jones, 2005), c-myc expression is linked to cell proliferation and its 
over-expression is associated with cancer development (Musgrove et al., 2008). 
     Also, Bifidobacterium longum subspecies longum strain NCC2705 has been shown to 
produce the extracellular elastase-like protease inhibitor (serpine) (Ivanove et al., 2006). In 
this regard, serpine can deactivate the neutrophils elastase that is released by activated 
neutrophils during inflammation of the mucosa. Neutrophils elastase is known to cause 
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extracellular matrix destruction and tissue damage (Chua and Laurent, 2006). Because 
numerous biological processes that take place inside the inflammasome and the apoptosome 
are initiated by proteolytic events it likely that Bifidobacterial serpine plays critical immune 
inhibitory function in the gut of the mammalian host (Ivanov et al., 2006). 
     Similarly, B. infantis has been shown to secret a bioactive soluble protein that increases 
transepithelial resistance and enhanced tight junction by increasing zonula-occludin-
1expression (decrease intestinal leakage) in human T84 epithelial cell line cocultered with 
tumor necrosis factor (TNF)-α and interferon (IFN)-γ (Ewaschuck et al., 2008). These 
immune modulations were associated with increased expression of the extracellular-regulated 
kinase (ERK) and decreased p38 mitogen-activated protein kinase (MAPK). Also, oral 
administration Bifidobacterium-conditioned media to IL-10-deficient mice ameliorated their 
intestinal inflammation and decreased colon permeability in vivo (Ewaschuck et al., 2008). 
Several yet-to-be characterized and identified bioactive proteins have been shown to be 
probiotic products are secreted primarily by Bifidobacteria and Lactobacilli play critical 
immuno-modulatory roles. 
     Also, a protein product of a Bifidobacteria breve C50 has been shown to induced DC 
maturation and increased expression of B7-1 and B7-2 via signaling through p38MAPK and 
phosphatidyleinositol 3-kinase (PI3K) pathway (Hoarau et al., 2008). Inhibition of ERK and 
glucose synthase kinase (GSK)-1 did not abolish B. breve C50 protein effect on DC 
maturation (Hoarau et al., 2008). Also, C50 protein-stimulated DC secreted high 
concentration of IL-10 and low concentration of IL-12 suggesting a tolerogenic phenotype. 
Secretion of IL-10 was completely abrogated by inhibiting p38MAPK and to a lesser extent 
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by inhibiting ERK and PI3K inhibitor (Hoarau et al., 2008). In contrast, inhibition of GSK-1 
and p38 MAPK completely abolished IL-12 secretion by C50 protein-stimulated DC. 
     Similarly, work by Konstantinov et al (2008) illustrated that Lactobacillus acidophilus 
strain NCFM surface layer A protein (SlpA) binds DC-specific ICAM-3 grabbing non-
integrin (DC-SIGN) receptor and program DC to secret copious amount of IL-10 and low 
amount of IL-12p70. Overall, probiotics interaction with DC appears to destine DC to the 
tolerogenic phenotype. 
     Probiotics secretory bioactive proteins have been implicated with triggering immune 
modifications in the mammalian host, such as induction of effector molecules (chemokines, 
and cytokines), antimicrobial peptides bactriocin and defensins). In addition, probiotics 
secretory bioactive proteins have been shown to increase the mucus secretion, enhance the 
tight junctions by increasing occluding and zonula-1(Ewaschuck et al., 2008), and promote 
the innate immunity via up-regulating DC maturation and survival (Hoarau et al., 2008; 
Konstantinov et al., 2008). 
     To  induce an immune response, probiotic microorganisms must ‘‘speak’’ to the immune 
cells that are endowed with conserved patterns recognition receptors (PRRs) sensitive to 
PAMPs, such as DNA, metabolites, and cell wall components.  
     Examination of the intestinal epithelial cells responses to cocultered adherent probiotics 
demonstrated the ability of probiotics to regulate the secretion of numerous anti- and 
proinflammatory cytokines (Haller et al., 2001; Ruiz et al., 2005).  
2.1.2.2 Regulation of NFkB and MAPK pathway.  
     It has been shown that Bifidobacterium lactis, after colonizing the intestinal tract of germ-
free rats, transiently phosphorylates and activate the Re1A subunit of NF-kB and the p38 
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MAPK in the intestinal epithelial cells (Ruiz et al., 2005). As a result, IL-6 gene expression 
was significantly increased.  
     On the contrary, Bacteroides vulgates administration to germ-free rats, though 
phosphorylated NF-kB subunit Re1A, it was failed to phosphorylate MAPK p38 and, thus, 
did not induce IL-6 gene expression (Ruiz et al., 2005).  Inhibition of MAPK pathway in 
intestinal epithelial cell line impaired the Bifidobacterium lactis induction of IL-6 gene 
expression in vitro (Ruiz et al., 2005).  
     To unravel the mechanism of the Bifidobacterium lactis-intestinal epithelial cell (IEC) 
cross-talk, Ruiz and colleagues (2005) fed Bifidobacterium lactis to toll-like receptor (TLR)-
2 knockout mice. TLR-2 deficiency abrogated the ability of Bifidobacterium lactis to 
promote IL-6 gene expression.  
     IL-6 signaling is essential to resolving the innate immunity and promoting the acquired 
immunity (Jones, 2005). Transition from innate to acquired immunity is pivotal to resolution 
of all inflammatory conditions, and disruption of this immunological switch may potentially 
promote the onset of chronic inflammatory disorders or autoimmune diseases (Hoebe et al., 
2004). 
2.1.2.3 Induction of the innate immunity. 
     To investigate the IECs and DC immune responses to probiotic and pathogenic bacteria, 
O’Hara et al (2006) incubated HT-29 human IECs with Bifidobacterium infantis 35624, 
Lactobacillus salivarius UCC118, or Salmonella typhimurium UK1 for different times.  
     Alternatively, IECs were cocultered with the probiotics Bifidobacterium infantis 35624, 
Lactobacillus salivarius UCC118 for 2 h before being exposed to S. typhimurium or flagellin. 
Examination of the inflammatory genes expression revealed that exposure of IECs to S. 
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typhimurium increased expression of 36 proinflammatory genes of the 847 genes assayed, 
including NF-kB and CXCL-8. In contrast, exposing the IECs to the commensal bacteria did 
not alter any gene expression of the 847 genes examined.  
     Also, the baseline and flagellin-induced secretion CXCL-8 by IECs was decreased by the 
exposure to B. infantis and L. salivarius. Though the treatment with the probiotics did not 
prevent adhesion of S. typhimurium to the HT-29 cell line, it did not increase MUC3 or E-
cadherin gene expression. Conversely, IL-10 and tumor necrosis factor (TNF)-α secretion by 
DC were augmented. This immune response suggests that whereas immune responses of HT-
29 IECs remained unaltered when exposed to probiotic bacteria, probiotics bacteria mediate 
host responses to flagellin and pathogenic bacteria via activating intestinal innate immunity 
cells, such as DC (O’Hara et al., 2006). 
2.1.2.4 Induction of immune tolerance. 
     It is now well established that the enormous number of intestinal microbiota share a 
plethora of PAMPs that are recognized by the innate immunity PRRs (Kim et al., 2008; Ryu 
et al., 2009). Curiously enough, the PRRs of the innate immunity are able to distinguish 
between pathogenic and probiotic PAMPs and maintain homeostasis of normal microbiota 
(Shi and Walker, 2004).  
     Ryu et al (2009) examined the immunogenic pattern of the lipoteichoic acid (LTA), an 
immunogenic protein on the cell wall of pathogenic, nonpathogenic, and probiotic Gram-
positive bacteria. Ultra pure LTA from Staphylococcus aureus (pathogenic) and Bacillus 
subtilis (non-pathogenic) activated TLR-2, downstream myeloid differentiation primary 
response gen 88 (MyD88), NF-κB, and the transcription factor activator protein-1 (AP-1) of 
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the RAW 264.7 murine macrophage cell line and stimulated their production of NO and 
TNF-α (Figure 5) (Ryu et al., 2009; Kim et al., 2008).  
 
Figure. 1. The effect of heat-killed bacteria on NO production by the RAW 264.7 
macrophage cells. RAW 264.7 at 1×105 cells/mL were stimulated with heat-killed 
Gram-positive bacteria L. plantarum, B. subtilis, or S. aureus at 0, 105, 106, 107, 108 
CFU/mL for 48 h. Nitrite accumulation was determined as an indicator of NO 
production in the cultured media. Values are mean ± S.D. of three replicas for each 
group. (*) indicates a significant difference compared with the control group at P-value 
≤ 0.05. Adopted from (Ryu et al, 2009).     
  
     On the contrary, ultra pure LTA from Lactobacillus plantarum (probiotic) failed to 
activate TLR-2 as verified by the decreased NFkB luciferase activity (Figure 2; Kim et al., 
2008). Also, ultra pure LTA from L. plantarum did not induce production of NO (Figure 1). 
This immunogenic pattern was further verified by showing that stimulation of the RAW 
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264.7 with the heat-killed S. aureus and B. subtilis triggered significant production of NO 
and TNF-α in a dose-dependent manner. In contrast, the stimulation of RAW 264.7 with the 
heat-killed L. plantarum induced only little NO and TNF-α production (Figure 1; Ryu et al, 
2009).   
 
Figure 2. Effect of liptoteichoic acid (LTA) from Lactobacillus plantarum and Staph 
aureus  on the luciferase activity of U937 macrophage cell line. U937 macrophages cell 
line were transiently cotransfected with L. plantarum NF-κB-luciferase and L. 
plantarum RL-SV40. Transfectants were prestimulated with or without 100 µg/ml of L. 
plantarum LTA for 20 h, and then restimulated with 50 µg/ml of either L. plantarum 
LTA or S. aureus LTA for 18 h. The cells were lysed, and the luciferase activity was 
measured. Data are normalized for Renilla activity. (**) indicates P ≤ 0.01 compared 
with S. aureus LTA alone. Adopted from Kim et al (2008). 
 
Also, the abrogation of TLR-2 on RAW 264.7 by NaOH or pretreating RAW 264.7 with  
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L. plantarum LTA abolished the ability of LTA from S. aureus to induce NO and TNF-α. 
Thus, it appears that TLRs are able to “finger print” various bacterial PAMPs and orchestrate 
a very unique immune response characterized by tolerance to probiotics and intolerance to 
pathogenic bacteria 
2.1.3   Health-promoting effects of probiotics 
     It is increasingly been accepted that the mammalian digestive tracts are intricate symbiotic 
systems of multispecies microorganisms (Forssten et al., 2011) that bestow numerous health 
benefits to the mammalian host.  
2.1.3.1   Antidyslipidemic effect 
      The interesting findings by Mann and Spoerry (1974) that serum cholesterol 
concentrations have decreased dramatically in male African Maasai warriors following 
consumption of large amounts of fermented milk that contained Lactobacillus strain drew 
great attention to the cholesterol-lowering effect of the probiotic lactobacilli. In a recent 
report, Pan et al (2010) examined the cholesterol-lowering ability of Lactobacillus fermentum 
strain SM-7 isolated from fermented milk. They inoculated the 1% (v/v) SM-7 strain into the 
MRS-cholesterol broths supplemented with 0, 1, 2, 3, or 4 g·L-1 Ox-gall (bile salt) at 37o C 
for 24 hours. The supernatant, washing buffer, and the pelleted bacterial cells were then 
collected and measured for their cholesterol content.  Cholesterol was lowered significantly 
when SM-7 was incubated in a concentration of 3 g· L-1 Ox-gall. Elevating the ox-gall 
concentration to 4 g·L-1 slightly decreased the cholesterol-lowering ability of SM-7, 
indicating that bile salts at 4 g·L-1 are likely to inhibit growth of SM-7.  
     Elegantly, Pan and coworkers (2010) examined the in vivo cholesterol-lowering effect of 
SM-7 in mice. Mice were fed daily for four weeks a high-fat diet that contained  
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10 g cholesterol, 100 g lard, 50 g yolk and 2 g ox-gall· kg-1 diet. Simultaneously, SM-7 was 
gavaged to mice daily for four weeks. They revealed that gavaging the SM-7 to mice 
decreased substantially the fasting serum total cholesterol and triacylglycerols by 21.2 and 
9.8%, respectively, lower than that of control mice fed the high fat diet only. Importantly, 
serum LDL-cholesterol was decreased significantly by 17.8% lower than that of the control. 
Overall, AI values showed a significant decrease whereas the anti-atherogenic index (AAI) 
values were increased in the group of mice fed the SM-7. 
    The mechanism whereby probiotics alleviate hypercholestermia is poorly understood.  
Some bacteria, however, can assimilate cholesterol in vitro. Decreased cholesterol absorption 
by the intestine has been pointed out as one mechanism that is triggered by probiotics  
(Anderson et al., 1995). 
     Microbiomics and metabolomic studies in humanized microbiome mouse model (germ-
free mouse colonized with human baby flora) have been conducted to explore the 
transgenomic and metabolic effects of L. paracasie or L. rhamnosus in mice (Marin et al., 
2008). Using multivariate compartmental analysis, it was shown that inclusion of the 
probiotic Lactobacilli in the mice microbiome decreased concentrations of LDL and VLDL 
and increased TAG and phosphorylcholin (PC) concentrations in plasma (Martin et al., 
2008). Also, bile acids excretion in feces was decreased (Martin et al., 2008). Previously, it 
has been shown that increased uptake of bile acids by Lactobacilli decreases their excretion 
(Kurdi et al., 2000). Alternatively, probiotics feeding alters the assimilation of bile acids and 
lowers cholesterol and plasma lipid concentrations (Nguyen et al., 2007). The probiotic-
induced cholesterol-lowering effects is mediated, at least in part, through down-regulation of 
the Niemann-Pick C1-like 1 and the liver X receptors.      
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2.1.3.2   Antiallergic effect 
     Allergic rhinitis is a widely prevalent disease that affects about 500 million people around 
the world (Bousquet et al., 2008).  Effect of short-term oral administration of Lactobacillus 
paracasei strain ST11 fed to patients with pollen grain-induced allergic rhinitis on their nasal 
congestion test and immune responses was conducted (Wassenberg et al., 2011). Subjects 
were randomized to either take placebo or ST11 fermented milk for four weeks. All subjects 
were intranasally nebulized with 0.2 mL of six pollen grains cocktail. 
     Remarkably, ST11 consumption decreased the nasal congestion and pruritus. In addition, 
secretion of IL-5, IL-8, and IL-10 by peripheral blood mononuclear cells decreased 
significantly compared with that of the placebo-fed group. Also, consumption of the ST11 
fermented milk lowered significantly the allergen specific IgG4. Elegantly, findings of 
Wassenberg et al (2011) suggest strongly that probiotics consumption down regulates 
important immune pathways that are active in the pathogenesis of allergic rhinitis. 
2.1.3.3   Intestinal diseases-preventive effect 
     The GALT starts developing in utero during the fetal stage and becomes able to trigger 
sensible immune response against pathogenic insults at birth (Insoft et al., 1996).  For the 
GALT, however, to be fully protective and able to trigger adequate immune response, 
exposure to commensal and probiotics microbiota is a prerequisite (Shi et al., 2004).    
     Stimulation of the GALT with microbiota enables the GALT to synthesize and secrete the 
polymeric IgA that neutralizes viruses, bacteria, and toxins. Also, microbiota-induced 
stimulation of the GALT balances the aberrant Th-1 and Th-2 to Th-3 ratios. A balanced T 
helper cells ratio is purported for oral tolerance induction and prevention of allergic and 
chronic bowel disorders (Moreau et al., 1988).       
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2.1.3.4   Antioxidative stress effect 
     Though Lactobacilli are sensitive to hydrogen peroxide (H2O2) damage, Lactobacillus 
sakei strain YSI8 expresses a novel heme-dependent catalase that degrades H2O2. In contrast, 
Lactobacillus rhamnosus lacks the ability to express catalase, but it is a valuable probiotic 
starter cultures that is extensively used for fermenting meat products. An and coworkers 
(2010) examined the heterologous expression of L. sakei catalase gene katA in L. rhamnosus 
on its resistance to oxidative stress. The recombinant L. rhamnosus strain AS 1.2466 
exhibited catalase activity and degraded H2O2 efficiently. In addition, the survival rate of L. 
rhamnosus strain  
AS 1.2466 was increased 10,000- and 600-fold when exposed to H2O2 at the exponential and 
stationary phases, respectively.  
2.1.3.5   Pain-soothing effect 
     Chronic inflammatory bowel disease (IBS) significantly increases gut permeability 
causing chronic intestinal pain. Chronic intestinal pain constitutes a leading symptom for 
referral to a specialist (Francavilla et al., 2010). Lactobacillus GG was tested for its efficacy 
to relieve recurrent abdominal pain in children. Feeding Lactobacillus GG for 8 weeks in a 
randomized, double-blind, placebo-controlled trial to children with inflammatory bowel 
disease decreased significantly the severity and frequency of abdominal pain (Francavilla et 
al., 2010). The GG pain-reducing effect persisted to the end of the eight-week follow-up 
period and was associated with a significant decrease of the gut permeability.  
     Probiotic feeding has been found to abolish pain response by decreasing dorsal root 
ganglion single unit activity and prevented the pressure-dependent bradycardia induced by 
distending the colorectum of Spraque-Dawley rats (Kamiya et al., 2005). Lactobacillus 
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paracasei administration to rat pups prevented stress-induced visceral pain and maintained 
gut permeability (Eutamene et al., 2007).  Molecular investigation revealed that 
Lactobacillus farciminis feeding suppresses expression of Fos, a marker of general neuron 
activity in the central nervous system indicating that L. farciminis downregulate the spinal 
nociceptive neurons sensitized by stress (Ait-Belgnaoui et al., 2009)  
In conclusion, antibiotics are clinically used to delete or inhibit growth of an overgrown 
member(s) of the microbiota. Deleterious side effects of antibiotic use include the 
evolvement of antibiotic-resistance genes. Horizontal transfer of these genes to other 
susceptible microbiota members could induce state of global antibiotic resistance (Nakano et 
al., 2011). 
     In contrast, the use of probiotics in animal feed re-introduces a deleted beneficial 
microbiota component or enhances its growth by inhibiting growth of competitors. The use 
of prebiotics in the feed can provides necessary nutrients required to enhance the growth of 
that microbiota component. Thus, the prebiotics and probiotics action is additive and 
provides a means to introduce beneficial alterations in the microbiome to enhance the health 
of animals (Martin et al., 2008; Preidis and Versalovic, 2009)   
2.1.4 Adverse side effect of probiotics 
     Probiotics could potentially have side effects in vulnerable humans, such as induction of 
microbial infection, aberrant immune stimulation, toxic metabolites production, and transfer 
of antibiotic resistance genes (Mateau and Seksik, 2004). Reported cases of bacterial 
infection caused by probiotics use are very scarce and occurred primarily in individuals with 
critical medical conditions (Mateau and Seksik, 2004).  
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     Recently a high death rate in a Dutch clinical trial carried out by researchers in Utrecht 
University has raised much concern (Vogel, 2008; Tavernier and Paye, 2011). Acute 
pancreatitis is known to affect patients with alcoholism and is induced by acute overgrowth 
and infection by commensal microbiota that is refractory to antibiotic therapy. It is 
characterized by acute abdominal pain associated with elevated plasma lipase by more than 
three-fold the physiological value (Vogel, 2008; Tavernier and Paye, 2011).  
     The Dutch Acute Pancreatitis Study Group fed about 100 patients diagnosed with acute 
pancreatitis fed them a combination of probiotics. Another 100 patients were fed the placebo. 
In fact, far more patient died in the probiotics group relative to those in the control group. 
The death rate was 16 and 6% in the probiotic and the placebo groups, respectively (Vogel, 
2008). An intriguing cause of death was multiple organ failure in the probiotics group, a side 
effect that triggered by the probiotic treatment (Vogel, 2008). 
2.2 Mechanisms of microbiota modulation of immune system 
2.2.1 Induction of the GALT development 
     In germ-free animals, GALT is ill developed. Thus, polymeric immunoglobulin (Ig) A 
secretion is retarded causing inadequate oral tolerance to commensals and food antigens 
(Rhee et al., 2004; Shi and Walker, 2004). To verify whether commensals microbiota are 
required for GALT development, Rhee and colleagues (2004) introduced commensal bacteria 
into rabbits in which the appendices were rendered germ-free and identified intestinal 
commensal species that promote GALT development.  
     The combination of Bacteroides fragilis and Bacillus subtilis predominantly promoted 
GALT development and increased the frequency of the somatic hypermutations in the B cell 
V(D)J genes of Ig.  Adequate somatic hypermutations is required to ensure development and 
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diversity of the IgM+ B cells repertoire. In humans, GALT has been shown to accommodate 
molecular tools that diversify the B cell repertoire by somatic hypermutation, class switch 
recombination, and receptor editing (Figures 2A and 3). Thus, a well-developed GALT is 
pivotal to enhancing the diversity of mature B cells and their clonal progeny of plasma cells 
to secret integrated range of highly diverse polyclonal antibodies (Spencer et al., 2009).  
     It was evident that the GALT-promoting effect of Bacteroides fragilis and Bacillus 
subtilis was synergistic and equally required. Intriguingly enough, neither species alone 
predominantly mediated GALT induction. Intriguingly, only commensals were required for 
GALT induction, and introduction of Escherichia coli, Clostridium subterminale, Bacillus 
fragilis or Staphylococcus epidermidis did not mediate GALT induction (Rhee et al., 2004).  
     To reveal the molecular mechanisms via which commensals microbiota mediate GALT 
induction, Rhee and coworkers (2004) introduced stress-response mutant B. subtilis into the 
germ free-appendix rabbits. It was found that Spo0A (gene that promotes postexponantial 
phase sporulation) and biofilm formation by B. subtilis is required to signal through YqxM 
(gene required for extracellular matrix development essential for biofilm formation) to 
induce GALT development (Rhee et al., 2004; Hera et al., 2008). Similarly, ligation of rabbit 
appendices at birth to prevent microbial colonization arrested lymphoid follicle development 
(Perey and Good, 1968). When the ligated appendix was reconnected with the intestinal 
lumen, the lymphoid follicle development was restored indicative of a developed GALT 
(Figure 3).   
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Figure 3. Paraffin-embedded sections of human GALT stained with hematoxylin and 
eosin. Panel A. Payer’s patch with prominent germinal center and intimate association 
with the follicle-associated epithelium (FAE). Panel B. Colonic lymphoid germinal 
center (LGC) with small or absent germinal center and a narrower FAE zone. Unlike 
the Payer’s patches that are exclusively in the mucosa, LGC cross the muscularis 
mucosa. Panel C. mucosal-associated lymphoid tissue (MALT) with a large germinal 
center in stomach. Normal stomach does not contain lymphoid tissue, but MALT can be 
acquired in response to infection with Helicobacter pylori. Adopted from Spencer et al., 
2009. 
 
2.2.2 Modulation of the antigen-regulated immune response 
 
     The symbiotic relationship with commensal microbiota and elimination of invading 
bacterial pathogens by the mammalian host is essential for survival of the mammal host. 
Recognition of microbes by the host immune system is brought about by detection of the 
highly conserved PAMPs by the host PRRs, such as the TLRs and nucleotide-binding 
oligomerization domain-like receptors (NOD-like receptors; NLRs) (Akira et al., 2006; 
Inhora et al., 2005).  
     Membrane-bound TLRs recognize bacterial ligands at the cell surface or inside the 
phagolysosomes (Akira et al., 2006). NLRs, on the other hand, induce innate immune 
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responses via recognizing PAMPs inside the cytosol (Ting and Davis, 2005; Inohara et al., 
2005). Two NLR family members, NOD-1 and NOD-2, sense bacterial muramyl dipeptide 
(MDP), a conserved sequence of all peptidoglycan (PG). 
 
Figure 4. Modification of the microbiota and its effect on the global immune response. 
Certain microbial members of the microbiota modulate the GALT immunity indirectly 
by secreting soluble molecules or directly via molecular interaction with GALT immune 
cells and IECs. Adopted from Preidis and Versalovic (2009 with permission from 
Elsevier on 6/19/2011. 
 
     This PAMPs-PRRs “cross-talk”, however, is intriguingly dependent on the 
microenvironment (Figure 4) (Koropatnick et al., 2004). For example, the tracheal cytotoxin 
(TCT), a component of the bacterial cell wall-associated PG, has been shown to cause 
extensive tissue damage, unique lesions to gonorrhea and whooping cough infections. 
Though components of PG and lipopolysaccharides (LPS) are typically associated with 
disease pathogenesis, the symbioant Vibrio fischeri also released TCT which act in synergy 
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with LPS to induce tissue development of its host squid Euprymna scolopes (Koropatnick et 
al., 2004).  
     It is evident, therefore, that the host interpretation of PAMPs-PRRs is dependent on the 
predominant microenvironment and differences in host interpretations to PAMPs-PRRs 
interaction results in disease development or symbiosis establishment (Figure 4; koropatnick 
et al., 2004).  
2.2.3 Regulation of the PRRs signaling by microbiota prevents GIT inflammation.  
2.2.3.1 Regulation of TLRs signaling    
     Of importance to note, ligands for the PRRs known as TLRs are not unique to pathogenic 
bacteria, and are also expressed by commensal microbiota (Rakoff-Nahoum et al., 2004).  It 
has been shown that under normal steady state microbiota is recognized by TLRs, and that 
this recognition is pivotal for the IECs homeostasis (Rakoff-Nahoum et al., 2004; Rhee et al., 
2004).  
     Compared to stimulation with pathogens, stimulation of TLRs by microbiota is required 
for developing protection against intestinal injury and ensuing deaths. To address the role of 
TLRs family in the intestinal inflammation, Rakoff-Nahoum and coworkers (2004) 
administered 2% (w/v) dextran sodium sulfate (DSS) in drinking water to mice deficient of 
MyD88 (Figure5). MyD88 is an adaptor molecule critical for all TLRs, IL-1, and IL-18 
receptors signaling (Takeda et al., 2003). DSS was also administered to WT- and TLR-2- and 
TLR-4-deficient mice. Curiously enough, MyD88-deficient mice developed sustained GIT 
inflammation and high mortality whereas all WT mice survived (Figures 5 and 6).  These 
findings indicated the critical role of commensal microbiota signaling via TLR in 
maintaining intestinal epithelial homeostasis and preventing intestinal inflammation.  
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 Figure 5. Signaling of microbiota through toll-like receptor (TLRs) is required for 
normalIntestinal homeostasis and prevention of intestinal injury. Severe colonic 
bleeding and anemia in MyD88-/- mice. Photograph of a representative colon from WT 
and MyD88-/- mice. Adopted from Rakoff-Nahoum et al (2004). 
 
      Similar intestinal injuries and subsequent mortalities were seen in the TLR-2- and TLR-
4-deficient mice administered DSS. These interesting findings revealed the critical role of the 
TLR family in maintaining IEC homeostasis to protect host from intestinal injury and drew 
the attention to the TLR family as therapeutic targets for the intestinal diseases (Rakoff-
Nahoum et al., 2004).   
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Figure 6. Protection from gut injury is dependent on recognition of commensals-derived 
ligands by TLRs. Photograph of representative colons from commensal-depleted WT 
mice with and without oral reconstitution of LPS at day five of DSS treatment. Adopted 
from Rakoff-Nahoum et al (2004).   
 
2.2.3.2 Regulation of nucleotide-binding oligomerization domain (NOD)-1 and 2 
signaling    
     The NOD family of cytoplasmic PRRs is involved in the innate recognition of the 
microbiota PAMPs, the muramyl dipeptide (MDP) (Girardin et al., 2003; Akira et al., 2006). 
MDP is a conserved structure in all type of PG (Girardin et al., 2003; Inohara et al., 2003). 
Upon recognition of MDP, NOD-1 and 2 mediate gene expression through a pathway 
involves NFkB transcription factor, the MAPK, and the adaptor molecule receptor interacting 
protein (RIP) 1 signaling (Girardin et al., 2000; Hsu et al., 2007).  
     Concordant with that of mutant TLRs (Rakoff-Nahoum et al., 2004), mutant NOD-1and 2 
have been implicated in the etiology of the mucosal injury and Crohn’s disease (CD) 
pathogenesis. To reveal the role of NOD family in the recognition of the commensal 
microbiota, Radkoff-Nahoum et al (2005) administered MyD88+/+, RIP-1-/- mice with DSS. 
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Unlike MyD88-/- mice, RIP-1-/- mice where completely resistant to intestinal injury 
suggesting that the protective role of commensal is mediated via TLRs, not RIP-1.  
     Abundant evidence exists that signaling of PG of microbiota through NOD-1 on epithelial 
cells is critical for induction of the intestinal lymphoid tissue and ß-defensin in mice 
(Bouskra et al., 2008). However, subsequent signaling of microbiota through the TLR is 
essential for maturation of intestinal lymphoid tissue into GALT with large B cell cluster. 
Mice with deficient intestinal lymphoid follicle exhibit significant dysbiosis (Bouskra et al., 
2008). 
     To elucidate mechanistically the cytoprotective role of commensal microbiota that is 
mediated through TLR signaling, production of IL-6, TNF-α, and keratinocyte-derived 
chemokines (KC)-1 was quantified in colonocytes from WT and MyD88-/- mice (Rakoff-
Nahoum et al., 2004). It was found that colonocytes of WT mice produce IL-6, TNF-α, and 
KC-1 at baseline, and production of IL-6 and KC-1 was substantially elevated after DSS 
administration. On the contrary, colonocytes of MyD88-/- mice release significantly low 
concentrations of these cytoprotective cytokines, and production of these cytokines was 
entirely abrogated after DSS administration (Rakoff-Nahoum et al., 2004).  
     It was evident, then, that commensal microbiota prevents intestinal injury via signaling 
through TLR and the downstream MyD88 to MAPK to translocate NFkB to the nucleus. 
Subsequent molecular events result in the production of the cytoprotective cytokines  
IL-6, KC-1, and TNF-α.  
     Besides promoting adaptive immunity (Ovlisen et al., 2009), a wide range of 
cytoprotective role has been ascribed to microbiota-regulated IL-6, KC-1, and TNF-α in 
numerous types of cell, such as alveolar epithelial cells (Kida et al, 2005), endothelial cells 
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(Liu et al., 2010), intestinal epithelial cells (Pagnini et al., 2010), and hepatocytes (Wruck et 
al., 2011). Also, IL-6 has been shown to have antioxidative stress functions (Wruck et al., 
2011).    
2.2.4 Induction of secretory IgA        
     Additionally, PRRs on DC allow DC to efficiently sample intestinal microbiota and even 
retain viable microbial cells for several days. Retention of viable microbiota by DCs enables 
the selective induction of a microbiota-specific sIgA that restrains microbiota translocation 
(Macpherson and Uhr, 2004) and ensures tolerance of commensal microbiota for symbiotic 
purposes. Depending on the pathogenicity of the engulfed bacteria, DC can trigger a pro- or 
anti-inflammatory immune response (Mazzoni and Segal, 2004; Smits et al., 2005). 
2.3 Prebiotics  
2.3.1 Prebiotics fermentation 
     The 2008 annual meeting of the International Scientific Association for Probiotics and 
Prebiotics (ISAPP) defined prebiotics as being “dietary prebiotics are selectively fermented 
ingredients that result in specific changes in the consumption and/or activity of the 
gastrointestinal microbiota, thus conferring benefit(s) upon host health”. Whereas a variety of 
molecules can be prebiotics, however, mainly dietary fibers and oligosaccharide are 
considered to be so (Courbeyre et al., 2011). Prebiotics, also along with the polyunsaturated 
fatty acids and phytochemicals constitute a wide proportion of the bioactive food ingredients 
known as nutraceuticals (Laparra and Sanz, 2010). 
     Prebiotics differ from probiotics in their mode of action. Prebiotics serve as “food” for 
specific members of the microbiota that exist within the microenvironment of the digestive 
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system to induce benefits to the host (ISAPP, 2008). The guidelines of the ISAPP (2008) and 
others (Roberfroid, 2007) classify food ingredients as prebiotics based on the followings: 
1. Non-digestible carbohydrates those are resistant to mammalian gastric and intestinal 
enzymes. 
2. Fermented chiefly by the digestive system microbiota.  
3. Selectively stimulates activity and/or growth of beneficial members of the digestive 
system microbiota.  
4. Heat- and desiccation-stable and can be stored at room temperature.  
     Prebiotics include non-digestible carbohydrates fibers, such as galacto- and 
fructooligosaccharides (GOS and FOS, respectively), and xylooligosaccharides (Arslanoglu 
et al., 2007; Shadid et al., 2007; Seifery and Watzl, 2008). GOS are obtained from fructose 
after it is treated with ß-galactosidase, whereas inulin and FOS are produced by enzymatic 
digestion of chicory (Macfarlane et al., 2006). 
     Inulin is a fructose polymer composed of 10 to 60 fructose residues linked ß (2-1). Partial 
hydrolysis of inulin produces FOS that are composed of 3 to 7 residues of fructose. Inulin 
and FOS are natural components of wheat, asparagus, and onion (Gibson, 1994; Macfarlane 
et al., 2006). FOS slow the gastric emptying rate, causing a decrease in the glycemic index of 
the diet and thus improve glucose and lipid metabolism of the host (Russo et al., 2010).  
     Prebiotics selectively stimulates growth of certain beneficial genera of the microbiome 
(Cummings and Macfarlane, 2001). FOS (fructose polymers) are fermented selectively by 
Lactobacilli and Bifidobacteria at a high rate (Gibson et al., 2005; Falony et al., 2009). It has 
been shown that fructose released during fermentation of FOS by Bifidobacteria is utilized as 
a source of carbon by local inhabitant bacteria (Falony et al., 2006). Anaerostipes caccae 
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DSM 14662 do not ferment FOS but survive on fructose released by Bifidobacteria during 
FOS fermentation. On the other hand, Roseburia intestinalis DSM 14610 degrades FOS 
merely in the presence of acetate produced by Bifidobacterium.  
       FOS can be fermented by other bacterial genera, such as Bacteroides and Clostridia. But 
because their absorption of FOS is inadequate, they grow slower than Bifidobacteria (Van 
der Meulen et al., 2006: Falony et al., 2009).   
2.3.2 Immune mechanisms of prebiotics 
     Prebiotics can have direct antimicrobial effects by acting as a decoy receptor that directly 
bind pathogens or their toxins (Futher et al., 2010).  Milk oligosaccharides have been shown 
to bind Clostridium difficile exotoxins by serving as a decoy receptor for inactivation of the 
exotoxins (El-Hawiet et al., 2011). Alternatively, GOS have bacterial receptor homolog that 
can compete with pathogenic bacteria on binding to sites on the enterocytes apical 
membrane. This prevents pathogens from binding to enterocytes and colonizing the gut an 
initial step in bacterial diseases pathogenesis(Searle et al., 2010; Quintero et al., 2011) 
(Figure 5B).  
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Figure 7. Prebiotics- and probiotics- induced modulation of the microbiota and its 
effects on the intestinal immunobiology. Modification of intestinal microbiota with the 
appropriate prebiotics or probiotics can inhibit pathogens, enhance gut barriers, and 
provides host with nutrients, such as SCFAs and vitamins. Adopted from Preidis and 
Versalovic (2009) with permission from Elsevier on 6/9/11.  
 
     Prebiotics fed to constipated rats reversed the constipation-induced decrease of superoxide 
dismutase and the increase in malondialdehyde, an oxidative stress marker (Li et al., 2011). 
Also, the prebiotic feeding resolved the histological damage induced by constipation and 
increased production of secretory IgA (Li et al., 2011).   
     The dust mite Dermatophagoides farina is a known etiologic agent of respiratory allergy. 
FOS supplement to diet of mice affected with D. farina-induced allergic bronchitis resolved 
the allergic and inflammatory symptoms as evident by the significant decrease in the 
allergen-specific IgG1 in the serum (Yasuda et al., 2011). Also, supplemental FOS tended to 
attenuate expression of eotaxin and IL-5 in the lungs of affected mice. The histopathological 
examination of the mucosa lining of the bronchi indicated a decrease in goblet cells 
hyperplasia and attenuation of the eosinophilic inflammation (Yasuda et al., 2011). The 
molecular interaction that underlies this immune response is yet to be precisely elucidated. 
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One possible mechanism of this immune response is thought to be via FOS-triggered 
alteration in microbiota (Yasuda et al., 2011). 
     Effect of prebiotic preparations of acidic oligosaccharides, FOS, and GOS that mimic 
human milk oligosaccharides were tested for their immuno-modulatory effects in a mouse 
model of influenza virus vaccine (Vos et al., 2007). Acidic oligosaccharides enhanced the 
influenza vaccine-specific delayed-type hypersensitivity (DTH) response and attenuated Th2 
responses in vitro. Feeding combination of three prebiotics to mice increased population of 
Bifidobacteria and Lactobacillus in their feces and adjuvanted their Th1 response to 
influenza vaccine (Vos et al., 2007). Of interest, at day 9 of feeding the prebiotic 
oligosaccharides, the cecal Lactobacilli numbers correlated with the DTH suggesting that 
prebiotic mediate its vaccine adjuvant effect by modifying the microbiome (Vos et al., 2010). 
     Scientists from Max Rubner Institute in Germany suggest that prebiotics can directly 
mediate an antiinflammatory response independent of the gut microbiota (Zenhom et al., 
2011).  To examine whether activation of the peptidoglycan recognition protein-3 (PGlyRP3) 
is involved in the oligosaccharides-induced modulation of the GALT immunity, Zenhom and 
colleagues (2011) treated Caco-2 cells with oligosaccharides, α-sialyllactose, or FOS. It was 
found that secretion of IL-12 was significantly decreased by Caco-2 cells. This finding was 
further supported by showing that gene expression of IL-12p35, IL-8, and TNF-α was 
simultaneously repressed (Zenhom, 2011). Because gene expression and translocation to the 
nucleus was inhibited, the authors concluded that these anti-inflammatory actions were 
mediated via a pathway involves NFkB (Zenhom et al., 2011).  
     Further characterization of the molecular mechanism to understand the anti-inflammatory 
action of these prebiotics indicated that the prebiotics treatment of Caco-2 cell induced 
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expression of PGlyRP3 in a time- and a dose-dependent manner and induced peroxisomes 
proliferator-activated receptor (PPAR)-γ. Targeting of PGlyRP3 with siRNA abrogated the 
prebiotics-mediated anti-inflammatory action. Also, co-culturing of the Caco-2 cells with the 
GW9662, a PPAR-γ antagonist, suppressed expression of PGlyRP3 by the prebiotics and 
prevented subsequent induction of the anti-inflammatory response. These findings implied 
that prebiotics provoke the anti-inflammatory response via increasing expression of PPAR-γ 
that induces PGlyRP3 expression (Zenhom et al., 2011).   
2.3.3 Health-promoting effects of prebiotics 
2.3.3.1 Anti-diabetic effect 
     Developmental plasticity allows the fetus to sense and respond to the biochemical milieu 
induced by the nutritional status of dam during gestation and lactation. Fetal responses to 
unbalanced nutrition of the dam are characterized by altered gene expressions that can 
destine the neonate to acquiring anomalous metabolism (Gniuli et al., 2008).  To examine 
such effect, Maurer and Reimer (2011) fed high-prebiotic fiber, high-protein, or regular chow 
diets to Wistar rat dams during gestation and lactation and monitored subsequent effects on 
their progeny metabolism profile. Weanling rat pups from all treatment groups were fed the 
regular rodent chow staring on d 21 postpartum. Feeding the high-prebiotics fiber diet 
decreased plasma glucose and amylin and increased glucagon-like peptide (GLP-1) on day 
28 postpartum (Gniuli et al., 2011). Also, feeding the high-prebiotic fiber to gestating and 
lactating Wistar dams increased gene expression of GLUT2 and the sodium-dependent 
glucose/galactose transporter in their progeny on day 21 postpartum (Gniuli et al., 2011).   
     The decrease of amylin concentrations in plasma of neonate rat pups of dams fed the high-
prebiotic fiber diet suggests significant health implication. Amylin has been shown to 
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generate H2O2 that oxidatively damages the pancreatic ß-cells and plays role in the 
pathogenesis of the type II diabetes (Masad et al., 2007).  GLP-1 is an anorectic incretin that 
decreases the energy intake by increasing satiety signal (Verhoef et al., 2011). Also, when 
FOS were given at 16 g/d to human subjects, their energy intake was significantly decreased 
by 11% and the area under the curve for GLP-1 was significantly increased over that of the 
placebo treatment on day 13 of the study (Verhoef et al., 2011).  
     Prebiotics have the potential to improve markers of diabetes type II in rats. The diabetes 
type II rat model Goto-Kakizaki (GK) rats were fed prebiotic resistant starch at 30% of their 
diet for 10 weeks. Rats were subsequently mated and after the pregnancy and lactation 
periods dams were euthanized. Feeding the prebiotic resistant starch increased ß-cell mass 
and the insulin content of the pancreas. In addition, plasma GLP-1 and cecal SCFA 
concentration were increased.  Also, the butyrate-producing bacterial population in the 
cecum was greatly enhanced (Shen et al., 2011). The anti-diabetic effect of the prebiotic 
seemed to be mediated through a microbiome shift that involves an increase of 
Bifidobacteria-associated GLP-1 (Shen et al., 2011; Neyrinck et al., 2011).   
     On the other hand, the neonate pups of GK rats fed the prebiotic fiber diet demonstrated 
normal growth rate and their fasting plasma glucose significantly improved (Shen et al., 
2011). The neonate GK rats developed pancreatic ß-cells aplasia by week three postpartum 
(Tourrel et al., 2002) that underlies the hyperglycemia characteristic of type II diabetes.  
Treating GK neonate with 400 µg/kg GLP-1 daily during the pre-diabetic stage (first week 
after birth) replenished ß-cell mass in their pancreas and improved their glucose tolerance 
test results at adulthood (Tourrel et al., 2002).   
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     The findings of (Gniuli et al., 2011; Verhoef et al., 2011; Shen et al., 2011) highlight the 
efficacy of prebiotics as likely therapy for type II diabetes and as preventative for the 
pregnancy-associated type II diabetes. The findings also indicate that some prebiotics 
mediate their immune effect through microbiota modulation-induced GLP-1. 
2.3.3.2 Antidyslipidemic effect 
     Glucan prebiotics, such as chitin-glucans (CG) from fungus has been shown to resolve the 
dysbiosis-induced obesity (Neyrick et al., 2011) and improve lipid and glucose metabolism. 
Supplementation of C57b16/J mice fed high-fat diets with 10% CG (w/w) increased the 
population of the clostridial cluster 14a that comprises Roseburia species, which was 
significantly decreased following high-fat diet feeding in C57b16 mice.      
     Of note, CG inclusion in the high-fat diet significantly prevented the weight gain by the 
high-fat diet and decreased fasting blood glucose and glucose intolerance. Also, CG feeding 
ameliorated hepatic triacylglycerols (TAG) and plasma cholesterol regardless of the energy 
density of the diet (Neyrick et al., 2011). Of importance to note, CG mediated its health-
enhancing effect independent of GLP-1, whose expression was not altered by feeding the 
CG.  
2.3.3.3 Antiinflammatory effect 
     Prebiotic feeding can ameliorate gut inflammation in obese diabetic mice through 
modulating gut microbiota to improve the epithelial tight junction (Cani et al., 2009). Obese 
diabetic mice exhibit greater intestinal permeability that lead to endotoxemia, a leading cause 
in the pathogenesis of metabolic disorders (Cani et al., 2008).  
     To explore the effect of feeding prebiotics to obese diabetic C57BL/6 mice on their 
intestinal permeability and inflammation, mice were fed either the prebiotic FOS or non-
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prebiotic carbohydrates (control) and, subsequently, treated with GLP-2 agonist or antagonist 
(Cani et al., 2009). Prebiotic treatment increased expression of the tight junction proteins 
occludin and zonula-occludin-1and increased GLP-2 expression. On the other hand, the 
prebiotic treatment decreased mRNA expression of TLR-4, monocytes chemo-attractant 
protein (MCP)-1, macrophage inflammatory protein (MIP)-1, and CD68 (markers of 
macrophage infiltration), TNF-α and plasminogen activator inhibitor (PAI-1) (inflammation 
markers), and iNOS and NADPH oxidase (oxidative stress markers), Also plasma LPS was 
significantly decreased. Indeed, these antiinflammatory effects of the prebiotic oligofructose 
were completely abrogated by GLP-2 antagonist administration in the prebiotic-treated mice. 
Conversely, administration of the GLP-2 agonist restored the antiinflammatory action of the 
prebiotics (Cani et al., 2009).  
     Subsequent denaturing gradient gel electrophoresis (DGGE) on the microbiome of the 
cecal microbiome undertaken to characterize the role of gut microbiota revealed a prebiotic-
induced increased of the total bacteria, Bifidobacteria, and Lactobacilli counts (Cani et al., 
2009).   
2.3.3.4 Intestinal disease-preventive effect 
     Prebiotics have shown efficacy in treating infant diarrhea (Passariello et al., 2011). In a 
single-blind, prospective, controlled study, children age 3-36 months affected with diarrhea 
were assigned to receive either a hypotonic rehydrant (59 males and 59 females) or a 
hypotonic rehydrant added with zinc sulfate and prebiotics (60 males and females) 
(Passariello et al., 2011). After 72 h of administering either treatment regimen, the diarrhea 
resolution rate was 50 and 72.9%  in the control and prebiotic treatment group, respectively. 
Palatability of the rehydrant-added prebiotics was higher and the average intake during the 
46 
 
 
 
first 24 h was 50 mL/kg bw. In the control group, the average intake during the first 24 h was 
22 mL/kg (Passariello et al., 2011). 
     Of economic importance, parents of infants in the prebiotics group missed only 0.39 
working days, whereas parents of infants in the control group missed 1.45 working days.  
Previously, it has been shown that addition of zinc sulfate to standard rehydrant, however, 
decreases duration of diarrhea and amount of stool (Bhatnagar et al., 2004). Findings of 
Passariello and colleagues (2011) would be of more value if a third treatment group that was 
given the standard hypotonic rehydrant plus zinc sulfate alone were examined 
simultaneously. 
2.3.3.5 Anticancer effect 
     Prebiotics have been shown to lower potential for developing colon cancer (Hijova et al., 
2011). Fecal ß-glucuronidase activity in individuals with colon cancer is 12.1-fold higher 
relative to healthy controls (Kim and Jin, 2001). To explore the ß-glucuronidase-lowering 
effect of prebiotics and thus prevention of colon cancer, Hijova and colleagues (2011) fed 
rats the high-fat diet (10% fat; control) or the high-fat diet supplemented with 2% of fat with 
probiotics in combination with or without  the bioactive food Hyppocastani extractum siccum 
at 2% or  Lini oleum virginale at 1% for two weeks. Subsequently, to induce ß-
glucuronidase, rats were injected with 20 mg/kg bw dimethylhydrazine intraperitonealy twice 
in two weeks.  
     Prebiotics alone or in combination with hyppocastani extractum siccum or Lini oleum 
virginale significantly decreased the secretion of bile acids and production of the bacterial  
ß-glucuronidase. Also, the prebiotic feeding decreased total plasma cholesterol and TAG and 
increased the production of the SCFA (Hijova et al., 2011).   
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     mRNA of osteopontin (OPN; anti-apoptotic for colon cancer cells) and cyclooxygenase 
(COX)-2 were shown to be increased substantially in ex vivo colon cancer tissues relative to 
those of the adjacent healthy colon tissues (Jahns et al., 2011). Addition of butyrate to the 
culture media decreased expression of OPN and COX-2 in all healthy and colon cancer 
tissues. Also, in colon cancer tissues, OPN mRNA expression was decreased by 50%, 
whereas that of COX-2 was decreased by 35% relative to the control after addition of the 
butyrate (Jahns et al., 2011). 
2.4. Johne’s disease 
      Johne’s disease (JD; paratuberculosis) is the infection with avium subspecies 
paratuberculosis (MAP) in wild and domesticated ruminant animals. Whereas subclinical JD 
is characterized by decreased milk production, clinical JD is causes diarrhea and wasting in 
infected animals.  
2.4.1. Etiology of Johne’s disease 
 
     MAP is the etiologic bacterium that causes JD in ruminant animals worldwide (Harris and 
Barletta, 2001; Olsen et al., 2002). MAP is a mycobactin J-dependent, acid-fast, slow-grower 
mycobacterial species that multiplies inside intestinal macrophages of the host (Momotani et 
al., 1988; Sweeney, 1996). The taxonomic classification of MAP indicates its kinship to the 
Suborder Corynebacterineae, order Actinomycetales, and phylum actinobacteria under the 
Domain Bacteria. 
2.4.2. Transmission and epizootology of Johne’s disease 
     Johne’s disease is a chronic granulomatous enterocolitis, local adenitis, and lymphangitis 
and is manifested as an intermittent or profuse watery diarrhea accompanied with progressive 
emaciation that concludes by death of the affected animal. Once described in 1885, by John 
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and Forthingham, JD was an episodic disease that posed insignificant economical loss. 
Economical impact of JD, however, has intensified by increasing animal densities in the 
modern animal farming industry (Hutchinson, 1996).  
     Ability of MAP to form a biofilm (Wu et al., 2009) makes MAP ubiquitously prevalent in 
the domesticated animal (Pickup et al., 2006) and wildlife environment (Davidson et al., 
2004), enhances its resistance to eradication by currently adopted control strategies, and also 
increases its pathogenicity.      
     As early as 1984, culturing ileocecal lymph nodes from cull cows indicated that JD is 
prevalent in about 2.9% of all cull cows in the US (Merkal et al., 1987).  On herd level, 
however, 34% of dairy herds in Wisconsin have been found infected with JD (Collins et al., 
1994). Wells and Wagner (2000) screened sera from about 79% of the US dairy herds in 
different geographical locations for antibodies to MAP by using ELISA assay. Results 
demonstrated that 3.4% of cows and 21.6% of dairy herds were infected with MAP.  
     Less preventative measures, such as delayed time of separation of calf from dam and 
nature of hygienic measures adopted including disinfecting teats and udder before collecting 
colostrum from dam, were highly associated with increasing prevalence of JD among herds 
(Wells and Wagner, 2000).  
     In another different approach, ELISA tests designed to detect MAP-specific IgG1 coupled 
with PCR to detect MAP IS900 genomic DNA in pooled bulk tank milk were used by Wilson 
and colleagues (2010) to examine prevalence of MAP in milk from dairies in Utah area. 
MAP was detected at least once in about 39% of dairy herds tested. The result highlights the 
fact that JD is steadily spreading among dairy cattle despite the raising awareness about the 
disease and the stringent control strategies being applied. 
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2.4.3. Morphology of Mycobacterium avium subspecies paratuberculosis  
     MAP average about 1.0 µm in length ranging from 0.5 to 1.5 µm. MAP possesses a 
relatively thick waxy cell wall that is composed of 60% lipid. This thick lipid layer permits 
MAP to gain the characteristics of resistance to decolorization by the acidic Ziehl-Neelsen 
stain (acid fastness), increased tolerance to disinfectants, such as chlorine (Whan et al. 2006), 
strong negative charge and hydrophobicity (Boster et al., 2009), resistance to pasteurization, 
(Grant et al. 1998), and ability to spread in bio-aerosols (Eisenberg et al., 2011). 
     MAP cell wall is composed of an internal PG layer surrounded by an intermediate bilayer 
of long-chain mycolic acid arabinoglactan complex and an external layer of 
peptidoglycolipids composed mainly of lipomannan (LM) and lipoarbinomannan (LAM), 
19-kDa lipoprotein, mycolyl-arabinoglactan peptidoglycan complex (Brennan and Nikaido, 
1995), and trehalose 6,6’-dimycolate (Welsh et al, 2008). 
     LM, the precursor of LAM, is composed of a mannan core immobilized to the cell wall by 
a phosphatidylinositol molecule. Arabinosylation of the mannan core of LM at its free side 
by an arabinan domain derives LAM. The arabinan domain is a highly branched 
arabinofuranosyl side chains that make up the basic cell wall component of both pathogenic 
and nonpathogenic mycobacteria (Chatterjee and Khoo, 2000).  
     The arabinan domain can be capped by various motifs (Briken et al., 2004). Pathogenic 
mycobacteria, such as MAP, possess a arabinan domain that is capped by an oligomannose 
cap (Man-LAM). In contrast, the arabinan domain of non-pathogenic Mycobacterium 
smegmatis is capped by phospho-inositol (PI-LAM) and that of Mycobacterium chelonae is 
uncapped (Ara-LAM) (Chatterjee and Khoo, 1998; Briken et al., 2004).  
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     Molecular pathogenesis studies of MAP suggest that recognition of MAP by the innate 
immunity surveillance patterns and the ensuing immune response outcome is dictated 
primarily by the presence or absence of the arabinan-capping motifs (Schlesinger, 1993; 
Maeda et al., 2002). Whereas AraLAM is proinflammatory, ManLAM is anti-inflammatory 
and allows MAP to evade the innate immunity detection through invasion of macrophage 
using the mannose receptor as a safe portal of entry (Schorey and Cooper, 2003).  
2.4.4 Signaling of Mycobacterium avium subspecies paratuberculosis surface proteins 
     Upon phagocytosis of MAP and other mycobacteria, PI-LAM and Man-LAM become 
integrated into the cell membrane and localized to the membrane lipid rafts of the 
macrophage anchored by its glycosylphosphatidylinositol anchor (Welin et al., 2008). 
Membrane rafts are cholesterol-rich bilayer that constitutes the cell signaling molecules 
aggregates (Pike, 2006). 
      Ara-LAM is expressed constitutively by nonpathogenic bacteria and demonstrates high 
affinity to binding CD14, a co-receptor associated with TLR-4 and the lymphocyte antigen-
96 (MD-2), that binds LPS and other PAMPs (Kitchens, 2000). Signaling of Ara-LAM via 
TLR-4 results in secretion of chemokines by macrophages and induction of TNF-α, IL-1α, 
IL-1ß, and IL-6 (Juffermans et al., 2000).   
     Alternatively, Man-LAM localization to the membrane lipid rafts suppressed the 
translocation of the lysosomal marker CD63 to the phagosome of human macrophage cell 
line hMDMs suggesting that Man-LAM inhibits phagosome maturation (Welin et al., 2008). 
Inhibition of phagosome maturation by Man-LAM did not seem to involve disruption of 
TLR- 2 and 4 signaling nor activation of p38 MAPK (Welin et al., 2008). 
51 
 
 
 
     In the bovine animal, the paradigm of immune responses triggered against MAP infection 
shows that Th1 responses targeted to MAP were the first to be activated and dominate during 
the subclinical stage (Stabel, 1996; Stabel, 2006). Indeed, the main Th1 cytokine involved is 
IFN-γ (Stabel, 1996) and single nucleotide polymorphism (SNP) in IFNGR that encodes the 
IFN-γ receptor is associated with JD in dairy cattle (Pant et al., 2011).  As the disease 
proceeds to the clinical stage, a switch to Th2 responses becomes dominant (Stabel, 2006) 
with increased IL-10 secretion.  Subsequent histopathological characterization of the disease 
uncovered that the subclinical stage in context of Th1 involves paucibacillary (tuberculoid) 
granulomatous reaction that sieges the MAP dispersion in tissues and causes significant 
destruction to the pathogen (Kurade et al., 2004). In contrast, the multibacillary form of JD 
involves humoral immunity development with increase of MAP-specific antibodies 
production.    
     In the ovine animal, the classical immune response shift has been noted by Kurade et al 
(2004). A JD transitional state characterized by upregulation of both Th1 and Th2 responses 
was seen in lambs (Kurade et al., 2004). These two forms of ovine JD are characterized by 
distinct molecular patterns dictated by differential chemokine expression, leading to the 
classical immune cell infiltration unique to each of the two JD forms (Smeed et al., 2010). 
Detection of different forms of JD, however, requires the concurrent use of the ELISA testing 
and the immune proliferation assay (Kurade et al., 2004). 
     Recently, the dogma of the classical switch of JD from the cell-mediated immunity in the 
early stage to the humoral immunity at later stage has been questioned (Begg et al., 2011). 
Simultaneous MAP-specific IFN-γ and antibody responses have been detected in the early 
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stage of JD in sheep (Robinson et al., 2009; Begg et al., 2011) and even as early as two 
weeks post-infection in calves (Water et al., 2003).  
     These findings indicated the fact that probably immune responses against MAP are likely 
more intricate than previously thought (Stabel, 2006; Begg et al., 2011). Because about 50% 
of all infected sheep exhibited concurrent cell-mediated and humoral immunity, Begg and 
colleagues (2011) suggested that rather than a classical shift to the multibacillary form, the 
immune system of a JD-affected animal becomes malfunctional resulting in initial permanent 
loss of the cell-mediated immunity (Begg et all., 2011).  
     Given the ability of MAP to subvert the initial strong cell-mediate immunity 
(characterized by IFN-γ secretion leading to the paucibacillary granulomas formation) and to 
induce the non-protective humoral immunity (characterized by increased IL-10 secretion and 
the lepromatous granulomas development), we would question the efficacy of developing JD 
vaccines that trigger Th1 responses.  It is well established that ruminant animal can overcome 
natural MAP infection and development of JD (Kurade et al., 2004). Stress, however, can aid 
MAP to break the host immune siege and disseminates (Chiodini et al., 1984) causing the 
fatal multibacillary form of JD. 
2.4.5  Metabolism in Mycobacterium avium subspecies paratuberculosis 
     Once inside the mammalian host cell, MAP has the privilege of a wide array of nutrients 
available for them to metabolize (Barclay and Wheeler, 1989).  MAP chiefly depends on 
glucose for harvesting energy (Wheeler, 1984). Metabolizing glucose in the glycolysis and 
pentose phosphate pathway generates a plethora of metabolic intermediates that can be 
utilized for building of macromolecules (Wheeler, 1984). 
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     Acetyl-CoA and oxaloacetate will be condensed in the tricarboxylic acid cycle to generate 
citrate and reducing equivalents (NADH and FADH2) (Wheeler, 1984).  Whereas citrate can 
be a building block for the synthesis of mycolic acid, a principal component of MAP cell 
wall, the reducing equivalent can be utilized by the oxidative phosphorylation to generate 
ATP (Bloom, 1994).  
     Because lipids are available to MAP cells in vivo in excess of carbohydrate, lipid 
synthesis enzymes will be feedback-inhibited (Wheeler et al., 1990; Wheeler and Ratledge, 
1992). Host-derived fatty acids by MAP acyl-hydrolase phospholipase (Wheeler and 
Ratledge, 1992) will be elongated and used by MAP to synthesize its own cell wall 
components (Wheeler et al., 1990). ß-oxidation of host-derived fatty acids can take place 
inside the MAP cells to produce additional ATP and acetyl-CoA that accelerate the 
tricarboxylic acid cycle to aid proliferation of MAP (Barclay and Wheeler, 1989). 
     Host cell-available amino acids are assimilated by MAP cell to synthesize enzymes for 
protein synthesis. Also, the host preformed purines, pyrimidines, and nucleotides are 
imported inside the MAP cell and are utilized for building MAP nucleic acids (Wheeler, 
1987).   
     MAP, however, is iron-requiring mycobacteria that fail to grow in artificial media 
deprived of mycobactin J, an iron-chelating substance (Bloom, 1994). Proliferation of MAP 
in macrophage cultured in vitro was inhibited by addition of iron-chelating substances 
(Fernandez et al., 2010). Microarray genomic comparison unraveled genetic divergence 
between two the MAP strains;  
S MAP that causes ovine JD and C MAP that induces bovine JD (Marsh et al., 2006). The 
genetic divergence involves three substantial genomic deletions in 24 open reading frames in 
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the S MAP (Marsh et al., 2006) that seem to underlay the distinct microbiological variance of 
each strain.  
     When iron is replete, S MAP express iron-dependent regulator SIdeR that suppresses gene 
expression of the putative bacterioferritin (BfrA) and hypothetical protein (MAP2073c), 
which is  indicative of a defective iron storage mechanism (Janagama et al., 2010). In 
contrast, C MAP upregulates iron storage gene BfrA, virulence-associated antigen-85 and 
Esx-5, and ribosomal proteins and inhibits aconitase and succinate dehydrogenase to spare 
iron for cell division and proliferation (Janagama et al., 2010).    
     As yet, some aspects of MAP metabolism are poorly characterized (Bloom, 1994).  For 
illustration, MAP is a facultative aerobe that may require O2 to grow and harvest energy in 
the oxidative phosphorylation pathway. Because the mammalian host holds O2 tightly bound 
to hemoglobin, myoglobin, and cytochromes, means by which MAP acquire O2 await full 
elucidation (Bloom, 1994). 
     The extremely slow growth of MAP (one division each 18 h), as an example of 
mycobacteria, compared to that of E. coli (one division each 20 min) has been a topic of 
research. Largely, the thick waxy cell wall has been implicated as being a less permeable 
barrier to hydrophilic nutrients. Uptake of hydrophobic nutrients by MAP is accomplished 
through porin channels that penetrate the thick waxy lipid bilayer (Trias et al., 1992; Trias 
and Benz, 1994). In addition, the nucleic acid synthesis by mycobacteria and their sensitivity 
to inhibition by rifampicin  has been hypothesized to be the rate-limiting step in the growth 
of the slow-growing mycobacteria  (Woodley et al., 1972). 
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2.4.6 Economic impact of Johne’s disease 
     Infection with JD significantly decreases milk production and thereby causes economic 
loss to dairy producers (Smith et al., 2009). Cows that test positive for MAP through ELISA 
serum testing and fecal culture produce about 1.0 Kg per day less 4% fat-corrected milk than 
herdmates that test negative for MAP (Aly et al., 2010). Detection of MAP at greater than 30 
CFU/g feces in a dairy cow fecal culture was associated with a decrease in milk production 
that amounted to about 4.0 Kg milk per day less than milk production of a JD-free cow 
(Smith et al., 2009).    
     Infection with MAP decreases milk quantity and alters its quality (Gonda et al., 2007). 
Deterioration of milk quantity was severer in cows that tested positive by fecal culture 
relative to cows that test positive by serum ELISA. Holstein cows that were infected with JD 
produced about 304 Kg less milk, 11.5 Kg less fat, and 9.5 Kg less protein per lactation 
relative to JD uninfected cows (Gonda et al., 2007). Despite its deep effect on milk 
production, JD, however, does not seem to affect the udder health or increase milk somatic 
cell counts (Hendrick et al., 2005: Gonda et al., 2007). 
     Additionally, MAP form feces of JD-infected cow may contaminate meat during 
slaughtering decreasing its quality (Alonso-Hearn et al., 2009; Mutharia et al., 2010). Despite 
that recent investigations have shown that viable MAP can be inactivated in lamb meat 
homogenate cooked to recommend standards (Whittington et al., 2010) prevalence of MAP 
in meat would exacerbate the economic burden to farmers because of JD. The findings also 
highlights the need for developing and maintaining more stringent biosafety measures to 
ensure fitness of meat intended for human consumption.   
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     The USDA National Animal Health Monitoring System's (NAHMS) 1996 national dairy 
study indicated that JD is prevalent in about 21.6% of all dairy herd tested. Also, JD-infected 
herds lost US$ 100 per cow in comparison with JD-free dairy herds as a result of decreased 
milk production and increased culling and replacement of infected cows (Ott et al., 1999).   
     When percentage of culled cows because of JD reached 10% of the herd, economic losses 
amounted to US$ 200 per cow. Also, milk production was decreased by 700 kg per cow in 
dairy herds that experienced high prevalence of JD. Overall, the increased cow mortality and 
premature culling coupled with the decreased productivity because of JD, the national dairy 
industry loses about US$ 250 million per year (Ott et al., 1999).  
     Because the prevalence of JD has increased from 21.6% in 1999 (Ott et al., 1999) to about 
68% in 2007 (NAHMS, 2007), the annual economic losses because of JD is currently greater 
than US$ 250 million.  
2.4.7 Prevention and control measures of Johne’s disease 
     Prevention and control strategies in play to eliminate MAP infection and the spread of JD 
among dairy animals include adopting sound husbandry practices to eliminate exposure of 
young animals to the disease. Prevention strategies also call for continuous testing of young 
heifers to detect and cull infected animals. The JD prevention program also necessitates 
raising awareness about JD among dairy and beef farmers and urges the development of an 
effective vaccine (Kennedy and Benedictus, 2001). The control JD, however, has been 
difficult because of lack of an effective vaccine.  
2.4.7.1 Husbandry and hygiene practices 
     MAP is ubiquitously present in the environment and in the untreated water from farm 
runoff Whan et al., 2005). In water, MAP can be ingested by the free-living naturally 
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occurring protozoa, such as Acanthamoeba castellanii and Acanthamoeba polyphaga (Whan 
et al., 2006). Ingested MAP can multiply inside the protozoa, and their number can increase 
by 1-1.5 log10 within three weeks of ingestion. Interestingly, ingestion of MAP by protozoa 
enhances resistance of MAP to killing by chlorine (Whan et al., 2006). 
      MAP also is carried in settled dust inside dairy farms where the herd is heavily infected 
with JD.  Cleaning barns of MAP “super shedder” dairy cows with cold, high-pressure water 
and disinfectants followed by depopulating the barns for two weeks effectively decreased 
detection of viable MAP from about 86% of the samples to zero (Eisenberg et al., 2010). 
Repopulating barns with MAP-shedding cows resulted in wide spread of viable MAP in the 
settled dust inside the farm and in the surroundings, suggesting spread of MAP in the bio-
aerosols (Eisenberg et al., 2011). 
     Minimizing the exposure of calves to adult feces has proven to be the most effective 
measure for eliminating JD in dairy herds (Merce et al., 2011). A compliance with this 
procedure is the removal of neonate calves from their dams during the first 12 hours after 
birth. Also, replacement heifers should be housed separately from the rest of milking herd 
until they are one year old. Segregation of calves before weaning, however, had no effect on 
transmission of JD. 
     Milk and colostrum from JD-infected dams can transmit JD to neonate calves (Streeter et 
al., 1995; Nielsen et al., 2008). Significant transmission of MAP infection, however, occurs 
through consumption of MAP-contaminated colostrum rather than of milk (Nielsen et al., 
2008).  
     Indeed, feeding neonate calves pasteurized colostrum from JD-uninfected dams alleviates 
JD incidence in calves during the first year of life (Stabel, 2008). Of noteworthy, a JD-
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preventative effect of the pasteurized colostrum was demonstrated in neonate calves born to 
dams naturally infected with MAP. The high thermal resistance of MAP, however, could 
enable a few number of MAP to survive pasteurization (Grant et al., 2001) and seed an 
infection.  
     Similarly, feeding plasma-derived colostrum replacer to neonate Holstein calves born in 
JD-infected herds prevented significant transmission of MAP infection relative to claves fed 
raw colostrum (Pithua et al., 2009). Calves fed the plasma-derived colostrum seemed less 
likely to become JD-infected (R2 = 0.55) based on the serological and bacteriological testing 
modalities used (Pithua et al., 2009). 
     In addition to peripartal infection, congenital infection with JD has been reported (Koets, 
2006) and about 9% of neonatal calves could acquire MAP infection when JD prevails in 
40% of the herd (Whittington and Windsor, 2009). Adult cattle are also susceptible, and 
yearling cattle can acquire JD after intensive grazing of a MAP-contaminated pasture 
(Fecteau et al., 2010).   
     The use of new technology, such as the radiofrequency power to thermally disinfect 
wastewater from dairy farms and kill livestock pathogens, such as MAP, E. coli 0157:H7, 
and Salmonella species, has proven effective (Laqunas-Solar et al., 2005). Bacterial 
pathogens were heat-killed completely by raising the wastewater temperature to 65o C for 
less than one minute.   
      Milk bulk tank somatic cell counts (BTSCC) indicates milk quality and are used to price 
milk.  Current SCC standards are more rigorous requiring that BTSCC be no greater than 
400,000 (Reneau, 2001). To lower BTSCC, dairy farmers use milk from cows with high SCC 
to feed calves (Babtista et al., 2008).  
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     Appreciable correlation between detection of MAP antibodies in milk and high SCC 
could not be established after screening 1,733 dairy cows milk in Danish dairy herds 
(Babtista et al., 2008). A log-linear relationship between the age at first elevated SCC and the 
age at first positive ELISA was found, suggesting that feeding milk with high SCC to young 
calves could pose a risk factor for acquiring JD (Babtista et al., 2008). Remarkably, MAP in 
milk can be efficiently eradicated by pasteurizing milk for 15 seconds at 72o C (Pearce et al., 
2001). 
2.4.7.1.1 Testing and culling of infected heifers. 
     The use of the IFN-γ assay to measure the cell-mediated immunity triggered against MAP 
PPD (johnin) intradermal skin test to identify and cull infected heifers at a young age has 
significant limitations (Jungersen et al., 2011). The chronic nature of JD confounds definitive 
interpretation of the assay result. On the other hand, the testing modalities adopted to detect 
and cull carrier heifers are far much less sensitive. During subclinical JD, the sensitivity of 
fecal culture and ELISA to detect JD-infected cows is about 30 and 15%, respectively 
(Whitlock et al. 2000). 
     Eventually, the IFN-γ assay indicates primarily whether an animal has been exposed to JD 
infection. Indeed, the IFN-γ assay doesn’t define conclusively the progression of JD in a 
given animal (Jungersen et al., 2011) or otherwise the animal will continue to harbor latent 
JD or becomes cured and immunized against the disease.   
     Early culling of affected heifers has been long advocated measure to limit spread of JD 
within a dairy herd (Kennedy et al., 2001). A recent report proposed that heifers younger than 
two years that test positive for JD are not significantly different than other herdmates that test 
negative for JD in respect to longevity and milk production parameters (Pillars et al., 2011). 
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Along with the difficulty of making conclusive interpretation of the IFN-γ testing, findings of 
Pillars and coworkers (2011) underscore the validity of testing dairy heifers for JD early in 
life.  
2.4.7.2 Vaccination 
     In addition to its economic impact on dairy industry (Ott et al., 1999;  McKenna et al., 
2006; NAHMS, 2008),  MAP have been raising considerable public health concern because 
of its controversial role in the pathogenesis of CD, an inflammatory bowel disease in humans 
(Mendoza et al., 2010; Rosenfeld and Bressler, 2010; Tuci et al., 2011; Lee et al., 2011).  
     As yet, effective antibiotic therapy for JD is lacking (Rosenfeld and Bressler, 2010). 
Additionally, significant concern has been raised about the efficacy of the currently available 
oil suspension heat-killed JD bacterin that produced inconsistent results (Kalis et al., 2001; 
Rosseels and Huygen, 2008). Given that as many as 15 different strains of MAP could be 
infecting animals within a herd simultaneously (Paradhan et al., 2011), strain specificity 
could be the main limitation of the whole cell JD bacterin.    
     Additionally, the heat-killed MAP bacterin also impedes the early diagnosis and detection 
of tuberculosis (TB) and JD infections during the assurance programs because it gives false 
positive results (Muskens et al., 2002). The heat-killed bacterin also impinges on animal 
welfare because the bacterin is a tissue irritant that causes significant tissue reaction and 
granuloma formation that may result in abscessation of the injection site (Muskens et al., 
2002; Huntley et al., 2005). Because of concern about these limitations, oil suspension JD 
bacterin use has been restricted to herds with high prevalence of clinical cases of JD 
(Muskens et al., 2002). 
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2.4.7.2.1 The use of heat-killed MAP vaccine 
     The efficacy of long-term vaccination with the heat-killed MAP vaccine in preventing 
fecal shedding of MAP was evaluated (Kalis et al., 2001). In the first study, fecal samples 
were collected from 25 vaccinated and 29 non-vaccinated dairy herds. Fecal culture results 
were positive in about 4.4% of the 25 dairy herds. No significant difference in fecal shedding 
was revealed among the 25 vaccinated dairy herds.  In the 29 non-vaccinated herds, fecal 
culture results were positive in 6.7% of the herds.  
     In the second study, fecal samples were cultured for MAP four times at six-month 
intervals from two vaccinated and two non-vaccinated dairy herds from cows older than six 
months (Kalis et al., 2001) followed by culling of cows that cultured positive for MAP. 
Curiously, after culling of cows that had positive fecal culture in the two vaccinated herds, 
the percentage of MAP-positive fecal culture decreased from 10.9 and 5.7 to 3.5 and 0.0%, 
respectively. In contrast, in the two non-vaccinated herds, percentages decreased from 6.1 
and 16.5 to 0 and 2.3%, respectively.  Investigation of the husbandry practices adopted by the 
different participant herds indicated that feeding raw milk to neonate calves is strictly 
prohibited in the unvaccinated herds. Thus, it was concluded that a heat-killed MAP bacterin 
is ineffective at preventing fecal shedding of MAP in dairy cows (Kalis et al., 2001).  
     By using different testing modalities Muskens and colleagues (2002) evaluated induction 
of the cell-mediated and humoral immunities by the heat-killed MAP bacterin. For this 
purpose, serum IFN-γ concentrations were quantified by using ELISA. Also, serum MAP 
antibodies were determined by using ELISA and complement fixation (Muskens et al., 
2002). Though both the cell-mediated and humoral immunity were enhanced by the vaccine, 
significant inconsistence in immune response was observed among animals of the same herd. 
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Additionally, results obtained by the ELISA and complement fixation did not correlate. Thus, 
conclusive conclusions about efficacy of the vaccine could not be made, and it was projected 
that the vaccine will induce a long-lasting interference with diagnosis of TB and JD 
(Muskens et al., 2002). 
2.4.7.2.2 The use of adjuvanted, live, attenuated MAP vaccines 
     The immunologic inference with diagnosis of TB by an oil- or aqueous-adjuvanted, live, 
attenuated MAP strain 316F vaccines was evaluated in farmed red deer (Cervus elaphus) 
(Mackintosh et al., 2005). Five-months-old farmed red deer were assigned to treatment 
groups (n = 15) that either received  no vaccine (control), received one dose of 2 mL oil-
adjuvanted, live, attenuated MAP vaccine, or received two doses of 2 mL aqueous-
adjuvanted vaccine six months apart (Mackintosh et al., 2005).  
     It was found that the oil-adjuvanted, live, attenuated, MAP vaccine induced considerable 
cell- mediated immunity that might confer protection against JD in red farmed deer 
(Makintosh et al., 2005). Subsequent evaluation of the immune responses by the deer, 
however, indicated that vaccination by the oil-adjuvanted vaccine caused significant cross 
reactivity with tuberculin skin testing. Though the cross reactivity to TB testing declined with 
time, its potential to cause false TB positive results cannot be ruled out because of the 
persistently elevated MAP antibodies in serum of deer (Kohler et al., 2001; Mackintosh et al., 
2005).  
     On the other hand, the aqueous-adjuvanted, live, attenuated MAP vaccine triggered less 
cross reactivity with tuberculin skin testing but induced less significant MAP antibody 
concentrations.  
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2.4.7.2.3 The use of adjuvanted, live, non-attenuated MAP vaccine 
     IL-12 induces selectively the differentiation of naïve T cells into IFN-γ-producing Th1 
cells (Schmitt et al., 1994). The effect of co-administration of 0.5 mL of 20 µg/mL 
recombinant rIL-12 on JD vaccine efficacy to confer protection against JD was evaluated in 
neonate Holstein claves (Uzonna et al, 2003). Human or murine rIL-12 was used as an 
adjuvant to non-attenuated field-isolate or strain 18 MAP vaccine. Both vaccines induced 
modest cell-mediated immunity as evident by the slight increase of IFN-γ (Uzonna et al., 
2003). Tissue culture for MAP suggested that co-administration of rIL-12 and the non-
attenuated MAP vaccine did not significantly lower the MAP burden in tissues. The study 
concluded that the use of rIL-12 adjuvanted non-attenuated MAP vaccine confers limited 
protection against bovine JD (Uzonna et al., 2003).  
     It became evident now that neither form (heat-killed, live attenuated and the live non-
attenuated) of the MAP bacterin confers protection against future infection with MAP in 
cattle (Koets et al., 2006). Also, immunization of cattle with the MAP bacterin only slightly 
limits number of subclinically infected cattle that still shed MAP into the environment 
(Kohler et al., 2001; Muskens et al., 2002; Uzona et al., 2003; Mackintosh et al., 2005;  
Koets et al., 2006). 
2.4.7.2.4 The use of recombinant MAP DNA vaccine: 
     Scientists from the USDA-ARS-NADC and the College of Veterinary Medicine at Iowa 
State University pioneered the search in the genome of MAP using DNA expression library 
to uncover potential DNA vaccine sequences against MAP infection (Huntley et al., 2005). 
Generated clone pools of sequence were injected into mice by using gene gun delivery 
followed by challenging mice with virulent MAP to determine sequences that would confer 
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immune protection against MAP (Huntley et al., 2005). Nucleotide sequencing of the clones 
that conferred protection to MAP revealed that 26 genes are potential vaccine subunits 
against MAP infections (Huntley et al., 2005).  
     The heat-shock protein70 (Hsp70) subunit is a chaperone protein that enhances correct 
protein folding and prevents protein aggregate formation (Morano, 2007). Gene and protein 
expression of Hsp70 is upregulated during cellular stress and in response to infection (Koets 
et al., 2006; Wieten et al., 2009). Also, Hsp70 is an immuno-dominant antigen in bovine JD 
and can trigger vigorous cell-mediated and humoral immune responses (Wieten et al., 2009). 
      Koets and colleagues (2006) evaluated immune responses of neonate claves to 
recombinant MAP Hsp70. Forty calves were assigned randomly to four treatment groups (n 
= 10). Group I represents animals that were neither immunized nor infected, group II 
contained calves that were non-infected but immunized, group III contained infected calves 
that were not immunized, and group IV contained calves that were both immunized and 
infected. Subsequently, group 1 and II calves were mixed together but kept separate from 
groups III and IV (Koets et al., 2006). 
     Infected calves received 20 g of feces from a known infected cow that had been mixed 
with 100 mL of milk daily for the first 21 days of life. For immunization, 200 µg of 
recombinant MAP Hsp70 suspended in 1 mL sterile PBS containing 20 mg/mL dimethyl 
dioctadecyl ammonium bromide (DDA) adjuvant was injected under the skin. A booster dose 
was given on day 308 of the study. Koets et al (2006) demonstrated, for the first time, that 
vaccination of cattle with Hsp70/DDA significantly decreased shedding of MAP in feces 
with significant implication on decreasing the spread of JD in cattle herds. Of significance, 
contrary to the whole cell bacterin, vaccination with Hsp70/DDA enabled the differentiation 
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between the vaccinated and infected animals. Whether Hsp70/DDA-vaccinated calves might 
exhibit false positive results on tuberculin testing, however, remained to be verified (Koets et 
al., 2006). 
     Extensive evaluation of the immunogenicity of various MAP antigens as well as their 
ability to induce Th1 responses when used as vaccine subunits received increased interest. 
Work by Park and co-workers (2008) from the College of Veterinary Medicine at Cornell 
University showed that the MAP 85 antigen complex (85A, 85B, and 85C), superoxide 
dismutase (SOD) and 35 kDa protein induces robust lymphocyte proliferation and secretion 
of Th1-associated IFN-γ, IL-2, IL12, and TNF-α secretion.  
     Motivated by these findings, MAP 85 antigens, SOD and 35 kDa proteins were cloned 
and recombined in eukaryotic expression plasmid pVR1020. To evaluate the vaccine 
efficacy, C57BL/6 mice were injected intramuscularly with the recombinant DNA vaccine 
cocktail three times. The control mice received the pVR1020 DNA alone (Park et al., 2008). 
     Following vaccination, all mice were infected with MAP. The vaccine cocktail generated 
robust CD4+ and CD8+ T cell responses and higher lymphocytes proliferation compared with 
that of control mice (Parke et al., 2008).  
     In vitro splenocyte cell cultures from vaccinated mice showed enhanced IFN-γ 
production. Also, MAP burden in livers and spleens of vaccinated mice was significantly 
decreased relative to the control (Park et al., 2008). Histopathological examination of tissues 
from the control mice unveiled severe histopathological injury evident by the increased 
numbers of granulomas and their content of acid-fast bacilli. The substantial Th1 responses 
observed coupled with reduction of MAP burden in tissue led the researcher to conclude that 
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MAP 85 antigens, SOD, and the 35 kDa cocktail vaccine has potential to protect mice against 
infection with JD (Park et al., 2008). 
     Similarly, the differential immune responses and the protective efficacy of these four 
recombinant antigens with two different adjuvants, the monophosphoryl lipid A (MPLA) or 
the bovine IL-12 were examined in calves (Kathaperumal et al., 2008).  
     Group I calves were administered the four MAP antigens together with MPLA and IL-12. 
Group II calves were administered with the four antigens and MPLA. Calves in group III 
received MPLA and IL-12. Calves in group IV received MPLA alone (Kathaperumal et al., 
2008). In group I and II animals, all the MAP antigens, except for SOD, induced significant 
Th1 responses as indicated by the increase of IFN-γ, antigen-specific IL-2, IL-12p40, and 
TNF-α concentrations. Similarly, expression of CD4+, CD8+, CD25+, and CD3+ was 
increased dramatically, indicative of enhanced cell-mediated immunity (Kathaperumal et al., 
2008).  
     As far as the bacterial burden is concerned, whereas 4 and 3 out of 8 calves in each of 
group I and II, respectively, were cultured positive, 3 out of 4 animals in each of group III 
and IV were cultured positive suggesting that the recombinant MAP antigens could confer 
protection to calves against JD infection (Kathaperumal et al., 2008).   
     The same research group examined the protective efficacy and differential immune 
response of the recombinant 85A, 85B, SOD, and the fusion protein Map 74F along with 
DDA as an adjuvant in week-old goat kids (Kathaperumal et al., 2009). Goat kids were 
chosen from herds that were JD free.  Initially, goats were randomized into three treatment 
groups (n = 8). Animals in group I were immunized subcutaneously with DDA-adjuvanted 
recombinant antigen cocktail at 100 µg. Group II animals were immunized with the non-
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DDA adjuvanted antigen cocktail. Goat kids in group III were administered adjuvant DDA 
alone to serve as a control.  
     All goat kids in the different groups were boostered after three weeks. Three weeks later, 
all goat kids were administered 5 × 108 CFU of MAP per animal in 10 mL of milk replacers 
for seven consecutive days.  
     In group I and II, T lymphocyte proliferation became significant three weeks after the 
booster dose and peaked after the fourth week. In group I goats, the antigen-specific IFN-γ 
increased significantly three weeks after the booster dose and remained significantly elevated 
for 10 weeks. Similarly, the CD4+ subset was higher in the immunized animals (groups I and 
II) six to 10 weeks after the immunization compared with the control animals (Kathaperumal 
et al., 2009).  
     Remarkable reduction of MAP burden in tissues was seen at necropsy of group I 
(Kathaperumal et al., 2009). It was evident that immunization with the 85A and Map 74F 
antigens along with adjuvant DDA triggers Th1 responses and imparted protection against 
MAP infection in a goat model (Kathaperumal et al., 2009). 
     Because MAP rHsp70 subunit conferred protection against MAP infection in mice and 
goats (Park et al., 2008; Kathaperumal et al., 2008; 2009), it was hypothesized that Hsp70 in 
intact MAP must be exposed to the anti-Hsp70 antibodies (Santema et al., 2006). Two B cell 
linear epitopes on the cell wall of the intact MAP that are ligand for Hsp70-induced 
antibodies have been identified by using mAb (Koets et al., 2006). The same epitopes were 
identified in Hsp70-immunized goat and calves (Santema et al., 2006). Further work 
illustrated that the epitopes exist in the intestinal tissue lesions and in naturally infected JD 
animals (Santema et al., 2011). These findings further showed that vaccination by MAP 
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rHsp70 induces recognition by B cell of epitopes on rHspt70 and generation of protective 
antibodies against native Hsp70 that impart protection against JD (Santema et al., 2009). 
    Subsequent work to characterize the MAP Hsp70-specific T cell epitopes in cows 
immunized with MAP Hsp70 and cows infected with experimental JD has been conducted 
(Hoek et al., 2010). Several peptides of the Hsp70 induced proliferation and IFN-γ secretion 
by T cells from cattle infected with JD or immunized with Hsp70 (Hoek et al., 2010). Of 
these Hsp70 peptides, five peptides induced T cell responses in about 82% of the infected 
calves. Further molecular characterization unraveled that the antigenic peptides were 
presented to T cells by multiple BoLA cells II DRB3 alleles indicating ability of Hsp70 
subunit to induce protection against JD in cattle (Hoek et al., 2010). 
     Overall, polarization of immune response to either Th1 or Th2 is dictated by the host-
pathogen interaction (Santema et al., 2011). Infection with virulent MAP generates initial 
Th1 responses in the first stage of infection (Watkins et al., 2010). Despite this, infected 
animals are unable to overcome MAP infection and eventually succumb to the clinical stage 
of the JD (Souza et al., 2007). Vaccination with the Hsp70 can induce anti-MAP antibodies 
that can bind surface epitopes and neutralize MAP (Sentema et al., 2011). Coupled with the 
initial cell-mediated immunity triggered by the natural infection with MAP the Hsp70 might 
protect the animal against JD and lessen JD economical loss to farmers. 
     In conclusion, rHsp70 has been shown to express linear epitopes that are recognized by T 
(Hoek et al., 2010) and B cells (Santema et al., 2011). Vaccination with Hsp70 induced 
robust Th1 responses (Hoek et al., 2010) and decreased MAP shedding in cattle (Koetz et al., 
2006). Importantly, Hsp70-induced immune responses do not interfere with the 
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immunodiagnosis of TB (Santema et al., 2009). Interference with TB diagnosis via ELISA 
has been eliminated by inclusion of a Hsp70 pre-absorption step (Santema et al., 2009). 
2.4.8 Johne’s disease-related intestinal disorders 
     Association of MAP with chronic granulomatous disease in humans is receiving strong 
debate now (Sing et al., 2008; Parrish et al., 2009; Mendoza et al., 2010; Lee et al., 2011) 
2.4.8.1 The Chronic inflammatory bowel disease  
      Inflammatory bowel disease (IBD) is unremitting intestinal inflammation that is classified 
into two subtypes; CD and ulcerative colitis (UC) (Podolsky, 2002; Baumgart and Carding, 
2007). CD is a chronic inflammation of the gastrointestinal tract and has a poorly defined 
etiology (Fiocchi, 1998). Similarly, UC is a chronic inflammatory disorder of the colon 
mucosa whose etiology remains largely ill characterized (Bamias et al., 2011).  It is likely 
that CD and UC develop in genetically susceptible individuals because of an overly 
intolerant immune response to commensal microbiota of the ileum and colon (Fiocchi, 1998; 
Bamias et al., 2011).  
     The genetically dictated miscommunication between the otherwise tolerated commensal 
inhabitants of the gut and GALT seemed to involve mutations of the intracellular bacterial 
sensors known as the NOD-2/caspase activation and recruitment domain15 (NOD-2/ 
CARD15) (Bianchi et al., 2007) and the autophagic regulator gene (ATG16L1) (Plantinga et 
al., 2011). Mutations of these genes have been linked to aberrant excessive secretion of 
proinflammatory IL-1ß, IL-6 (Plantiga et al., 2011), IL-13 from NK T cells (Mannon et al., 
2011), and IL-33 (Sponheim et al., 2011) in ileal and colonic mucosa. 
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 2.4.8.1.1 Crohn’s disease 
     Research findings that argue for association of MAP with CD cite significant prevalence 
of MAP DNA in ilea of individuals with CD (Lee et al., 2011). In mucosal biopsies taken 
from the terminal ilea of pediatric patients, MAP IS900 genomic DNA was detected in 1 out 
of 19 (5%) pediatric controls and 7 out of 20 (35%) pediatric subjects with CD. In mucosal 
biopsies taken from colon, MAP IS900 genomic DNA was not detected in all 19 control 
pediatric subjects. In contrast, MAP IS900 genomic DNA was detected in 5 of 19 (26 %) 
pediatric subjects diagnosed with CD (Lee et al., 2011). Despite that MAP IS900 genomic 
DNA did not seem to associate with CD prognosis, it was significantly associated with CD in 
pediatric subjects with significant tropism to the ileal tissues (Lee et al, 2011).  
     Detection of MAP IS900 genomic DNA in a population of subjects, however, might be 
less revealing of the actual MAP infection. A study aimed at detecting viable MAP or MAP 
IS900 DNA in blood of individuals with or without CD and UC demonstrated presence of 
MAP IS900 genomic DNA in all blood samples from patients tested by IS900 PCR and 
confirmed by using the dot blot assay including the controls (Mendoza et al., 2010).  
     Of significance, the cell wall-deficient spheroblast MAP was detected only in blood from 
the CD patients by culturing blood on specific medium (Mendoza et al., 2011). Positive 
cultures were further identified to be negative for the Ziehl-Neelsen stain (Mendoza et al., 
2011) but positive for the phenolic acridine orange fluorescent stain (Smithwick et al., 1995; 
Mendoza et al., 2011). Positive blood cultures of MAP neither correlated with CD-linked 
SNPs (Parish et al., 2009; Mendoza et al., 2010) nor with the use of immunosuppressive 
drugs against CD (Mendoza et al., 2010). 
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     A striking finding was reported by Sing and coworkers (2008). In this report MAP was 
cultured positive from four stool samples out of five CD-diagnosed shepherds who cared for 
goat herds infected with JD.  ELISA using indigenous MAP 'bison type' genotype of goat 
origin was positive on sera of all CD-diagnosed shepherds. Curiously enough, in the same 
study, Ziehl-Neelsen staining was positive on eight normally healthy individuals who have 
regular contact with MAP-infected goat herds (Sing et al., 2008). 
     On the other hand, research done at Johns Hopkins University examined prevalence of 
MAP in blood of 130 CD subjects and 130 controls (Parrish et al., 2009). All CD subjects 
had high rate of SNPs in their NOD-2 and CARD-15, indicating a direct association with CD. 
Only one individual of the CD subjects’ blood samples was cultured positive for MAP 
(Parrish et al., 2009). 
     Considerable evidence suggests that MAP is present in the gut of individuals inflicted 
with CD (Sing et al., 2008; Mendoza et al., 2010; Lee et al., 2011). As yet, the actual role of 
MAP in the pathogenesis of CD remains poorly understood. Research to unveil whether 
MAP is an incidental opportunistic pathogen that proliferates in immunocompromised gut of 
CD individuals or otherwise a malicious pathogen of the human gastrointestinal tract is 
warranted.       
2.4.8.1.2 Ulcerative Colitis (UC) 
     Typically, UC thought to be a Th2-driven colon inflammation that involves upregulation 
of IL-4 and IL-13 cytokines (Bouma and Strober, 2003). It has been shown that IL-13 
induces apoptosis of IEC and dissociation of IEC tight junction. This damaging effect of IL-
13 is believed to be mediated through the TNF-like weak inducer of apoptosis (TWEAK) 
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and its receptor Fn14 (Kawashima et al., 2011). Also, aggravation of the UC symptoms by 
Th17-type responses has been implicated in the pathogenesis of UC (Kobayashi et al., 2008). 
2.4.9 Interaction of Mycobacterium avium subspecies paratuberculosis with probiotics 
     Van Brandt and colleagues (2011) studied the survival of MAP in yoghurt and 
commercially fermented milk containing probiotic bacteria. For this purpose, whole and 
skimmed milk was pasteurized by using the UHT method, inoculated with MAP, and used to 
produce yoghurt and fermented milk. Subsequently, yoghurt and fermented milk were stored 
at 6o C for 6 weeks. During the incubation period, MAP growth was monitored frequently by 
using conventional culture method. It was unveiled that the fat content or type of probiotic 
starter culture did not significantly alter MAP growth in yoghurt. Of significance, MAP 
prevalence in fermented milk was lowered by 1.2 to 3.8 log10, depending on the probiotic 
starter in the fermented milk and the strain of MAP inoculum (Van Brandt et al., 2011). 
     Rhodococcus maris, previously known as Flavobacterium maris, is a member of the 
mycolic acid-containing bacteria such as the Mycobacterium, Rhodococcus, 
Corynebacterium, and Nocardia genera (Nesterenko et al., 1982). Based on 16S sequencing 
of the ribosomal DNA, Rainey et al (1995) suggested that Rhodococcus maris must be 
reclassified as the new genus Dietzia with the species maris. 
     Dietzia subspecies 79793-74, however, was isolated as Mycobacterium gordonae from the 
fecal matter of dairy cow that was diagnosed positive by using the culture and ELISA 
modalities (Richards, 1989). Based on 16S rRNA sequencing data, M. gordonae was 
reclassified as Dietzia.   
     Dietzia subspecies 79793-74 has been shown to cure JD in different breeds of 48 dairy 
cattle (Click and Van Campen, 2010). During the life time of the animal, close monitoring of 
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the seroprevalence of MAP coupled with fecal culture demonstrated that decreased MAP 
shedding relative to that of 22 JD-infected control cows used in the study. Also, longevity of 
Dietzia-treated cows was enhanced and correlated positively with the initial MAP-specific 
antibodies. In addition, the cured animals were only those that were given the probiotic 
Dietzia. The mechanism by which Dietzia subspecies 79793-74 inhibits MAP growth in vivo 
calls for further immunobiological elucidation.           
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ABSTRACT 
     We evaluated tolerance to and effects of varying doses of viable and heat-killed 
Lactobacillus acidophilus strain NP51 fed to specific pathogen-free Balb/c mice on their 
immune responses and intestinal histopathology. We hypothesized that feeding the probiotic 
NP51 would enhance innate immunity of Balb/c mice in a dose-dependent manner without 
inducing intestinal injury. Thus, Balb/c mice were randomized to treatment groups to 
consume either the viable or heat-killed NP51 (VNP51 or HNP51, respectively). VNP51 or 
HNP51 were fed at 104, 105, or 106 CFU·mouse-1·day-1 for 6 weeks along with the sterile 
normal mouse chow until the end of the study. On day 45, ten mice from each group were 
euthanized. Small intestinal tissues were excised and stained with E&H and examined for 
histopathological tissue injury. Spleens were dissected and used in splenocyte in vitro 
cultures that were either nonstimulated or stimulated with concanavalin A and examined for 
proliferation of T lymphocyte subpopulations and intracellular cytokine secretion pattern. 
Overall, feeding the VNP51 or HNP51 to specific-pathogen free Balb/c mice at 104, 105, or 
106 CFU·mice-1·day-1 did not perturb the intestinal histology. Most importantly, feeding 
VNP51 or HNP51 expanded CD4+CD25+ and CD4+CD25+ T reg cells and induced CD8α+ 
immune cells-secreting IL-12, IFN-γ, and TNF-α in a dose-dependent manner. These data 
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suggest that feeding either the VNP51 or HNP51 up to 106 CFU·mice-1·day-1 is well tolerable 
by Balb/c mice and induce CD8+-oriented immunity.  
Key words: PROBIOTICS, NP51, BALB/C MICE. 
INTRODUCTION 
      Probiotic bacteria members of the gut microbiota prevent pathogen colonization of the 
gut.  Probiotic Lactobacilli and Bifidobacterium fed to immunocompetent and 
immunodeficient human microbiota-associated mouse model in Balb/c mice challenged with 
either Campylobacter jejuni or Salmonella enterica completely prevented C. jejuni 
colonization and significantly decreased S. enterica numbers in their intestines (Wagener et 
al., 2009). Lactobacilli prevented Salmonella enterica-induced immunosuppression in 
immunocompetent Balb/c mice by repressing activation of caspase 3 and 7 of the B and T 
lymphocytes and preventing induction of immune cells apoptosis (Wagner et al., 2009).  
     Additionally, Lactobacillus paracasei fed at 109 CFU for one month increased body 
weight gain by 50% and decreased intestinal inflammation in Rag2-/- murine model of 
inflammatory bowel disease as revealed by the significant decrease of the neutrophils 
infiltration and secretion of IL-1ß, IL-6, and IL-12 in the colon (Oliveira, et al., 2011).  
     Probiotic lactobacilli decrease intestinal inflammation via inhibition of CXCL-8 
production by intestinal cells and increase of glutathione production by hepatocytes (Arribas 
et al., 2011) suggesting that oral probiotic immune modification is not limited to the GALT.  
     These probiotic strain-dependent immune effects are attributed to unique interaction 
between the probiotics-associated molecular patterns (PAMPs) and pattern recognition 
receptors (PRRs) on DC (Mazzoni and Segal, 2004). Specificity of DC-probiotic interaction 
is mediated by the affinity of the DC-specific intracellular adhesion molecule-3 (ICAM-3)-
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grabbing nonintegrin (DC-SIGN) on DC to interact with certain probiotic bacteria (Smits et 
al., 2005).  
     Probiotic lactobacillus rhamnosus LcR35 programmed DC maturation in a dose-
dependent manner. At high dose, LcR35 upregulated DC expression of CD86 (B7.2), CD83, 
HLA-DR, and TLR-4. Alternatively, DC-SIGN (mediates DC rolling and adhesion to 
endothelium) and CD14 (lipopolysaccharide-binding protein) expression was downregulated 
(Evrard et al., 2011), suggesting enlisting of DC to recognize certain bacterial strains. 
Subsequently, mature DC dictates the type of the ensuing immune response via secreting 
distinct cytokine profile depending on the DC phenotype (Mazzoni and Segal, 2004). Factors 
that destined DC to specific immune phenotype include the DC maturation-inducing 
stimulus, cytokines and chemokines dominate the microenvironment, and lineage of DC 
(Mazzoni and Segal, 2004).    
     In support of Mazzoni and Segal (2004) findings, treating immature DC with different 
strains of probiotics caused a dose-dependent alteration of their IL-10/IL-12p70 secretion. 
Lactobacillus salivarius Ls-33 and Bifidobacterium infantis 35624 predominantly 
programmed DC to secrete IL-10, an antiinflammatory cytokine with pleiotropic effects. On 
the other hand, probiotic Lactobacillus acidophilus NCFM and the probiotic cocktail VSL#3 
selectively induced secretion of IL-12p70, a proinflammatory cytokine.  Escherichia coli 
Nissle 1917, however, equally provoked IL-10 and IL-12p70 secretion by DC (Gad et al., 
2011). 
     We hypothesized that feeding either the heat-killed or viable Lactobacillus acidophilus 
strain NP51 to specific pathogen-free Balb/c mice would differentially modulate their 
immune response in a dose-dependent manner. Our objective was to examine the intestinal 
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tolerance and immune response of Balb/c mice to various concentrations of viable and heat-
killed NP51. 
MATERIALS AND METHODS 
 
Experimental Design. 
     Eighty pathogen-free, 6-week-old Balb/c mice (Jackson Laboratories) were randomly 
assigned to eight treatment groups that included four major groups (Table 1). Group 1 was 
fed the sterile chow meal. Group II was fed the maltodextrin (MDX) carrier at 3% of their 
chow meal. Group III was fed the heat-killed NP51 (HNP51) at 104, 105, or 106 CFU·mouse-
1
·day-1. Group IV was fed the viable NP51 (VNP51) at 104, 105, or 106 CFU·mouse-1·day-1 
for 45 days. 
Table 1. Designation of treatment groups. 
 Treatment groups 
 
Group 
 
I 
 
II 
 
III 
 
IV 
Probiotic Cntrol MDX 
 
HNP51 
 
VNP51 
 
Dose 0 3%  104 105 106 104 105 106 
No. of 
mice 
10 10 10 10 10 10 10 10 
Cntrl: Control mice fed the regular sterile regular chow diet. MDX: maltodextrin (carrier for HNP51 and the 
VNP51). HNP51 and VNP51: heat-killed and viable Lactobacillus acidophilus strain NP51®.  
 
     Mice were housed in a BSL-2 rodent room in the animal facility of the Iowa State 
University.  The environment within the room was maintained to provide a temperature of 
22.2O C, a relative humidity of 35-45%, and 12 h light/dark cycle. Mice were housed in 
autoclaved standard mice cages fitted with raised-wire floors and High Efficiency Particulate 
Air (HEPA) filters.  
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     Mice were offered ad libitum sterile water, but fed restricted amount of chow meal 
(Harlan Laboratories) throughout the study. Mice were adapted to the sterile chow meal for 
one week prior to the addition of the probiotic HNNP51 or VNP51 to the chow diet. Either 
the HNP51 or VNP51 was fed at 1× 104, 1 × 105, or 1× 106 CFU·mouse-1·day-1 contained in 
3.0 g of the chow meal. To prepare the HNP51, VNP51 was incubated in a preheated oven at 
85o C for 15 minutes. The offering of chow meal was increased by 0.5 g chow·mouse-1 every 
15 days until it reached a maximum of 4.0 g of chow·mouse-1·day-1 by day 30 of the study. 
Mice continued to be offered 4.0 g until the end of the study on day 45. The experiment was 
conducted in accordance with guidelines established by the Iowa State University 
Institutional Animal and Care Use Committee. 
Sampling and Analyses 
     On day 45 of the study, 10 mice from each treatment group were euthanized. Spleens 
were dissected and used for splenocyte single-cell suspension preparation. Splenocytes were 
cultured in vitro in 48-well plates at 2 × 106 cells per mL in RPMI 1640 (Invitrogen, 
Carlsbad, CA) plus 10% heat-inactivated FCS (Fisher Scientific, Hanover Park, IL) and 1% 
antibiotic/antimycotic (Invitrogen, Carlsbad, NM). Splenocytes in vitro cultures were either 
nonstimulated or stimulated with concanavalin A (ConA) (Sigma-Aldrich, St. Louis, MO) at 
3 µg/mL.  
     Following stimulation with ConA, splenocyte cultures were incubated at 370 C and 5% 
CO2 for 72 hours. The pelleted splenocytes were washed twice with cold sterile PBS and 
stained for the surface markers CD4 (anti-mouse CD PerCP-Cy5.5, eBioscience, San Diego, 
CA), CD8α (anti-mouse CD8α APC, eBioscience, San Diego, CA), and CD25 (anti-mouse 
CD25 phycoerythrin; PE, eBioscience, San Diego, CA).  
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     Subsequently, frequencies of these T cell subpopulations were determined by using the 
Fluorescence-Activated Cell Sorter (BD Facsaria II; Becton Dickson Biosciences, Franklin 
Lakes, NJ). Data were analyzed by using the FlowJo software (Tree Star Inc., Ashland, OR) 
for IFN-γ, TNF-α, IL-2, IL-4, and IL-10 concentrations. 
     To examine tolerance of Balb/c mice to the HNP51 and VNP51, we examined the 
histological architecture of the small intestine. Briefly, the whole duodenum, jejunum, and 
ileum were fixed in 10% formaldehyde, stained with hematoxylin and eosin (H&E), and 
imbedded in paraffin. Subsequently, 4 µm sections were examined under the microscope by a 
histopathologist to determine effects of feeding the HNP51 or VNP51 on the crypt and villus 
areas and the villus area: crypt area ratio. 
     Also, upon euthanizing mice, we withdraw 0.9 mL of blood by cardiac puncture and used 
it to isolate blood serum. Briefly, blood in eppendorf tubes was kept at 4o C overnight to clot. 
Blood was then spun in eppendorf centrifuge at 5000 rpm for 15 minute. Subsequently, 
serum was pipetted out in a another sterile eppendorf tube and stored at -20o C until analyzed 
for IgG2a and IgG1 using commercially available kit (Kamiya Biomedical, Seattle, WA).   
Statistical Analyses 
 
     A linear mixed-effects model was fit to the data for each response variable by using the 
PROC MIXED procedure of the Statistical Analysis System (SAS; SAS Institute Inc., Cary, 
North Carolina, USA) version 9.2. Each linear mixed-effects model included random cage 
effect and fixed effects for probiotic dose, stimulation of cells, and their interactions. The 
standard errors of the means were reported and the pairwise differences among the estimated 
means were considered significant when the probability (P) value was ≤ 0.05. Tendency for a 
trend was declared when 0.05 ≤ P ≤ 0.1.  
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RESULTS 
Surface Markers and Intracellular Cytokines Staining 
     CD4+ T helper cells.  On the whole, feeding either the VNP51 or HNP51 at different 
doses to pathogen-free Balb/c mice did not significantly (P = 0.13; Figure 1A) change CD4+ 
T helper cells frequency. On the contrary, the effects of the stimulation with ConA and its 
interaction with VNP51 and HNP51 feeding (treatment) were significant (P = 0.0001 and P = 
0.04,  
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Figure 1. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their splenic 
CD4+ T helper cell and CD4+CD25+ T reg proliferation and CD4+ T helper cells 
intracellular cytokine secretion. Panel A. CD4+ T helper cell proliferation. Panel B. 
CD4+CD25+ T reg cell proliferation. Panel C. CD4+ T helper cell-secreting IL-2.   Panel 
D. CD4+ T helper cell-secreting IL-4. Panel E. CD4+ T helper cell-secreting IL-10. Panel 
F. CD4+ T helper cell-secreting IL-12. Panel G. CD4+ T helper cell-secreting IFN-γ. 
Panel C. CD4+ T helper cell-secreting TNF-α. Data are mean ± SEM. (*) indicates 
significant difference at P ≤ 0.05; (#) indicates tendency for a significant difference at 
0.05 < P ≤ 0.10; NS, nonstimulated in vitro splenocyte cultures; ConA, concanavalin A-
stimulated in vitro splenocyte cultures.  
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respectively; Figure 1A).  In particular, feeding either the VNP51 or the HNP51 at differing 
dosages did not significantly (P ≥ 0.49) alter frequency of CD4+ T helper cells in the in vitro 
nonstimulated splenocyte cultures (Figure 1A). When the splenocytes cultures were 
stimulated  
with ConA mitogen, feeding either VNP51 or the HNP51 at 104 CFU appreciably (P = 0.04 
and P = 0.03, respectively) increased CD4+ T helper cells proliferation (Figure 1A). Also, 
HNP51 fed at 106 CFU tended (P = 0.09) to increase CD4+ T helper cells proliferation 
(Figure 1A). 
     CD4+CD25+ T reg cells. Overall, feeding the VNP51 and HNP51 to Balb/c mice and 
stimulation with ConA had significant (P = 0.0005 and P = 0.0001) effects on CD4+CD25+ T 
reg cells proliferation (Figure 1B). Precisely, feeding the HNP51 at 104 or 105 CFU 
significantly (P = 0.004 and P = 0.0007; Figure 1B) increased CD4+CD25+ T reg cells 
repertoire. On the other hand, feeding the HNP51 at 106 or feeding the VNP51 at different 
doses did not appreciably (P ≥ 0.14) modify CD4+CD25+ T reg cells repertoire (Figure 1B). 
     CD4+ T helper cells intracellular cytokine secretion. Examination of the intracellular 
cytokines secretion by CD4+ T helper cells from splenocytes of Balb/c mice stimulated with 
ConA revealed no significant (P ≥ 0.32, P ≥ 0.35,  P ≥ 0.22, P ≥ 0.28, and P ≥ 0.21), effect 
of VNP51 or HNP51 feeding on number of IL-2-, IL-4-, IL-10-, IFN-γ-, and TNF-α-secreting 
CD4+ T helper cell repertoire, respectively, (Figures 1C, D, E, G, and H).  In contrast, 
feeding HNP51 at 105 CFU tended (P = 0.10) to increase IL-12-secreting CD4+ T helper cells 
(Figure 1F). Repertoire of IL-12-secreting CD4+ T helper cells, however, was not altered by 
feeding the VNP51 at any doses (P ≥ 0.31) or by feeding the HNP51 at 104 or 105 CFU (P ≥ 
0.33; Figure 1F).  
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Figure 2. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their splenic 
CD8α+ immune cells and CD8α+CD25+ T reg cell proliferation and CD8α+ immune cells 
intracellular cytokine secretion. Panel A. CD8α+ immune cells proliferation. Panel B. 
CD8α+CD25+ T reg cell proliferation. Panel C. CD8α+ immune cells-secreting IL-2.   
Panel D. CD8α+ immune cells-secreting IL-4. Panel E. CD8α+ immune cells-secreting 
IL-10. Panel F. CD8α+ immune cells-secreting IL-12. Panel G. CD8α+ immune cells-
secreting IFN-γ. Panel C. CD8α+ immune cells-secreting TNF-α. Data are mean ± SEM. 
(*) indicates significant difference at P ≤ 0.05; (#) indicates tendency for a significant 
difference at 0.05 < P ≤ 0.10; NS, nonstimulated in vitro splenocyte cultures; ConA, 
concanavalin A-stimulated in vitro splenocyte cultures.  
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     CD8α+ immune cells. Overall, there was no significant (P = 42) VNP51 or HNP51 
treatment effect. ConA stimulation, however, exerted significant (P = 0.0001) effect.  On 
contrast, the interaction of treatment by ConA stimulation effect was not significant (P = 
0.67; Figure 2A).     Feeding the MDX to Balb/c mice tended (P = 0.07) to decrease CD8α+ 
immune cells repertoire in their splenocyte cultures relative to that of control mice fed the 
chow diet only (Figure 2A). But VNP51 or HNP51 did not significantly (P ≥ 0.33) change 
CD8α+ immune cells repertoire in comparison with that of the MDX-fed control mice 
nonstimulated in vitro splenocyte culture (Figure 2A). Of note worthy, feeding the VNP51 or 
the HNP51 at different dosages to Balb/c mice did not significantly (P ≥ 0.22; Figure 2A) 
alter CD8α+ immune cells repertoire in their in vitro ConA-stimulated splenocyte cultures 
relative to that of the MDX-fed control mice. 
     CD8α+CD25+ T reg cells.  Generally, feeding the VNP51 or the HNP51 to Balb/c mice 
did not significantly (P = 0.21) change the CD8α+CD25+ T reg cell repertoire. Stimulation 
with ConA exerted significant (P = 0.0001) effect. In particular, feeding the HNP51 at 104 
CFU tended (P = 0.08) to increase and at 105 CFU significantly (P = 0.01) increased 
CD8α+CD25+    T reg cell repertoire (Figure 2B). Intriguingly, feeding the HNP51 at 106 
CFU did not (P = 0.48) expand CD8α+CD25+ T reg cells repertoire (Figure 2B). Also, 
feeding the VNP51 at any dose did not significantly (P ≥ 0.27) change CD8α+CD25+ T reg 
cell repertoire in the nonstimulated or ConA-stimulated splenocyte in vitro cultures (Figure 
2B). 
     CD8α+ immune cells intracellular cytokine secretion.  Feeding the VNP51 or the HNP51 
to Balb/c mice did not significantly (P ≥ 0.16, P ≥ 0.17, and P ≥ 0.24) change IL-2-, IL-4-, 
and IL-10-secreting CD8α+ immune cells repertoire, respectively, in the nonstimulated or 
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ConA-stimulated in vitro cultures (Figure 2C, D, and E). Importantly, in the nonstimulated in 
vitro cultures, feeding VNP51 at 106 CFU or HNP51 at 104 or 105 CFU to Balb/c mice 
tended (P ≤ 0.09) to expand IL-12-secreting CD8α+ immune cells repertoire (Figure 2F).  
Note worthy, increasing HNP51 feeding dose to 106 CFU dramatically (P = 0.04) expanded 
IL-12-secreting CD8α+ immune cells repertoire compared with that of the MDX-fed control 
mice (Figure 2F). On the contrary, stimulation of the cultures with ConA did not significantly 
(P ≥ 0.18) modify IL-12-secreting CD8α+ immune cells (Figure 2F). 
     In addition, intracellular IL-12 secretion was substantially (P = 0.02 and P = 0.03) 
enlarged in the CD8α+ immune cells of Balb/c mice fed the VNP51 or the HNP51 at 106 and 
105 CFU, respectively, compared with that of  MDX-fed control (Figure 2F). Similarly, 
HNP51 fed at 106 CFU tended (P = 0.06) to enhance IL-12 secretion in the CD8α+ immune 
cells in in vitro cultures of Balb/c mice fed the HNP51 at 106 CFU (Figure 2F). 
     Of note worthy, feeding the VNP51 at 106 CFU coupled with ConA stimulation 
substantially (P = 0.04 and P = 0.01) increased intracellular production of IFN-γ and TNF-α, 
respectively, by the CD8α+ immune cells of Balb/c mice relative to that of MDX-fed mice 
(Figures 2G and H). Feeding the VNP51 or the HNP51 at 104 or 105 CFU did not (P ≥ 0.54 
and P ≥ 0.24) appear to cause changes in the intracellular secretion of IFN-γ or TNF-α by the 
CD8α+ immune cells when stimulated with ConA and compared to that of the MDX-fed 
control mice (Figure 2G and H).  
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Figure 3. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their splenic 
T cells intracellular cytokine secretion. Panel A. T cells-secreting IL-2. Panel B. T cells-
secreting-secreting IL-4. Panel C. T cells -secreting-secreting IL-10. Panel D. T cells-
secreting-secreting IL-12. Panel E. T cells-secreting -secreting IFN-γ. Panel F. T cells-
secreting-secreting TNF-α. Data are mean ± SEM. (*) indicates significant difference at 
P ≤ 0.05; (#) indicates tendency for a significant difference at 0.05 < P ≤ 0.10; NS, 
nonstimulated in vitro splenocyte cultures; ConA, concanavalin A-stimulated in vitro 
splenocyte cultures.  
     Splenic immune cells intracellular cytokine secretion. It was obvious that VNP51 or 
HNP51 fed to specific pathogen-free Balb/c mice did not significantly (P ≥ 0.29, P ≥ 0. 0.27, 
P ≥ 0.20, and P ≥ 0.13) alter their splenic T cells secretion of IL-2, IL-10, IFN-γ, or TNF-α, 
respectively (Figures 3 A, C, E, and F) relative to secretion by splenic T cells from MDX-fed 
mice. Of importance, feeding the HNP51 at 105 CFU to Balb/c mice tended (P = 0.07) to 
increase IL-4 secretion by their splenic T cell when stimulated with ConA (Figure 3B). Note 
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worthy, HNP51, not VNP51 (P ≥ 0.13), fed at 104 CFU tended (P = 0.07) to increase IL-12 
secretion by splenic T cells and at 105 CFU it increased it significantly (P = 0.03) higher than 
that of the MDX-fed control mice when stimulated with ConA (Figure 3D).  
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Figure 4. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their 
intestinal histological structure and spleen cellularity. Panel A. Effect on crypt length.  
Panel B. Effect on villus height. Panel C. Effect on crypt to villus ratio. Data are mean ± 
SEM. Panel D. Effect on spleen cellularity. (*) indicates significant difference at P ≤ 
0.05; (#) indicates tendency for a significant difference at 0.05 < P ≤ 0.10. 
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     Histopathological effects of VNP51 and HNP51. Compared to specific pathogen-free 
Balb/c mice fed the chow diet only, feeding the MDX carrier at 3% of the chow significantly 
(P = 0.01; Figure 4A) decreased the crypt length of the intestine (Figure 4A). Subsequent 
inclusion of VNP51 or the HNP51 at 104, 105, or 106 CFU did not significantly (P ≥ 0.15) 
decrease the length of crypt relative to that of the MDX-fed control mice (Figure 4A). In 
addition, feeding the VNP51 or the HNP51 at 104, 105, or 106 CFU to pathogen-free Balb/c 
mice did not significantly (P ≥ 0.18) affect the villus height in their small intestines 
compared to the noise of the MDX-fed control or the chow-fed control (Figure 4B). 
Subsequently, the ratio of the crypt to villus was not significantly (P ≥ 0.26; Figure 4C) 
altered by the VNP51 or the HNP51 feeding compared with that of the MDX-fed control or 
the chow-fed control.  
     Feeding the VNP51 at different dosages did not significantly (P ≥ 0.15) alter the 
cellularity of the spleen. On the contrary, HNP51 fed at 104 and 106 CFU tended to increase 
spleen cellularity by day 45 compared with that of the MDX-fed group (Figure 4D). 
DISCUSSION 
     VNP51- and HNP51-induced modulation of CD4+ T helper cell repertoire was dose-
dependent (Figure 1A). Both VNP51 and HNP51 fed at 104 CFU·mouse-1·day-1 significantly 
expanded CD4+ T helper cells repertoire. Increasing the VNP51 and HNP51 concentrations 
to 105 CFU abrogated CD4+ T helper cells expansion. But HNP51 at 106 CFU, not VNP51, 
tended to restore CD4+ T helper cells expansion (Figure 1A). This finding agree with finding 
of  Mane et al (2011) that Lactobacillus plantarum CECT 3715 and CECT 3716 at low dose 
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induce proliferation of  CD4+ T helper and this immune response is abolished at higher dose 
in human subjects.  
     Feeding the VNP51 or HNP51 per se enlarged IL-12-secreting CD8α+ immune cells 
repertoire in the nonstimulated in vitro cultures, suggesting activation of CD8α+ DC 
(Mashayekhi et al., 2011; Figure 2F). Intriguingly, stimulation with ConA ablated effect of 
VNP51 and HNP51 on IL-12-secreting CD8α+ immune cells (Figure 2F), but expanded IFN-
γ- and TNF-α-secreting CD8α+ immune cells repertoire (Figures 2G and H). Unlike 
plasmacytoide DC, conventional DC includes CD8α+ and CD8α- subsets. CD8α+ DC is 
efficient at presenting exogenous antigenic peptides on MHC class 1 to activate CD8+ 
cytotoxic T cells (Schnorre et al., 2006), but is less efficient at presenting antigenic peptide 
on MHC class II to activate CD4+ T helper cells (Kamphorst et al., 2010). We are lured to 
speculate that the source of IFN-γ and TNF-α stimulated by ConA is likely CD8α+ cytotoxic 
and NK cells. 
      Probiotic Lactobacillus salivarius CECT5713 and Lactobacillus fermentum CECT5716 
co-cultured at 105, 106, or 107 CFU/mL with human PMNs activated CD8+ CD56+ NK cells 
and CD8+ T cells as revealed by the high expression of CD69 and CD25. Subsequently, 
probiotics-activated CD8+ NK and T cells secreted high concentrations of TNF-α (Perez-
Cano et al., 2010). Similar to our findings, Lactobacillus salivarius CECT5713 
and Lactobacillus fermentum CECT5716 did not seem to fully activate CD4+ T helper cells 
(Perez-Cano et al., 2010). Additionally, in splenocytes cultures, probiotic Lactobacillus casei 
induced IL-12 production by CD11b expressing cells (Chiba et al., 2010). CD11b has been 
suggested a unique marker for activated CD8+ cytotoxic T cells (Christensen et al., 2001). 
124 
 
 
 
Recently, Gad and colleagues (2011) showed that treating immature DC, with different 
strains of probiotics causes a dose-dependent alteration of their IL-10/IL-12p70 secretion. In 
agreement with our findings, Lactobacillus acidophilus strain NCFM and the probiotic 
cocktail VSL#3 at high dose destined DC to predominantly secrete IL-12 (Drakes et al., 
2004). Signaling of IL-12 through STAT-4 promotes differentiation of naïve T cells into Th1 
and CD8+ cytotoxic T cells lineages (Ely et al., 1999; Rao et al., 2010). Subsequently, DC-
activated T cell secretes TNF-α, IFN-γ, and IL17 depending on the T cell lineage involved 
(Neurath, 2007).  Thus, it is evident that the IL-12-secreting CD8α+ immune cells repertoire 
that was significantly expanded in the nonstimulated in vitro cultures by VNP51 and HNP51 
feeding were mainly splenic CD8α+ DC (Figure 2F). In contrast, IFN-γ- and TNF-α-secreting 
CD8α+ immune cell repertoire that was enlarged by HNP51 feeding and ConA stimulation 
was mainly CD8α+ NK and cytotoxic T cells (Figure 2F). It is highly possible that IL-12 
secreted by CD8α+ DC activated secretion of both IFN-γ and TNF-α by NK cells (Jewett et 
al., 1996) and CD8α+ cytotoxic T cells (Denton et al., 2011). Notably, feeding the VNP51 or 
HNP51 did not expand the IFN-γ- and TNF-α-secreting CD4+ T helper cells (Figures 1G and 
H), suggesting that Th1 cells were not induced by VNP51 and HNP51 feeding. 
    Thus, our findings support other laboratories findings that probiotic Lactobacilli accelerate 
the adaptive immunity via accelerating the innate immunity (Neurath, 2007; Gad et al., 2011; 
Evrard et al., 2011). We are tempted to speculate that VNP51 and HNP51 stimulate CD8α+ 
DC maturation as seen by the upregulated secretion of IL-12 in the nonstimulated in vitro 
cell cultures. Differentially, under ConA stimulation, HNP51 induces CD8α+ cytotoxic and 
NK cell expansion (Figure 2F) and upregulation of their IFN-γ and TNF-α secretion.  
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    Typically, induction of TNF-α has been linked to induction of mucosal inflammation and 
tissue damage (Nenci et al., 2007). Recent evidence, however, has shown that probiotics 
VSL#3-induced TNF-α is pivotal for maintaining gut health and permeability. On the 
contrary, mucosal TNF-α deficiency is implicated in the pathogenesis of the inflammatory 
bowel disease (Pagnini et al., 2010).  
     We observed that VNP51 fed to mice increased their CD8α+CD25+ T reg cells when their 
splenocytes were stimulated with ConA (Figure 2B). In line with our findings, stimulation of 
human PMNs with probiotic Lactobacillus casei Shirota promoted expansion of 
CD8α+CD25+ T reg cells and 56+ NK (Dong et al., 2010).     
     Feeding VNP51 or HNP51 to Balb/c mice at 106 CFU·day-1 (6,000 times higher than the 
dose typically prescribed for human expressed per kg of body weight) had no adverse effect 
on intestinal mucosa (Figure 4A, B and C). This finding lend support to similar findings by 
Lara-Villoslada and coworkers (2007) that feeding probiotic Lactobacillus salivarius 
CECT5713 at 1010 CFU daily is not pathogenic to Balb/c mice. 
CONCLUSIONS 
     We concluded that Lactobacillus acidophilus NP51 fed at 104. 105, or 106 CFU·mouse-
1
·day-1 is not pathogenic to healthy, specific pathogen-free Balb/c mice and is well tolerated. 
Also, NP51 program splenic DC to secrete IL-12, however, CD8α+ cytotoxic T and NK cell- 
and NK T cell-secreting IFN-γ and TNF-α are upregulated only after additional stimulation 
with a mitogen, suggesting that NP51 induce a Th1-like immune response in context of an 
infection .       
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CHAPTER 4. THE PROBIOTIC LACTOBACILLUS ACIDOPHILUS 
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ABSTRACT 
     We examined the immunologic effects of feeding the probiotic Lactobacillus acidophilus 
strain NP51® to Balb/c mice infected with Mycobacterium avium subspecies 
paratuberculosis (MAP) as the murine model of Johne’s disease. We hypothesized that 
feeding the probiotic NP51 would induce the adaptive immunity to prevent development of 
MAP infection in mice. Specific pathogen-free Balb/c mice were randomized to treatment 
groups with mice either fed the viable or heat-killed NP51 (VNP51 or HNP51, respectively) 
at 1 × 106 CFU· mice-1 ·  day-1 along with normal mouse chow until the end of the study. On 
day 45, mice were challenged with 1 × 108 CFU of heat-killed or a viable MAP (VMAP or 
HMAP, respectively) injected intraperitonealy. Ten mice from each group were euthanized 
on days 45, 90, 135, and 180. At each sampling period, tissues were excised from mice and 
cultured for MAP. Also, the fecal pellets were collected and examined for the presence of 
MAP IS900 genomic DNA. Overall, feeding the HNP51 or VNP51 to mice significantly 
increased the cellular density of the spleens of mice infected with VMAP and decreased the 
acid-fast bacilli numbers in their livers. Most importantly, burden of VMAP was decreased in 
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the mesenteric lymph nodes, livers, ceca, and spleens of mice fed either HNP51 or VNP51 
compared with the HMAP- and VMAP-infected controls on days 135 and 180. These results 
suggest that feeding probiotic NP51 modifies the immune responses favorably and prevents 
progression of MAP infection in Balb/c in mice.  
Key words: MAP, NP51, Johne’s disease. 
INTRODUCTION 
     Johne’s disease (JD) is a chronic granulomatous enteritis of domestic and wild ruminants. 
The etiologic agent of JD, Mycobacterium avium subspecies paratuberculosis (MAP), is a 
mycobactin J-dependent, acid-fast mycobacterial species that multiplies inside macrophages 
of the host (Momotani et al., 1988; Sweeney, 1996). It is well established that neonatal calves 
acquire JD soon after birth through the ingestion of MAP-contaminated colostrum or milk 
(Streeter et al., 1995). Significant transmission of MAP infection, however, occurs through 
consumption of MAP-contaminated colostrum rather than milk (Nielsen et al., 2008). Indeed, 
pasteurization of colostrum significantly decreases MAP infection in newborn calves (Stabel, 
2008). In addition to peripartal infection, congenital infection with JD has been reported 
(Koets, 2006) and about 9% of neonatal calves could acquire MAP infection when JD 
prevails in 40% of the herd (Whittington and Windsor, 2009). Adult cattle are also 
susceptible and yearling cattle can acquire JD after intensive grazing of a MAP-contaminated 
pasture (Fecteau et al., 2010). Introduction of MAP-shedding cattle to the herd results in 
detection of viable MAP on the farm and its surroundings suggesting transmission of MAP in 
bio-aerosols (Eisenberg et al., 2010; 2011).  
     After the infection with MAP is established, MAP remains latent, causing the infected 
cattle to go through protracted subclinical phase that might reach 5 years (Nielsen, 2006). 
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During the subclinical phase, infected cattle have decreased milk production and shed MAP 
intermittently, increasing the intra-herd transmission of the disease. In contrast, clinically 
affected cattle develop chronic, intermittent diarrhea and progressive emaciation that leads to 
death (Chiodini et al., 1984).  
     In 1996, JD prevailed in about 22% of the U.S. dairy herds (NAHMS, 1996), causing an 
annual loss of 225 million U.S. dollars to the dairy industry (Ott et al., 1999). Currently, 68% 
of dairy herds in the U.S. have been declared to be infected with MAP (NAHMS, 2008). 
Thus, we estimate the current annual losses to the U.S. dairy farmers to approach 700 million 
U.S. dollars because of decreased milk production, premature culling, and death of animals 
infected with JD. In addition, valuable genetic traits of high milk production and disease 
resistance can be lost by the premature culling of cows infected with JD (Stabel, 1998).  
     The severity of MAP infection and shedding of MAP in feces could be attenuated by 
vaccination of cattle with either the killed or the live whole cell MAP bacterin (Gwozdz et 
al., 2000; Muskens et al., 2002; Uzonna et al, 2003). Vaccination with either the whole cell 
killed or live MAP bacterin, however, did not prevent the transmission of MAP within the 
herd (Kalis et al., 2001), and it also interfered with the diagnosis of bovine tuberculosis.  
     Recombinant antigen vaccines, which include MAP 85 antigen complex (85A, 85B, 85C), 
superoxide dismutase, and 35 kDa proteins, could enhance host immunity as demonstrated by 
increased lymphocyte proliferation as well as secretion of Th1-associated cytokines including 
interferon gamma (IFN-γ), interleukin-2 (IL-2), IL-12, and tumor necrosis factor alpha 
(TNF-α) in C57BL/6 mice (Park et al., 2008) and calves (Kathaperumal et al., 2008). 
Though MAP burden decreased in livers and spleens of mice vaccinated with antigen 85, the 
increased secretion of the TNF-α and IFN-γ might perpetuate further intestinal tissue 
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destruction and inflammation, thereby exacerbating the ileitis and further comprising nutrient 
absorption in carrier or subclinical animals.  
     In agreement, neutralization of IL-18 decreased the production of colonic IFN-γ in vivo 
and TNF-α in vitro and attenuated the severity of colitis in Balb/c and C57BL/6 mice 
(Siegmund et al., 2001). Similarly, antibiotic-induced amelioration of ileitis in a murine 
model of Crohn’s disease was accompanied by a significant decrease of IFN-γ and TNF-α 
concentrations (Bamias et al., 2002).  
     Indeed, a safer and more efficacious therapeutic for JD is a research priority. Recently, 
Nerstedt and colleagues (2007) showed that feeding Lactobacillus acidophilus to mice 
upregulates genes involved in host defense against pathogens as well as genes that control 
energy homeostasis. Additionally, Lactobacilli administration improved the immunological 
gut barrier via enhancement of germinal center formation and promotion of sIgA secretion. 
Also, feeding Lactobacilli activated phagocytosis by macrophages and alleviated the 
intestinal inflammatory responses (Ibnou-Zekri et al. 2003; Wei et al., 2007).  
     On the basis of previous findings, we hypothesized that pre-feeding the probiotic 
Lactobacillus acidophilus NP51 to Balb/c mice would induce the adaptive immunity to 
prevent later development of MAP infection. To test the hypothesis, we evaluated the effect 
of pre-feeding the viable or heat-killed probiotic NP51 on immune responses of Balb/c mice 
infected with virulent MAP strain. We also examined the effect of pre-feeding the NP51 on 
colonization resistance to MAP in tissues and MAP shedding in feces of infected Balb/c 
mice.   
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MATERIALS AND METHODS 
 
Experimental Design. 
     Pathogen-free, 6-week-old 360 Balb/c mice (Jackson Laboratories) were randomized to 
nine treatment groups in a factorial design that included three major groups (Table 1). Group 
1 was fed the maltodextrin (MDX) carrier at 3% of their chow diet. Group II was fed the 
heat-killed NP51 (HNP51) at 1× 106 CFU·mouse-1·day-1 in MDX as 3% of the diet. Group III 
was fed the viable NP51 (VNP51) at 1× 106 CFU·mouse-1·day-1 in MDX as 3% of the diet.  
Table 1. Designation of treatment groups. 
 Treatment groups 
 
group 
 
I 
 
II 
 
III 
Probiotic MDX 
3% of the diet 
HNP51 
106 CFU·mouse-1·day-1 
VNP51 
106 CFU·mouse-1·day-1 
Code Cntrl HMAP VMAP HNP51 HNP51+HMAP HNP51+VMAP VNP51 VNP51+HMAP VNP51+VMAP 
HMAP ---   --- ---   --- ---   --- 
VMAP --- ---   --- ---   --- ---   
No. of 
mice 
40 40 40 40 40 40 40 40 40 
Cntrl: Control noninfected mice fed the sterile chow diet only. MDX: maltodextrin (carrier 
for VNP51 and HNP51). VNP51 and HNP51: viable and heat-killed NP51, respectively. 
VMAP and HMAP: viable and heat-killed MAP, respectively. 
 
     Group I contained a non-infected control (n = 40) fed chow plus MDX, heat-killed MAP-
infected control (HMAP; n = 40), and viable MAP-infected control (VMAP; n = 40) 
subgroups. Group II included non-infected control (HNP51; n = 40), heat-killed MAP-
infected (HNP51+HMAP; n = 40), and viable MAP-infected (HNP51+VMAP; n = 40) 
subgroups. Group III included non-infected control (VNP51; n = 40), heat-killed MAP-
infected (VNP51+HMAP; n = 40), and viable MAP-infected (VNP51+VMAP; n = 40) 
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subgroups (Table 1). HMAP or VMAP was injected intraperitonealy at 1× 108 CFU·mouse-1 
once on day 45 of the study. Viability of MAP was continuously monitored before injection. 
     Mice were housed in a BSL-2 rodent room in the animal facility of the Iowa State 
University.  
 The environment within the room was maintained to provide a temperature of 22-25O C, a 
relative humidity of 35- 45%, and 12/12 h light/dark cycle. Mice were housed in autoclaved 
standard mice cages fitted with raised-wire floors and high efficiency particulate air (HEPA) 
filters.  
     Mice were offered ad libitum sterile water and chow meal (Harlan Laboratories) 
throughout the study. Mice were adapted to the sterile chow meal for a week prior to the 
addition of NP51. During the adaptation period, mice daily feed intake was precisely 
determined. 
     To ensure complete consumption of the probiotics, mice in the VNP51 or HNP51 
treatment subgroups were fed the NP51 at 1 × 106 CFU·mouse-1·day-1 in 3.0 grams of the 
chow meal. The offering of chow meal was increased by 0.5 g chow·mouse-1 every 15 days 
until it reached a maximum of 5.0 g of chow·mouse-1·day-1 by day 105 of the study. Mice 
continued to be offered 5.0 g until the end of the study. To prepare the HNP51, the viable 
probiotic NP51 was incubated in an oven at 85o C for 15 minutes. Similarly, HMAP was 
prepared by incubating the VMAP in a water bath at 85o C for 20 minutes (Stable, USDA-
ARS-NADC, Ames, IA). The experiment was conducted in accordance with guidelines 
established by Institutional Animal Care and Use Committee at Iowa State University. 
     Inoculation with Mycobacterium avium subspecies paratuberculosis.  MAP inoculum 
was prepared according to Stabel et al (2009). Briefly, 50 mL of sterile oleic acid at 0.60 
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mL·L-1, albumin at 50 g·L-1, dextrose at 20 g·L-1 , catalase at 0.04 g·L-1, and sodium chloride 
at 8.50 g·L-1 (OADC) enrichment were added to 450 mL of sterile Middlebrook broth 7H9 
(PML Microbiology, Wilsonville, OR). Subsequently, 25 mL of a virulent MAP clinical 
isolate of strain 167 grown to the OD540nm = 0.2 (USDA, National Animal Disease Center, 
Ames, IA) were inoculated into the broth.  
     After thoroughly mixing, the VMAP culture was incubated at 37o C and the OD540nm was 
measured weekly.  The bacteria was harvested in the log phase (OD540nm = 0.2-0.4). The 
VMAP culture was decanted into sterile 500 mL Beckman bottles with O-ring caps followed 
by centrifugation at 1000 x g for 30 minutes in the refrigerated Beckman J2-21 centrifuge 
using the JA-10 rotor. The supernatant was decanted and the VMAP pellets were washed 
twice by suspension in 500 mL of sterile, cold PBS (pH = 7.2). Subsequently, VMAP 
suspension was centrifuged for 30 minutes and the supernatant discarded. The formed 
VMAP pellets were re-suspended in 5 mL of cold sterile phosphate buffered saline (PBS; 
0.14 M NaCl, 0.003 M KCL, 0.01 M Na2 HPO4, and 0.0018 M KH2PO4; pH 7.4) and placed 
on ice. The OD540 was measured to verify the initial concentration of the bacteria. Then, the 
PBS was used to adjust the concentration to 109 CFU/mL as determined by OD540 (OD540nm = 
1.0-1.2 absorbance units). To prepare the HMAP, VMAP suspension was heated in a water 
bath at 85o C for 20 minutes, then cooled to room temperature, and kept on ice until used for 
inoculating mice. 
     On day 45 of the study, mice were challenged intraperitonealy with 1 × 108 CFU of the 
virulent clinical isolate 167 as either HMAP or VMAP suspended in 100 µL of sterile PBS.  
Control groups received 100 µL of sterile PBS. Following inoculation with MAP, 10 mice 
from each treatment group were euthanized on days 45, 90, 135, and 180 of the study.  
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     Microbiological quantification of tissue VMAP burden:      
     To quantify VMAP burden in tissues, tissue homogenates were cultured on Herrold’s 
Egg-yolk Agar with mycobactin J, amphotricin, nalidixic acid, and vancomycin (Stabel and 
Osman USDA-ARS-NADC), Briefly, weighed mouse tissues was added to half strength 
Brain Heart Infusion Broth containing 0.75% hexadecylpyridinium chloride monohydrate 
(Sigma-Aldrich, St. Louis, MO) in a whirl bag and stomached for two minutes. The 
stomached samples were then incubated in 15-mL graduated tube for 3 hours to 
decontaminate. Following the incubation, the samples were centrifuged at 900 × g for 10 
minutes and the supernatant was discarded. The pellets were suspended in one mL of mixed 
antibiotic solution composed of 10 mg/mL of vancomycin, nalidixic acid, and amphotricin B 
(Sigma-Aldrich, St. Louis, MO) and incubated at 37o C over night.  
     Subsequently, for each sample, four Herrold’s egg yolk Agar slants (BD Diagnostic 
Systems, Franklin Lakes, NJ) were inoculated with 200 µL each of the tissue samples. The 
inoculated tubes were incubated tilted with loosen lids to aid excess moisture evaporation for 
a week at 37o C. Then, the lids were tightened and the tubes were incubated in an upright 
position for four months and examined every two weeks for growth of VMAP.   
     Histopathological examination of the tissue injury. To examine effect of VNP51 and 
HNP51 on VMAP- and HMAP-induced tissue injury, we excised the liver on days 135 and 
180, fixed them in 10% formaldehyde, stained them with hematoxylin and eosin or Zeihl-
Neelsen stain, and imbedded them in paraffin. Subsequently, 4 µm sections were examined 
under the microscope for the granulomatous reaction intensity and acid-fast bacilli numbers 
by a pathologist who was unaware of the designation of the treatment groups. 
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     ABI Prism 7900HT PCR assay for detection of MAP IS900 genomic DNA in fecal 
pellet. To verify whether the decreased VMAP burden in tissues was accompanied by 
decreased VMAP shedding in fecal pellets, we examined the presence of MAP IS900 
genomic DNA, the insertion element IS900, by PCR (Kim et al., 2002). Briefly, total nucleic 
acids were extracted from fecal pellets (MagMax Total Nucleic Acids Isolation Kit; Ambion, 
Inc., Austin, TX). To conduct the ABI Prism 7900HT PCR assay, 20 µL of assay reaction 
containing 12.5 µL of the TaqMan Universal Master Mix (AB Applied Biosystems, Foster 
City, CA), 6.75 µL of water, 0.25 µL of the 20 µM IS900 forward primer (5’-CCG CTA 
ATT GAG AGA TGC GAT TGG-3’), 0.25 µL of the 20 µM IS900 reverse primer (5,-AAT 
CAA CTC CAG CAG CGC GGC CTC G-3,) and 0.125 µL of the IS900 fluorescent probe 
(5,-fluorescent FAM label, 3’-TAMRA quencher; sequence TCC ACG CCC GCC CAG 
ACA GG-3’) were added to each well containing 5 µL of the total nucleic acid extracted 
from fecal pellets. A 10 ng/µL MAP genomic DNA stock solution was 10-fold serially 
diluted to make four standards that were used to construct the standard curve by using the 
ABI Prism® 7900 Sequence Detection System (AB Applied Biosystems, Foster City, CA). 
The thermocycler was adjusted to run in the first stage at 50o C for 2 min, in the second stage 
at 95o C for 10 min, and in the third stage at 94o C for 15 sec followed by 40 cycles at 66o C 
each for 1 min.   
Statistical Analysis:  
     A linear mixed-effects model was fit to the data for each response variable by using the 
PROC MIXED procedure of the Statistical Analysis System (SAS; SAS Institute Inc., Cary, 
North Carolina, USA) version 9.2. To overcome natural immune variability among mice of 
the same treatment group, means were log transformed. Each linear mixed-effects model 
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included fixed effects for infection status, gender, and their interactions. The least squared 
means were computed by using the LSMEANS option of SAS. Subsequently, different 
among least squared means were determined by using the PDIFF CL option of SAS. The 
standard errors of the means were reported, and the pairwise differences among the estimated 
means were considered significant when the probability (P) value was ≤ 0.05. Tendency for a 
trend was declared when 0.05 ≤ P ≤ 0.1.  
RESUTS 
     Modulation of the histopathological lesions. To evaluate the effect of feeding either the 
VNP51 or HNP51 on the immune responses of infected and non-infected mice, we examined 
the cellularity of the spleen in mice euthanized on day 45 of the study. Feeding the probiotic 
VNP51 or HNP51 to VMAP- or HMAP-infected mice did not significantly alter the 
cellularity of the spleen on day 45 (P = 0.12; Figure 1A). Nor it caused significant gender (P 
= 0.13) or treatment by gender interaction (P = 0.99) effects on the same variable.  
     Similarly, the histopathological examination of the granuloma formation in the hepatic 
tissue stained with hematoxylin and eosin (H&E) revealed no significant differences among 
VMAP- or HMAP-infected control mice and the VMAP- and HMAP-infected mice fed 
either the VNP51 or HNP51 (P ≥ 0.46; Figure 1B) on day 45 of the study.  
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Figure 1. Effect of probiotic VNP51 and HNP51 feeding on the immune responses of 
specific pathogen-free Balb/c mice noninfected or infected with VMAP or HMAP on 
day 45 of the study. Panel A. Effects on the spleen cellularity (SEM = 0.54 – 3.8). Panel 
B. Effects on hepatic granuloma formation (SEM = 0.13 to 0.15).   Panel C. Effects on 
acid-fast bacilli enumeration (SEM = 0.14 to 0.17). Panel D. Effects on MAP shedding 
in the fecal pellets. Unless otherwise specified, VMAP (controls infected with viable 
MAP) were compared to HNP51+VMAP or VNP51+VMAP. Also, HMAP (controls 
infected with the heat-killed MAP) were compared to HNP51+HMAP or 
VNP51+HMAP. Additionally, the cntrl (non-infected controls) were compared to 
HNP51 (mice fed the heat-killed HNP51) or VNP51 (mice fed the viable NP51). 
Similarly, HNP51+VMAP were compared to VNP51+VMAP. Data are the mean ± 
SEM. (*) indicate significant difference at P ≤ 0.05; (#) indicates tendency for 
significant difference at 0.05 < P ≤ 0.10.   
142 
 
 
 
 Feeding the VNP51 or HNP51 to non-infected mice did not seem to induce significant 
hepatic granulomatous reaction compared with control mice fed the MDX (P = 1.0; Figure 
1B). 
     Additionally, hepatic tissues stained with Ziehl-Neelsen stain showed no significant 
difference (P ≥ 0.2; Figure 1 C) in the acid-fast bacilli burden in livers of HMAP- or VMAP-
infected mice fed either the HNP51 or VNP51 in comparison with the infected control mice 
on day 45. Also, MAP DNA could not be detected in all VMAP-infected groups regardless 
of the HNP51 and VNP51 feeding (Figure 1D). 
     As mice proceeded to day 90 of the study, largely, there were significant treatment, 
gender, and treatment by gender interaction effects (All P = 0.0001; Figure 2A) on the spleen 
cellularity. Feeding the HNP51 to VMAP- or HMAP-infected mice substantially increased 
their spleen cellularity (P ≤ 0.009; Figure 2A) to be greater than that of the VMAP- or 
HMAP-infected control mice. Increased spleen cellularity, however, was not accompanied (P 
≥ 0.17; Figure 2B) with significantly enhanced granulomatous reactions in their livers when 
compared with those of the VMAP- and HMAP-infected control mice.  
     It was clearly demonstrable that feeding the VNP51 or HNP51 to control non infected 
mice did not induce hepatic granuloma formation at any time during the study (P ≥ 0.37; 
Figures 2B, 3B and 4B) compared with the noninfected nonprobitic fed control mice. 
     On the contrary, feeding the VNP51 increased enormously the cellular density of the 
spleen (P = 0.0001; Figure 1A) in HMAP-infected mice, but not (P = 0.23; Figure 2A) in 
VMAP-infected mice by day 90 of the study. In contrast, the increased spleen cellularity of 
HMAP-infected mice fed the VNP51, unlike that of VMAP-infected (P = 0.59; Figure 2B), 
was accompanied with a significant (P = 0.009; Figure 2B) granulomatous reaction in livers.  
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     Also, the acid-fast bacilli number was remarkably increased (P = 0.002; Figure 2C) in 
livers of mice fed the VNP51 and inoculated with the HMAP compared with that of the 
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Figure 2. Effect of probiotic VNP51 and HNP51 feeding on the immune responses of 
specific pathogen-free Balb/c mice noninfected or infected with VMAP or HMAP on 
day 90 of the study. Panel A. Effects on the spleen cellularity (SEM = 0.17 – 0.47). Panel 
B. Effects on hepatic granuloma formation (SEM = 0.17 – 0.51).   Panel C. Effects on 
acid-fast bacilli enumeration (SEM = 0.10 – 0.54). Panel D. Effects on MAP shedding in 
the fecal pellets (SEM = 0.15-0.22). Unless otherwise specified, VMAP (controls infected 
with viable MAP) were compared to HNP51+VMAP or VNP51+VMAP. Also, HMAP 
(controls infected with the heat-killed MAP) were compared to HNP51+HMAP or 
VNP51+HMAP. Additionally, the cntrl (non-infected controls) were compared to 
HNP51 (mice fed the heat-killed HNP51) or VNP51 (mice fed the viable NP51). 
Similarly, HNP51+VMAP were compared to VNP51+VMAP. Data are the mean ± 
SEM. (*) indicate significant difference at P ≤ 0.05; (#) indicates tendency for 
significant difference at 0.05 < P ≤ 0.10.   
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HMAP-infected control mice. Because HMAP cannot reproduce, we reasoned that the 
multibacillary phenotype of the granulomas observed is indicative of effective containment 
of HMAP in liver on day 90.  
     In addition, MAP IS900 genomic DNA was detected readily in the fecal pellets of 72.2%, 
60%, and 60% of mice in the VMAP-infected controls, VMAP-infected fed the HNP51, and 
VMAP-infected fed the VNP51, respectively (Figure 2D). Feeding the HNP51 or the VNP51 
to VMAP-infected mice did not significantly influence (P ≥ 0.46) shedding of MAP IS900 
genomic DNA in their fecal pellets compared with the VMAP-infected control mice on day 
90 (Figure 2D).  
       By day 135 of the study, the VNP51 and HNP51-induced immune modulating effect was 
readily detectable. Feeding the VNP51 to VMAP-infected mice amplified significantly  
(P = 0.0005; Figure 3A) the cellularity of the spleen compared with that of the VMAP-
infected controls. In contrast, VNP51 feeding decreased (P = 0.01; Figure 3A) the cellularity 
of the spleen in the HMAP-infected mice compared with the HMAP-infected controls.  
     On the other hand, feeding the HNP51 to mice infected with the VMAP or HMAP did not 
significantly alter (P ≥ 0.14; Figure 3A) their spleen cellularity compared with the VMAP-
and HMAP-infected controls indicating a resolution of the infection with the VMAP and 
HMAP (Figure 3A). On the whole, we detected probiotic-induced significant treatment, 
gender, and treatment by gender interaction effects (All P = 0.0001). 
    We also examined the intensity of the granulomatous reaction liver of infected mice on 
day 135. Feeding either the VNP51 or HNP51 to VMAP- or HMAP-infected mice did not 
significantly alter (P ≥ 0.37; Figure 3B) the granulomatous reaction in their livers. 
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Consequently, numbers of the acid-fast bacilli in the hepatic tissues stained with Zeihl-
Neelsen stain did not differ (P ≥ 0.59; Figure 3C) from that of the VMAP- or HMAP-
infected control mice. Despite this, there was a robust (P = 0.0001) treatment effect and a 
tendency (P = 0.06; Figure 3C) for a gender effect.  
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Figure 3. Effect of probiotic VNP51 and HNP51 feeding on the immune responses of 
specific pathogen-free Balb/c mice noninfected or infected with VMAP or HMAP on 
day 135 of the study. Panel A. Effects on the spleen cellularity (SEM = 0.35 – 1.33). 
Panel B. Effects on hepatic granuloma formation (SEM = 0.10 – 0.55).   Panel C. Effects 
on acid-fast bacilli enumeration (SEM = 0.13 – 0.63). Panel D. Effects on MAP shedding 
in the fecal pellets (SEM = 0.08 – 0.22). Unless otherwise specified, VMAP (controls 
infected with viable MAP) were compared to HNP51+VMAP or VNP51+VMAP. Also, 
HMAP (controls infected with the heat-killed MAP) were compared to HNP51+HMAP 
or VNP51+HMAP. Additionally, the cntrl (non-infected controls fed no probiotics) 
were compared to HNP51 (mice fed the heat-killed HNP51) or VNP51 (mice fed the 
viable NP51). Similarly, HNP51+VMAP were compared to VNP51+VMAP. Data are 
the mean ± SEM. (*) indicate significant difference at P ≤ 0.05; (#) indicates tendency 
for significant difference at 0.05 < P ≤ 0.10.   
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     Notably, MAP IS900 genomic DNA was readily detected in the fecal pellets of 44.4, 11.1, 
and 31.3% of mice in the VMAP-infected controls, VMAP-infected fed the HNP51, and 
VMAP-infected fed the VNP51, respectively (Figure 3D). Feeding the HNP51 to VMAP-
infected tended (P = 0.08) tended to decrease shedding of MAP IS900 genomic DNA 
compared with VMAP-infected controls. Overall, female mice shed less (P = 0.01) MAP 
IS900 genomic DNA in their fecal pellets compared with male mice on day 135 (data not 
shown). 
     On day 180, VNP51 fed to mice challenged with either the VMAP or HMAP decreased 
significantly (Both P = 0.0001; Figure 4A) their spleen cellularity higher than that of the 
HMAP- or VMAP-infected controls. Similarly, feeding the HNP51 to mice challenged with 
the VMAP induced a similar and substantial increase (P = 0.0001) in spleen cellularity. On 
the contrary, HNP51 feeding did not significantly alter (P = 0.77; Figure 4A) spleen 
cellularity of HMAP-infected mice on day 180. 
     Despite the significant overall treatment (P = 0.0001) and gender (P = 0.006; Figure 4B) 
effects, feeding the VNP51 or HNP51 to mice infected with either the VMAP or HMAP had 
no effects (P ≥ 0.44; Figure 4B) on their liver granuloma formation on day 180. VNP51 
feeding, nonetheless, moderately (P = 0.09) lowered the acid-fast bacilli numbers in livers of 
HMAP-infected mice. In contrast, the VNP51-induced acid-fast bacilli-reducing effect was 
significantly pronounced (P = 0.01) in livers of VMAP-infected mice. On the contrary, 
feeding the HNP51 did not alter significantly (P ≥ 0.15) hepatic acid-fast bacilli content 
(Figure 4C).  
     Importantly, MAP IS900 genomic DNA was detected in the fecal pellets of 30% of the 
VMAP-infected control mice (Figure 4D). On the contrary, MAP IS900 genomic DNA was 
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undetectable in fecal pellets of VMAP-infected mice fed either the HNP51 or the VNP51 
(Figure 4D). Thus, feeding the HNP51 or the VNP51 to VMAP-infected completely 
prevented (Both P = 0.02) shedding of MAP IS900 genomic DNA in their fecal pellets 
compared with VMAP-infected controls on day 180 (Figure 4D).  
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Figure 4. Effect of probiotic VNP51 and HNP51 feeding on the immune responses of 
specific pathogen-free Balb/c mice noninfected or infected with VMAP or HMAP on 
day 180 of the study. Panel A. Effects on the spleen cellularity (SEM = 0.58-1.50). Panel 
B. Effects on hepatic granuloma formation (SEM = 0.20 -0.50).   Panel C. Effects on 
acid-fast bacilli enumeration (SEM = 0.10 -0.36). Panel D. Effects on MAP shedding in 
the fecal pellets (SEM = 0.12). Unless otherwise specified, VMAP (controls infected with 
viable MAP) were compared to HNP51+VMAP or VNP51+VMAP. Also, HMAP 
(controls infected with the heat-killed MAP) were compared to HNP51+HMAP or 
VNP51+HMAP. Additionally, the cntrl (non-infected controls) were compared to 
HNP51 (mice fed the heat-killed HNP51) or VNP51 (mice fed the viable NP51). 
Similarly, HNP51+VMAP were compared to VNP51+VMAP. Data are the mean ± 
SEM. (*) indicate significant difference at P ≤ 0.05; (#) indicates tendency for 
significant difference at 0.05 < P ≤ 0.10.   
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     Amelioration of MAP burden in tissues. After observing the dramatic HNP51- and 
VNP51-induced modulation of the spleen cellularity and attenuation of the VMAP DNA 
shedding in fecal pellets (Figures 2A, 3A, 4A, 3D, and 4D) coupled with the significant 
decrease of the acid-fast bacilli in livers (figure 4C), we verified whether HNP51 or VNP51 
decreased VMAP burden in tissues of VMAP-infected mice fed either the VNP51 or the 
HNP51.  
     Of significance, feeding either the VNP51 or HNP51 considerably lowered (P = 0.03 and 
P = 0.003, respectively; Figure 5A) VMAP CFUs in livers of VMAP-infected mice on day 
135. Overall, feeding HNP51 or VNP51 induced a significant treatment effect (P = 0.008) 
with no (P = 0.17) gender effect. Similarly, VMAP burden was remarkably decreased in 
mesenteric lymph nodes (MLN) of VMAP-infected mice fed either the HNP51 (P = 0.04) or 
the VNP51 (P = 0.006; Figure 5B) compared with the VMAP-infected control regardless (P 
= 0.44) of their gender.  
     A similar remarkable decrease (P = 0.0001 and P = 0.0001, respectively; Figure 5C) of 
VMAP burden in the spleens of VNP51- or HNP51-fed mice infected with the VMAP on day 
135 was readily detected. The decrease of VMAP burden, however, was greater (P = 0.004) 
in spleens of females mice than that of spleens of males. In addition, there were overall 
significant treatment (P = 0.0001) and treatment by gender interaction (P = 0.05; Figure 5C) 
effects on day 135.  
     To verify whether the decreased VMAP burden in tissues was accompanied by decreased 
shedding of VMAP in feces, we examine presence of MAP IS900 genomic DNA in the fecal 
pellets by using PCR assay based on the ABI Prism® 7900HT. Feeding either VNP51 or the 
HNP51 significantly decreased VMAP shedding in  
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Figure 5. Effect of probiotic VNP51 and HNP51 feeding on VMAP burden in tissues of 
specific pathogen-free Balb/c mice infected with VMAP on day 135. Panel A. Effect on 
liver VMAP burden (SEM = 5.56 -73.16). Panel B. Effect on mesenteric lymph node 
(MLN) VMAP burden (SEM = 1016.9-1600.2). Panel C. Effect on spleen VMAP burden 
(15.76-1596.44). VMAP is controls mice infected with viable MAP fed no probiotics, 
HNP51+VMAP is VMAP-infected mice fed the heat-killed NP51, and VNP51+VMAP is 
VMAP-infected fed the viable VNP51). Data are the log-transformed mean ± SEM. (*) 
indicate significant difference at P ≤ 0.05; (#) indicates tendency for significant 
difference at 0.05 < P ≤ 0.10.   
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fecal pellets (P = 0.01 and P = 0.01, respectively, Figure 4D) compared with that of VMAP-
infected controls on day 135.  
     By day 180 of the study, feeding either the VNP51 or HNP51 maintained VMAP burden 
decreased significantly (P = 0.01 and P = 0.01, respectively; Figure 6A) in livers of VMAP-
infected mice compared with VMAP-infected controls. In general, we observed significant 
treatment (P = 0.01) and gender (P = 0.001) effects, but no (P = 0.43; Figure 6A) treatment 
by gender interaction effect.  
     Notably, VNP51 fed to VMAP-infected mice decreased significantly (P = 0.05; Figure 
6B) VMAP burden in their MLN compared with VMAP-infected controls. The decrease of 
VMAP burden in MLN of females Balb/c mice tended to be greater (P = 0.09; Figure 6B) 
than that in MLN of males.  
     On the contrary, feeding the HNP51 to VMAP-infected mice did not decrease (P = 0.25) 
VMAP burden in their MLN, but decreased it significantly (P = 0.003) in their ceca on day 
180. Also, feeding the VNP51 to VMAP-infected mice decreased (P = 0.03; Figure 6C) 
VMAP burden in their ceca compared with the VMAP-infected control mice. Generally, 
there was significant (P = 0.008) treatment effect, but no significant (P = 0.62) gender effect 
(Figure 6C).  
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Figure 6. Effect of probiotic VNP51 and HNP51 feeding on VMAP burden in tissues of 
specific pathogen-free Balb/c mice infected with VMAP on day 180 of the study. Panel 
A. Effect on liver VMAP burden (SEM = 5.10 – 151.4). Panel B. Effect on mesenteric 
lymph node (MLN) VMAP burden (SEM = 644.67 – 1161.22). Panel C. Effect on cecum 
VMAP burden (SEM = 8.67- 13.11). VMAP (controls infected with viable MAP fed no 
probiotics, HNP51+VMAP is VMAP-infected fed the heat-killed NP51, and 
VNP51+VMAP is VMAP-infected fed the viable VNP51). Data are the log-transferred 
means ± SEM. (*) indicate significant difference at P ≤ 0.05.  
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DISCUSSION 
     It was no surprise that we detected acid-fast bacilli and granulomatous reactions following 
inoculation with HMAP and VMAP on day 45 (Figures 1B and C). It is well established that 
following intraperitoneal injection, bacterial inocula are drained to the celiac, mesenteric, and 
peripartal lymph nodes. Inocula are either phagocytosed by the intraperitoneal resident 
macrophages or suspended in lymph and transported towards the mediastinal lymph node and 
thoracic duct prior to systemic dissemination (Parungo et al., 2006; Marco et al., 1992).  
     Selbitz and coworkers (1986) detected considerable numbers of Listeria monocytogenes 
in the secondary lymphoid organs as early as 10 minutes after the intraperitoneal inoculation. 
Also, Indian ink (inert) or viable Listeria monocytogenes injected intraperitonealy in mice 
were detected in Kupffer cells in liver and in the marginal zone of the white pulp in the 
spleen four hours after injection (Marco et al., 1992).  
     The intriguingly elevated spleen cellularity owing, at least in part, to recruitment and 
expansion of lymphocytes and phagocytes as a result of HNP51 and VNP51 administration 
to HMAP- or VMAP-infected mice on day 90 indicates the adjuvant effects of HNP51 and 
VNP51 and its ability to augment the natural immune responses against HMAP or VMAP 
pathogen in Balb/c mice (Figure 2A). Decreased spleen cellularity during mycobacterial 
infection was associated with increased susceptibility in alcoholic rats (Li et al., 1998). 
     Feeding the VNP51 to HMAP-infected mice was coupled to increased number of 
granulomas of multibacillary phenotype as indicated by the increased acid-fast bacilli 
numbers (Figures 2B and C). Because HMAP lacks the ability to replicate, it is but logical to 
assume that the multibacillary phenotype of granulomas we observed indicates effective 
containment of MAP, rather than HMAP proliferation (Figures 2B and C). On the other 
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hand, feeding the VNP51 to VMAP-infected mice did not alter the granulomas formation or 
the number of the acid-fast bacilli (Figures 2B and C) in their livers compared with that of 
the VMAP-infected controls on day 90 (Figure 2B), suggesting that triggering HNP51- or 
VNP51-induced anti-VMAP immune response require longer time compared with similar 
immune response triggered against the HMAP.  
     Of noteworthy, the enhanced granulomatous reaction in livers of HMAP- or VMAP-
infected mice fed the VNP51 was associated with an increased of MAP-specific IFN-γ 
secretion in their in vitro splenocyte cultures (data not shown).  
     By day 135, the HNP51- and the VNP51-induced anti-VMAP immune response became 
overtly robust compared with similar immune response triggered against HMAP. 
Administration of VNP51 dramatically increased the spleen cellularity of mice infected with 
VMAP  
(Figure 3A), which is indicative of a continuous recruitment and proliferation of immune 
cells. The increased cellularity of the spleens, however, was not coupled to an enhanced 
granulomatous reaction in liver (Figure 3B) or decrease of their content of acid-fast bacilli 
(Figure 3C). Secretion of MAP-specific IL-10 decreased, however, in their in vitro 
splenocyte cultures (data not shown), indicating decreased infectivity and dissemination of 
MAP (Denis and Ghadirian, 1993). This immune response was further validated by showing 
that feeding the HNP51 tended to decrease MAP IS900 genomic DNA shedding in fecal 
pellets (Figure 3D). 
     We confirmed the decreased infectivity of VMAP by culturing different tissues from 
VMAP-infected mice fed either the HNP51 or the VNP51 on Herrold’s egg yolk media. 
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Feeding the HNP51 or VNP5 induced a substantial decrease in the VMAP burden in viscera 
and secondary immune organs of VMAP-infected mice (Figures 5A, B, and C) on day 135. 
     On day 180, feeding of either the HNP51 or VNP51 to VMAP-infected mice decreased 
remarkably the cellularity of their spleens as an indicator of a resolved immune response 
against VMAP infection (Figure 4A). Also, histopathological examination of the hepatic 
tissues revealed the prevalence of paucibacillary granulomas in livers of the VMAP-infected 
and HMAP-inoculated mice fed the VNP51 (Figure 4C), suggesting efficient killing of 
VMAP pathogen by day 180 of the study. In Bovamine JD, the paucibacillary granuloma 
occurs first during the subclinical stage of the disease, whereas the multibacillary phenotype 
occurs during the clinical stage only. 
     Given the complicated structure and chronicity of granulomas, it is unlikely to see 
differences in granulomatous reaction intensity within short-term duration (Figure 4B). On 
the contrary a change of the acid-fast bacilli content of the granuloma is indicative of the 
efficacy of the immune response (Figure 4C).  
     The paucibacillary phenotype of granuloma observed was associated with an active 
secretion of VMAP-specific IFN-γ in the in vitro splenocyte cultures from VMAP-infected 
mice fed either the HNP51 or VNP51 (data not shown). It seems more prudent for the 
proinflammatory IFN-γ to increase at this time when the ileal inflammation has waned, as 
showed by the decreased numbers of acid-fast bacilli (Figure 4C) and VMAP burden 
(Figures 5A, B, and C and 6A, B, and C).  
CONCLUSIONS 
          These conclusive findings provide unequivocal evidence that feeding probiotic VNP51 
or the HNP51 to specific pathogen-free Balb/c mice infected with VMAP decreases tissue 
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VMAP burden and fecal VMAP shedding through and immune mechanism yet to be 
unraveled. Because both VNP51 and HNP51 impeded VMAP growth in vivo, we speculate 
that the VNP51- and HNP51-mediated immunomodulation effect is dependent on the 
bacterial cell components and doesn’t require the viability of NP51.  
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ABSTRACT 
     The objective of this study was to examine effects of feeding the probiotic Lactobacillus 
acidophilus strain NP51 to Balb/c mice challenged with Mycobacterium avium subspecies 
paratuberculosis (MAP), the causative agent of Johne’s disease. We hypothesized that 
feeding the NP51 would accelerate the innate immunity leading to rapid activation of the 
adaptive immunity to impede the development of MAP infection in mice. Thus, Balb/c mice 
were randomized to treatment groups in a factorial design including mice that either were fed 
the viable or heat-killed NP51 (VNP51 or HNP51, respectively) and challenged with either a 
viable or heat-killed MAP (VMAP or HMAP, respectively). Mice were fed 1 × 106 CFU of 
either HNP51 or VNP51· mice-1 · day-1 mixed with standard mouse chow until the end of the 
study. Subsequently, mice were challenged with 1 × 108 CFU of VMAP or HMAP injected 
intraperitonealy on day 45 of the study. Ten mice from each group were euthanized on days 
45, 90, 135, and 180. Spleens were excised and used for in vitro splenocyte cell cultures that 
were either stimulated with sonicated MAP antigen or concanavalin A and examined for 
cytokine secretion pattern and frequency of T lymphocyte subpopulations. Blood was 
withdrawn by cardiac puncture and used for examination of immunoglobulin production. 
VNP51 and HNP51 differentially stimulated the adaptive immunity. With VMAP as the 
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inoculum, both VNP51 and HNP51 stimulated CD8α+ immune cells-mediated immunity and 
decreased humoral immunity. When HMAP was used as the inoculum, VNP51 stimulated 
both CD8α+ immune cell-mediated and the humoral immunity. In contrast, HNP51 feeding 
induced CD8α+ immune cells-mediated immunity only as verified by the differential 
cytokine and immunoglobulin secretion pattern. 
Key words: MAP, NP51, Johne’s disease, innate immunity. 
INTRODUCTION 
     Mycobacterium avium subspecies paratuberculosis (MAP) is an obligate 
intramacrophage inhabitant that causes Johne’s disease (JD; paratuberculosis), a chronic 
granulomatous ileitis of ruminant animals (Harris and Barletta, 2001). Recently, MAP has 
been implicated with causing Crohn’s disease, a progressive severe ileocolitis in humans 
(Behr and Kapur, 2008) that resembles JD in pathophysiology. Because of the intensive 
modern animal farming, JD has emerged as a worldwide epidemic (Hutchinson, 1996). The 
pathogenesis of JD, however, is dictated primarily by the genetic susceptibility of the 
mammalian host and the type of invading MAP strain (Weiss and Souza, 2008).  
     Among the macrophage surface receptors, CR and PRRs (C-type lectin mannose receptor, 
CD14, and TLRs) have been shown to bind Mycobacteria (Aderem and Underhill, 1999) and 
facilitate its phagocytosis. Complement fragment C3b-opsonized Mycobacteria mediate 
phagocytosis by macrophage via binding to CR1 (CD35), CR3 (CD11b/CD18), and CR4 
(CD11c/CD18) (Souza et al., 2007). In contrast, phagocytosis of non-opsonized 
Mycobacteria is mediated primarily through mannose receptor (Astarie-Dequeker et al, 
1999). Mycobacteria also bind TLR-1, 2, and 4 on host macrophages (Heldwein and Fenton, 
2002).    
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     The cell membrane of Mycobacteria is known to express lipomannan (LM), 
lipoarabinomannan (LAM), mycolyl-arabinogalactan peptidoglycan complex, a 19-KDa 
lipoprotein (Brennan and Nikaido, 1995), and the cord factor trehalose 6,6’-dimycolyl 
(Spargo et al., 1991).  
     LAM, a well characterized primary virulence factor of MAP, is a glycolipid composed of 
a mannopyranosol central molecule attached with arabinofuranosyl side chains, and is 
immobilized to the cell membrane via a mannosyl-phosphatidylinositol membrane anchor 
(Briken et al., 2004). The mannan core is attached to an arabinan domain that is capped by 
various motifs. LAMs of pathogenic Mycobacteria, such as Mycobacterium tuberculosis and 
Mycobacterium avium, are capped with mannose caps (ManLAM). In contrast, the arabinan 
domain of non-pathogenic Mycobacterium smegmatis is capped with phospho-inositol 
(PILAM) and the arabinan domain of Mycobacterium chelonae is uncapped (AraLAM).  
     Recognition by innate immunity PRRs is induced by the arabinan domain capping motifs. 
ManLAM selectively binds C-type lectin mannose receptor on macrophages or dendritic cell-
specific ICAM-3 grabbing non-integrin receptor-1 (DC-SIGNR1) on dendritic cells (DC) 
(Schlesinger, 1993; Maeda et al., 2002). AraLAM binds the co-receptor CD14 and induces 
TLR signaling and production of TNF-α, IL-8, and IL-12p40. In a sharp contrast, ManLAM 
binding to the mannose receptor is coupled neither to macrophage activation nor to 
phagosome maturation, and abrogates induction of IL-12p40, a highly pivotal cytokine for 
Th-1 activation (Nigou et al, 2001). Thus, the mannose receptor constitutes a safe portal for 
entry of pathogenic Mycobacteria.  
     The mycobacterial 19-kDa lipoprotein, on the other hand, binds the mannose receptor and 
TLR-2 (Pai et al., 2004). Signaling of 19-kDa through TLR-2 and the adaptor protein 
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myeloid differentiation primary response gene 88 (MyD88) represses MHC class I and II 
expression, antigen presentation, and subsequent CD4+ T helper cell recruitment. These 
inhibitory machineries allow MAP to evade the immune surveillance and survive longer in 
the host macrophage (Noss et al. 2001; Pai et al., 2004; Weiss and Souza, 2008). Abrogation 
of phagosome maturation has been ascribed to cord factor trehalose 6,6’-dimycolyl (Spargo 
et al., 1991; Welsh et al., 2008) 
     The ManLAM and 19-kDa-induced immune inhibitory effects are further potentiated by 
signaling of the MAP cell wall mycolyl-arabinoglactan peptidoglycan via a signal 
transduction pathway that does not involve TLR-2 and MyD88 (Noss et al., 2001). Overall, 
mycobacterial invasion of macrophage inhibits phagosome maturation and phagosome 
lysosome fusion and acidification (Sturgil-Koszycki et al., 1994). This mycobacterium-
induced inhibition of phagosome maturation is evident by the persistence of the phagosome 
early maturation markers the lysosome-associated membrane proteins (Lamp-1), Rab5, and 
the transferrin receptors.  
      Suppression of the innate immunity through deactivating APC prevents subsequent 
generation of protective adaptive immunity. The interaction between the host innate 
immunity and MAP-induced inhibitory immune mechanisms aimed at subvert the innate 
immunity is a significant determinant of JD pathogenesis.  
     Recent work by Pagnini and colleagues (2010) showed that probiotics fed to a mice model 
of Crohn’s disease prevented the onset of intestinal inflammation by local stimulation of 
epithelial innate immunity, resulting in increased production of epithelial-derived TNF-α and 
restoration of epithelial barrier in vivo. Subsequent work indicated that this immune effect is 
mediated through NF-κB (Pagnini et al., 2010). Indeed, probiotic Lactobacillus casei fed to 
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Balb/c mice increased the expression of macrophage mannose receptor-1 (CD206) and TLR-
2, markers of innate immunity (Galdeano and Perdigon, 2006) and pivotal PRRs for MAP 
uptake by macrophage (Pai et al., 2004; Bhatt and Salgame, 2007). 
     Feeding probiotics to mice can program DC to adopt certain immune phenotype that 
orchestrates subsequent immune response accordingly (Hart et al., 2004).  Lactobacillus 
rhamnosus LcR35 fed to mice at high dose induced DC maturation as revealed by increased 
expression of B7.2, CD83 (sialic acid-binding Ig-like adhesion receptor), HLA-DR, and 
TLR-4 and decreased expression of DC-SIGN and CD14 (Evrard et al., 2011) suggesting 
development of a tolerogenic DC phenotype. Induction of DC phenotype by probiotics 
seemed to be strain-dependent. Stimulation of immature DC with different strains of 
probiotics caused a dose-dependent modification of their IL-10/IL-12p70 secretion. 
Lactobacillus salivarius Ls-33 and Bifidobacterium infantis 35624 predominantly destined 
DC to secret IL-10. On the other hand, probiotic Lactobacillus acidophilus NCFM and the 
probiotic cocktail VSL#3 selectively induced secretion of IL-12p70 by DC.  Escherichia coli 
Nissle 1917, however, equally provoked IL-10 and IL-12p70 secretion by DC (Gad et al., 
2011). 
     Abundant evidence outlining the ability of DC to “cross talk” with NK has rapidly 
evolved (Fernandez et al., 1999; Guiton et al., 2009).  DC-NK cells interaction caused 
bidirectional activation characterized by induced DC maturation (Vitale et al., 2005) and 
enhanced NK cytotoxicity and secretion of effector molecules (Ferlazzo et al., 2002). CD8+ 
cytotoxic T cells are the dominant effector cells following DC activation and infection with 
intracellular pathogen, such as Toxoplasma gondii (Guiton et al., 2009). Previous studies 
conducted to identify surface receptors involved in the DC-NK cells interaction revealed that 
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signaling of C-type lectin-like protein NKG2D immunoreceptor is crucial to the mutual 
activation of DC and NK (Raulet, 2003). NKG2D is expressed by macrophage, NK cells, NK 
T cells, and CD8+ cytotoxic T cells (Rauelt, 2003).  Intriguingly, in CD4+ T helper cell-
deficient mice, NK cells activated CD8+- cytotoxic T cell-mediated immunity against 
intracellular parasites (Combe et al., 2005). 
     Thus, mice immune system can purposely be programmed to trigger requisite immune 
response against specific pathogen infections. Programming of mice immune system can be 
accomplished by selectively feeding certain probiotic strain that induce the intended DC 
phenotype. We hypothesized that pre-feeding the probiotic Lactobacillus acidophilus NP51 
to Balb/c mice infected with MAP would induce DC maturation and accelerate the innate 
immunity resulting in efficient induction of the adaptive immunity against MAP. Our 
objective is to elucidate the NP51-induced immune response that targets in vivo MAP growth 
and proliferation in a murine model of JD.   
MATERIALS AND METHODS 
Experimental Design. 
    Three hundred sixty pathogen-free, 6-week-old Balb/c mice (Jackson Laboratories) were 
randomized to nine treatment groups in a factorial design that included three major groups 
(Table 1). Group 1 was fed the maltodextrin (MDX) carrier at 3% of their chow diet. Group 
II was fed the heat-killed NP51 (HNP51) at 1× 106 CFU·mouse-1·day-1. Group III was fed the 
viable NP51 (VNP51) at 1× 106 CFU·mouse-1·day-1.  Both VNP51 and HNP51 were mixed 
with a MDX carrier at 7.5 × 106 CFU of VNP51or HNP51·g of MDX-1. 
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Table 1. Designation of treatment groups. 
 Treatment groups 
 
group 
 
I 
 
II 
 
III 
Probiotics/carrier MDX 
3% of the diet 
Heat-killed NP51 (HNP51) 
106 CFU·mouse-1·day-1 
Viable NP51 (VNP51) 
106 CFU·mouse-1·day-1 
Code Cntrl HMAP VMAP HNP51 HNP51+HMAP HNP51+VMAP VNP51 VNP51+HMAP VNP51+VMAP 
HMAP ---   --- ---   --- ---   --- 
VMAP --- ---   --- ---   --- ---   
No. of mice 40 40 40 40 40 40 40 40 40 
Cntrl: Control mice fed the regular sterile regular chow diet. MDX: maltodextrin (carrier for HNP51 and the 
VNP51). VNP51 and HNP51: heat-killed and viable Lactobacillus acidophilus strain NP51®.  VMAP and 
HMAP: heat-killed and viable Mycobacterium avium subspecies paratuberculosis (MAP). 
 
     Group I mice contained a non-infected control (n = 40), a heat-killed MAP-infected 
control (HMAP; n = 40), and a viable MAP-infected control (VMAP; n = 40) subgroups. 
Group II mice included a non-infected control (HNP51; n = 40), a heat-killed MAP-infected 
(HNP51+HMAP; n = 40), and a viable MAP-infected (HNP51+VMAP; n = 40) subgroups. 
Group III mice included a non-infected control (VNP51; n = 40), a heat-killed MAP-infected 
(VNP51+HMAP; n = 40), and a viable MAP-infected (VNP51+VMAP; n = 40) subgroups. 
HMAP or VMAP was injected intraperitonealy at 1× 108 CFU·mouse-1 once on day 45 of the 
study. Mice were housed in a BSL-2 rodent room in the animal facility of the Iowa State 
University. The environment within the room was maintained to provide a temperature of 
22.2O C, a relative humidity of 35-45%, and 12 h light/dark cycle. Every four female or male 
mice were housed in autoclaved standard mice cages fitted with raised-wire floors and high 
efficiency particulate air (HEPA) filters.  
All the experimental procedures were done in accordance with the guidelines of the Iowa 
State University Institutional Animal Care and Use Committee IACUC. 
     Mice were offered sterile water ad libitum and chow meal (Harlan Laboratories) 
throughout the study. Mice were adapted to the sterile chow meal for a week prior to the 
addition of NP51. Mice in the HNP51 or VNP51 treatment groups were fed the NP51 at 1× 
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106 CFU·mouse-1·day-1 contained in 3.0 grams of the chow meal. To prepare the HNP51, the 
viable probiotic NP51 was incubated in an oven preheated to 85o C for 15 min. The offering 
of chow meal was increased by 0.5 g chow·mouse-1 every 15 days until it reached a 
maximum of 5.0 g of chow·mouse-1·day-1 by day 105 of the study. Mice continued to be 
offered 5.0 g·mouse-1·day-1 until the end of the study.  
     Inoculation with Mycobacterium avium subspecies paratuberculosis. MAP was grown 
on Middlebrook broth 7H9 (PML Microbiology, Wilsonville, OR). MAP inoculum was 
prepared according to Stabel et al (2009) using strain 167 isolate (Stabel, USDA-ARS-
NADC, Ames, IA). Briefly, 50 mL of oleic acid at 0.60 mL·L-1, albumin at 50 g·L-1, dextrose 
at 20 g·L-1, catalase at 0.04 g·L-1, and sodium chloride at 8.50 g·L-1 (OADC) enrichment 
were inoculated in 450 mL of sterile Middlebrook broth 7H9. Subsequently, 25 mL of a 
virulent MAP clinical isolate of strain 167 (USDA, ARS, NADC, Ames, IA) were inoculated 
into the broth. After thoroughly mixing, the VMAP culture was incubated at 37o C and the 
OD540nm was measured weekly.  The bacteria were harvested in the log phase (OD540nm = 0.2-
0.4). The MAP cultures were decanted into sterile 500 mL Beckman bottles with O-ring caps 
followed by centrifugation at 1000 × g (7500 rpm) for 30 minutes in a refrigerated Beckman 
J2-21 centrifuge using the JA-10 rotor. The supernatant was decanted and the MAP pellets 
were washed twice by suspension in 500 mL of sterile, cold phosphate buffered saline (PBS; 
0.14 M NaCl, 0.003 M KCL, 0.01 M Na2 HPO4, and 0.0018 M KH2PO4; pH 7.4). 
Subsequently, MAP suspension was centrifuged for 30 minutes and the supernatant 
discarded. The formed MAP pellets were re-suspended in 5 mL of cold sterile PBS and 
placed on ice. The OD540 was measured to verify the initial concentration of the bacteria. 
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Then, the PBS was used to adjust the concentration to 109 CFU/mL as determined by OD540 
(OD540nm = 1.0-1.2 absorbance units).  
     To prepare the HMAP, VMAP suspension was heated in a water bath at 85o C for 20 
minutes, then cooled to room temperature, and kept on ice until used for inoculating mice 
(Stabel, USDA, ARS, NADC, Ames, IA). 
     On day 45 of the study, mice were challenged intraperitonealy with 1 × 108 CFU of either 
HMAP or VMAP suspended in 100 µL of sterile PBS (Stabel, USDA, ARS, NADC).  
Control groups received 100 µL of sterile PBS.  
Sampling and Analysis 
     Following inoculation with MAP, 10 mice from each treatment group were euthanized on 
days 45, 90, 135, and 180 of the study. Upon euthanizing mice, about 0.9 mL of blood were 
withdrawn by cardiac puncture and allowed to clot at 4o C over night before serum was 
separated by centrifugation at 5000 RPM for 15 min. Also, the liver, mesenteric lymph node, 
and small intestine were dissected aseptically and frozen at -80o C until used for 
determination of MAP burden. Spleen was dissected and homogenized in RPMI until used 
for in vitro splenocyte culture. 
     Quantification of immunoglobulin production. To quantify total immunoglobulin (Ig) G1 
and IgG2a, 100 uL of 1:50,000 diluted sera were used according to the manufacturer’s 
instruction (Kamiya Biomedical Company, Seattle, WA).  
     To quantify MAP specific IgG1 and IgG2a, 96-well plates were coated with 100 µL/well of 
HMAP suspended in coating buffer (Sigma Chemical) at 2000 ng/mL. Plates were incubated 
while covered at 4o C overnight. After the incubation, the coating buffer was decanted inside 
a biosafety cabinet and the plates were washed four times by filling the wells with 300 µL of 
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the washing buffer (Sigma Chemical). To block the nonspecific binding, 300 µL of blocking 
buffer (Sigma Chemical) were pipetted in each well and the plates were incubated for 30 min 
at room temperature. Subsequently, the blocking buffer was decanted and the plates were 
allowed to dry before they were stored at 4o C until the IgG1 and IgG2a were determined as 
previously mentioned.     
     Quantification of cytokine secretion. Spleens were dissected and used to prepare 
splenocyte single-cell suspension. Splenocytes were cultured in vitro in 48-well plate at 2 × 
106 cells per mL RPMI 1640 (Invitrogen, Carlsbad, CA) plus 10% heat-inactivated FCS 
(Fisher Scientific, Hanover Park, IL) and 1% antibiotic/antimycotic (Invitrogen Carlsbad; 
NM). In vitro splenocyte cultures were either nonstimulated (negative control) or stimulated 
with concanavalin A (Sigma-Aldrich, St. Louis, MO) at 3 µg/mL (positive control), or with 
sonicated MAP antigen at 10 µg/mL.  
     The splenocytes cultures were incubated at 370 C and 5% CO2 /95% O2 for 72 hours. 
Following incubation, the cell-free supernatant was collected and stored at -700 C for later 
analysis of interferon (IFN)-γ and interleukin (IL)-10 concentrations by using enzyme-linked 
immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN).  
     Determination of T lymphocyte subpopulations. The pelleted splenocytes were washed 
twice with cold sterile PBS and stained for the surface markers CD4 (anti-mouse CD4 
PerCP-Cy5.5, eBioscience, San Diego, CA), CD8α (anti-mouse CD8α APC, eBioscience, 
San Diego, CA), and CD25 (anti-mouse CD25 phycoerytherin; PE, eBioscience, San Diego, 
CA). Subsequently, frequencies of these T cell subpopulations were determined by using the 
fluorescence-activated cell sorter (BD FACSAria II; Becton Dickson Biosciences, Franklin 
Lakes, NJ). Data were analyzed by using FlowJo software (Tree Star, Inc., Ashland, OR). 
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Commercially available ELISA kits from R&D Systems (McKinley Place NE, MN) were 
used to determine IFN-γ and IL-10 concentrations.  
Statistical Analyses  
 
     For the flow cytometric data, a linear mixed-effects model was fit to the data for each 
response variable by using the PROC MIXED procedure of the Statistical Analysis System 
(SAS; SAS Institute Inc., Cary, NC, USA) version 9.2. Each linear mixed-effects model 
included random cage effect and fixed effects for diets, infection status, day of euthanization, 
gender, and all possible interactions among these fixed effects factors.  
     For the cytokine and immunoglobulin data, means of response variables were log-
transformed to overcome the natural variability in immune response. Then the PROC 
MIXED procedure of SAS was used with CLASS statement of treatment and gender and 
MODEL statement of log-transformed mean equal treatment, gender and their interaction. 
The least squared means were computed by using the LSMEANS procedure and differences 
among least squared means were computed by using the PDIFF CL procedure. The standard 
errors of the means were reported, and the pairwise differences among the estimated means 
were considered significant when the probability (P) value was ≤ 0.05. Tendency for a trend 
was declared when 0.05 ≤ P ≤ 0.1. 
RESULTS 
Day 45 Results 
 
     CD4+ T helper cells. Effect of feeding the HN51 and VNP51 on the frequency of the T 
cell subpopulations was examined. Overall, there were significant treatment (P = 0.004) and 
day (P = 0.0007) effects on frequency of CD4+ T helper cells (Figure 1A). In the non-
stimulated T cell cultures, feeding the VNP51 to mice infected with the HMAP or VMAP did 
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not significantly change (P ≥ 0.16) their CD4+ T helper cell frequency (Figure 1A).  Feeding 
the HNP51, however, decreased (P = 0.009) CD4+ T helper cell frequency (Figure 1A) in the 
VMAP-infected mice. In contrast, feeding the HNP51 to HMAP-infected mice did not alter 
(P = 0.31) their CD4+ T helper cell frequency (Figure 1A) on day 45. We observed that 
feeding VNP51 to noninfected control mice significantly (P = 0.02) decreased CD4+ T helper 
cells (Figure 1A). On the contrary, HNP51 did not significantly (P = 0.35) change CD4+ T 
helper cells relative to that of the noninfected control mice (Figure 1A). 
     Stimulation of the splenocyte culture with the VMAP antigen revealed that feeding 
HNP51 to HMAP-infected mice decreases (P = 0.04) their CD4+ T helper cells in 
comparison with that of the HMAP-infected control mice on day 45 (Figure 1A).  Of interest, 
feeding the VNP51, not the HNP51 (P = 0.17), tended (P = 0.07) to decrease their CD4+ T 
helper cell repertoire in the splenocyte cultures when stimulated with VMAP antigen relative 
to that of the noninfected control mice (Figure 1A).  
     ConA stimulation of the splenocyte cultures from mice fed the HNP51 and infected with 
the HMAP tended to decrease (P = 0.06; Figure 1A) CD4+ T helper cell frequency. Also, 
stimulation of the in vitro T cell cultures with sonicated MAP antigen decreased (P = 0.04) 
CD4+ T helper cell frequency (Figure 1A).   On the contrary, feeding the HNP51 to VMAP-
infected mice or feeding to the VNP51 to HMAP- or VMAP-infected mice did not 
substantially (P ≥ 0.13) change their CD4+ T helper frequency (Figure 1A) when T cell 
culture where stimulated with ConA or MAP antigen on day 45.  
     CD4+ CD25+T helper cells. Similarly, non-stimulation, stimulation with ConA, or 
simulation with MAP antigen of the splenocytes cultures from mice fed the HNP51 or the 
VNP51 and infected with the HMAP or VMAP did not significantly change (P ≥ 0.17; 
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Figure 1B) CD4+CD25+ T reg cell frequency on day 45 compared with that of the VMAP- 
and HMAP-infected control mice. Feeding the VNP51 or HNP51 to noninfected mice 
significantly (P = 0.03 and P = 0.006, respectively) increased their CD4+CD25+ T reg cell 
repertoire compared with that of the noninfected control mice (Figure 1B). 
     CD8α+ immune cells. Overall, in the non-stimulated or ConA-stimulated splenocyte 
cultures, there were treatment (P ≤ 0.07), day (P = 0.0001), and day by treatment interaction 
(P ≤ 0.04) effects on CD8α+ immune cells. Despite this, in the non-stimulated in vitro 
cultures, feeding the HNP51 or the VNP51 to mice infected with HMAP or VMAP did not 
appear to modify (P ≥ 0.21) the frequency of CD8α+ immune cells (Figure 1C) relative to 
control mice infected with the HMAP or VMAP on day 45.  
     Feeding the HNP51 or the VNP51 to non-infected mice provoked a significant increase (P 
= 0.0001 and P = 0.0001, respectively; Figure 1C) of CD8α+ immune cells in the MAP 
antigen-stimulated splenocytes cultures in comparison to the control mice. In the ConA-
stimulated cultures, however, feeding the HNP51 or the VNP51 per se did not change 
significantly (P ≥ 0.37) the frequency of CD8α+ immune cells relative to the control (Figure 
1C).  
     On the other hand, stimulation of the splenocytes cultures with the sonicated MAP 
antigen, demonstrated that feeding HNP51 or the VNP51 to mice infected with the HMAP or 
the VMAP increased significantly (P ≤ 0.05; Figure 1C) the frequency of the CD8α+ immune 
cells on day 45. 
     CD8α+CD25+ T reg cells. In the non-stimulated or MAP-stimulated in vitro splenocyte 
cultures of HMAP- or VMAP-infected mice fed the HNP51 or the VNP51, frequency of 
CD8α+CD25+ T reg cells did not change (P ≥ 0.21) in comparison with the control mice 
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(Figure 1D). On the other hand, stimulation of the splenocyte cultures with the mitogen 
ConA increased considerably (P ≤ 0.002) the frequency of CD8α+CD25+ T reg cells in mice 
fed the HNP51 or the VNP51 and infected with the HMAP or the VMAP relative to the 
HMAP- and VMAP-infected control (Figure 1D).   
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Figure 1. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their in vitro 
splenic T cell subpopulations proliferation stimulated with ConA (open bars) or with  
MAP antigen (grey bars) or nonstimulated (dark bars) on day 45. Panel A. CD4+ T 
helper cells proliferation. Panel B. CD4+CD25+ T reg cells. Panel C. CD8α+ immune 
cells.  Panel D. CD8α+CD25+ T reg cells. Data are mean ± SEM. (*) indicates significant 
difference at P ≤ 0.05; (#) indicates tendency for a significant difference at 0.05 < P ≤ 
0.10. 
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     IL-10 and IFN-γ.  Feeding the HNP51 to mice infected with either HMAP or VMAP did 
not cause significant variation in the production of IFN-γ and IL-10 (P ≥ 0.41; Figures 2A 
and B, respectively) relative to that of control mice infected with either the HMAP or VMAP 
on day 45. In a sharp difference, feeding the VNP51 to mice challenged with the HMAP 
induced a significant increase in IFN-γ and IL-10 (P = 0.03 and P = 0.02; Figures 2A and B, 
respectively) on day 45.   
     On the other hand, feeding the VNP51 to mice infected with the VMAP did not 
significantly (P ≥ 0.33; Figures 2A and B) alter IFN-γ or IL-10 secretion by splenocytes 
stimulated with MAP antigen. Feeding the VNP51 per se, not HNP51 (P = 0.91), increased 
(P = 0.0003) IL-10 secretion relative to the control mice (Figure 2B). But feeding either the 
HNP51 or the VNP51 to non infected mice did not significantly change (P ≥ 0.69; Figure 
2A) IFN-γ secretion pattern on day 45. 
    Total and MAP-specific IgG isotypes. We also examined effects of feeding the probiotics 
on immune parameters of adaptive immunity. Feeding the VNP51 to Blab/c mice infected 
with VMAP decreased significantly (P = 0.0001; Figures 2C) serum total IgG1 concentration 
and simultaneously increased (P = 0.0001; Figures 1I) IgG2a concentration. In contrast, 
feeding the VNP51 to Balb/c mice infected with HMAP induced a substantial increase (Both 
P = 0.0001; Figure 2C and D) in their total IgG1 and IgG2a. Feeding the HNP51 to Balb/c 
mice infected with HMAP elevated significantly their total IgG2a (P = 0.001); however, total 
IgG1 was decreased (P = 0.04; Figure 2C and D) in comparison to that of HMAP-infected 
controls (Figures 2C and D). When HNP51 was fed to mice infected with the VMAP total 
IgG1 concentrations was not significantly altered (P = 0.61; Figure 2C). On the contrary, total 
IgG2a was remarkably increased (P = 0.0001; Figure 2D) on day 45 of the study. 
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     Quick significant elevation (P ≤ 0.02; Figures 2E and F) of MAP-specific IgG1 and IgG2a 
was detected in sera of mice infected with either HMAP or VMAP and fed VNP51. Immune 
effects of HNP51 suggested dependency on viability of MAP (Figures 2E and F). Whereas 
feeding HNP51 to mice infected with HMAP did not significantly alter (P ≥ 0.73; Figures 2E 
and F), feeding the HNP51 to VMAP-infected mice significantly raised (P ≤ 0.007; Figures 
2E and F) both MAP-specific IgG1 and IgG2a.  
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Figure 2. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their MAP-
specific interferon (IFN)-γ and interleukin (IL-) 10 and serum total and MAP-specific 
immunoglobulins (Ig) concentrations on day 45. Panel A. MAP-specific IFN-γ 
concentrations. Panel B. MAP-specific IL-10 concentrations. Panel C. Total IgG1 
concentrations. Panel D. MAP-specific IgG1 concentrations. Panel E. Total IgG2a 
concentrations. Panel F. MAP-specific IgG2a concentrations. Data are mean ± SEM. (*) 
indicates significant difference at P ≤ 0.05; (#) indicates tendency for a significant difference 
at 0.05 < P ≤ 0.10. 
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Day 90 Results 
     CD4+ T helper cells. In the non-stimulated splenocyte cultures, feeding the HNP51 to 
HMAP-infected mice tended to decrease (P = 0.09) the frequency of CD4+ T helper cells. 
Similarly, feeding the VNP51 to HMAP-infected mice decreased (P = 0.05) their CD4+ T 
helper cells on day 90 (Figure 3A). On the other hand, feeding the HNP51 or VNP51 to 
VMAP-infected mice did not alter (P ≥ 0.58) CD4+ T helper cells in their in vitro cultures 
(Figure 3A). Note worthy, infection with VMAP significantly (P = 0.01) decreased their 
CD4+ T helper cells in the nonstimulated in vitro cultures relative to that of the HMAP-
infected control mice (Figure 3A). 
     Stimulation with ConA or MAP antigen of splenocyte cultures from mice fed the HNP51 
or the VNP51 and infected with the HMAP or the VMAP did not significantly vary (P ≥ 
0.23; Figure 3A) the frequency of CD4+ T cells on day 90. 
     CD4+CD25+ T reg cells. Responses of CD4+CD25+ T reg cells on day 90 mimicked that 
of CD4+ T helper cells (Figure 2B). VNP51 and HNP51 fed to HMAP-infected mice, 
respectively, decreased (P = 0.02 and P = 0.01, respectively) the frequency of CD4+CD25+ T 
reg cells (Figure 3B) in the nonstimulated cell cultures. On the contrary, feeding the VNP51 
or the HNP51 to VMAP-infected mice did not modify (P ≥ 0.34) the frequency of 
CD4+CD25+ T reg cells repertoire. Again, infection with VMAP infection of the control mice 
significantly (P = 0.03) decreased CD4+CD25+ T reg cells  numbers in their nonstimulated in 
vitro cultures relative to that of the HMAP-infected control (Figure 3B). 
     Also, stimulation of the splenocyte cultures with ConA mitogen or MAP antigen did not 
significantly alter (P ≥ 0.35) the frequency of CD4+CD25+ T reg cells (Figure 3B). 
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     Also, ConA stimulation of splenocyte cultures of control mice fed the HNP51 did not 
affect (P = 0.11) the frequency of CD4+CD25+ T reg cells frequency in their in vitro 
splenocyte cultures. But, CD4+CD25+ T reg cells frequency in the cultures from VNP51-fed 
mice decreased (P = 0.02; Figure 2B). In contrast, CD4+CD25+ T reg cells frequency in 
cultures from HNP51- and VNP51-fed mice did not change (P ≥ 0.11) when cultures were 
stimulated with MAP antigen on day 90. 
     CD8α+ cytotoxic T cells. Non-stimulated in vitro cultures from mice fed the HNP51 and 
infected with the HMAP or the VMAP revealed higher (P ≤ 0.04) CD8α+ immune cells 
relative to the HMAP- and VMAP-infected controls (Figure 3C).  As well, nonstimulated in 
vitro cultures from HMAP-infected mice fed the VNP51 showed increased (P = 0.01) CD8α+ 
immune cells compared with those from HMAP-infected controls. Feeding the VNP51 to 
VMAP-infected mice did not significantly (P = 0.25) alter CD8α+ cells population on day 90. 
Feeding the HNP51 per se to non-infected control mice did not alter (P = 0.89) the CD8α+ 
immune cells. But feeding the VNP51 to non-infected control mice, however, increased (P = 
0.03) the frequency of these cells.  
     Stimulation with ConA of in vitro splenocyte cultures from HMAP-infected mice fed the 
HNP51 or the VNP51 did not change (P ≥ 0.20) the CD8α+ immune cells frequency (Figure 
2C). Similarly, feeding the VNP51 to VMAP-infected mice did not vary (P = 0.14) CD8α+ 
immune cells frequency.  Conversely, feeding the HNP51 to VMAP-infected mice tended to 
increase (P = 0.06) CD8α+ immune cells frequency (Figure 3C).  Feeding the HNP51 or the 
VNP1 to non-infected mice, however did not alter (P ≥ 0.38) the frequency in vitro CD8α+ 
immune cells frequency. 
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    Importantly, stimulation with MAP antigen of splenocyte cultures of HMAP- or VMAP-
infected mice fed the HNP51 or the VNP51 significantly increased (P ≤ 0.001) the CD8α+ 
immune cells frequency on day 90. Also, stimulation of splenocyte from non-infected mice 
fed the HNP51 or the VNP51 substantially increased (P ≤ 0.0003) CD8α+ immune cells 
frequency (Figure 3C).  
     CD8α+CD25+ T reg cells. Feeding the HNP51 or the VNP51 to HMAP-infected mice 
decreased (P ≤ 0.03) the population of CD8α+CD25+ T reg cells in their splenocyte cultures 
relative to that of the control (Figure 3D). Conversely, feeding the HNP51 or the VNP51 to 
VMAP-infected mice did not modify (P ≥ 0. 73) their CD8α+CD25+ T reg cells in vitro 
(Figure 2D). Similarly, feeding the HNP51 or the VNP51 per se did not alter (P ≥ 0.84) 
frequency of CD8α+CD25+ T reg cells on day 90. Notably, the frequency of CD8α+CD25+ T 
reg cells was higher in the HMAP-infected mice relative to that of the VMAP-infected ones 
(Figure 3D). 
     When the splenocyte cultures were stimulated with the mitogen ConA, frequency of 
CD8α+CD25+ T reg cells seemed significantly lower (P ≤ 0.02) in in vitro cultures of 
HMAP- or VMAP-infected mice fed the VNP51 in comparison with HMAP- and VMAP-
infected controls. Feeding the HNP51, on the other hand, decreased (P = 0.04) and tended to 
decrease (P = 0.06) the frequency of CD8α+CD25+ T reg cells in cultures of the HMAP- and 
VMAP-infected mice relative to the HMAP- and VMAP-infected controls (Figure 3D). Of 
importance, MAP antigen stimulation of splenocyte in vitro cultures of HMAP- or VMAP-
infected mice fed the HNP51 or the VNP51 lowered significantly (P ≤ 0.002) the population 
of CD8α+CD25+ T reg cells in comparison with the control mice (Figure 3D).   Unlike the 
stimulation with ConA, stimulation with the MAP antigen did not alter (P ≥ 0.64) the 
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frequency of CD8α+CD25+ T reg cells in non-infected mice fed the HNP51 or the VNP51 
(Figure 3D). 
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Figure 3. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their in vitro 
splenic T cell subpopulations proliferation stimulated with ConA (open bars) or with  
MAP antigen (grey bars) or nonstimulated (dark bars) on day 90.  Panel A. CD4+ T 
helper cell proliferation. Panel B. CD4+CD25+ T reg cell. Panel C. CD8α+ immune cells.   
Panel D. CD8α+CD25+ T reg cell. Data are mean ± SEM. (*) indicates significant 
difference at P ≤ 0.05; (#) indicates tendency for a significant difference at 0.05 < P ≤ 
0.10 
 
     IL-10 and IFN-γ secretion. With progression of MAP infection to day 90, MAP-specific 
IFN-γ secretion by splenocytes from mice fed the VNP51 and inoculated with HMAP tended 
to increase (P = 0.09; Figure 4A) relative to that of the HMAP-infected control mice. 
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HNP51- and VNP51-induced IFN-γ secretion on day 90 was coupled to enhanced 
granulomatous reaction in livers of infected mice (Osman et al. manuscript under review). 
     Secretion of IL-10, however, was significantly increased (P ≤ 0.003; Figure 4B) in the in 
vitro splenocytes cultures of VMAP- and HMAP-infected mice fed the VNP51 to be higher 
than that of the VMAP- and HMAP-infected control mice. Similarly, feeding HNP51 to mice 
challenged with VMAP elevated significantly (P = 0.009; Figure 4B) IL-10 concentrations in 
their in vitro splenocyte cultures to be greater than that of the VMAP-infected control.  
     Total and MAP-specific IgG isotypes. HNP51 or VNP51 fed to mice infected with the 
VMAP remarkably decreased (P ≤ 0.01; Figures 4C and D) their total IgG1 and IgG2a in 
comparison to control mice infected with HMAP or VMAP on day 90. On the other hand, 
feeding the VNP51 to mice infected with the HMAP highly significantly increased (P = 
0.002) increased their total IgG1 but decreased (P = 0.008; Figure 4C and E) their total IgG2a 
relative to that of the control. Similarly, feeding the HNP51 to HMAP-infected mice 
increased (P = 0.05) their total IgG1 and simultaneously decreased significantly (P = 0.0001) 
their total IgG2a.   
     Also, the anti-MAP IgG1 and IgG2a seemed to follow a pattern similar to that of total IgG 
isotypes (Figures 4D and F). It was obvious that HNP51 fed to mice infected with HMAP did 
not significantly change (P = 0.18) their MAP-specific IgG1 (Figure 4D). In comparison, 
HNP51 fed to VMAP-infected mice induced a significant decrease (P = 0.005) in their MAP-
specific IgG1 on day 90 (Figure 4D). Also, VNP51 fed to HMAP-infected mice tended to 
increase (P = 0.06; Figure 4D) their MAP-specific IgG1 compared with HMAP-infected 
controls. On the contrary, feeding VNP51 to VMAP-infected mice substantially lowered (P = 
0.0001) their MAP specific IgG1 compared with VMAP-infected controls (Figure 4D).  
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Figure 4. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their MAP-
specific interferon (IFN)-γ and interleukin (IL-) 10 and serum total and MAP-specific 
immunoglobulins (Ig) concentrations on day 90. Panel A. MAP-specific IFN-γ 
concentrations. Panel B. MAP-specific IL-10 concentrations. Panel C. Total IgG1 
concentrations. Panel D. MAP-specific IgG1 concentrations. Panel E. Total IgG2a 
concentrations. Panel F. MAP-specific IgG2a concentrations. Data are mean ± SEM. (*) 
indicates a significant difference at P ≤ 0.05 and (#) indicates a tendency for a significant 
difference at 0.05 < P ≤ 0.10. 
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     Serum concentrations of MAP-specific IgG2a was not significantly altered (Both P = 0.77) 
by feeding the VNP51 or the HNP51 to HMAP-infected mice relative to that of the HMAP-
infected control mice (Figure 4F). Also, HNP51 fed to VMAP-infected mice did not change 
(P = 0.22) their MAP-specific IgG2a concentrations compared with that of the VMAP-
infected control mice (Figure 4F). In contrast, MAP-specific IgG2a was significantly 
decreased (P = 0.03) in sera of VMAP-infected mice fed the VNP51 relative to that of 
VMAP-infected control (Figure 4F). 
Day 135 Results  
     CD4+ T helper cells. On day 135, in the non-stimulated, ConA-stimulated, or MAP 
antigen-stimulated splenocyte cultures, feeding either the HNP51 or the VNP51 to HMAP- 
or VMAP-infected mice did not modify (P ≥ 0.11) the frequency of CD4+ T helper cells 
(Figure 5A). 
     CD4+CD25+ T helper cells. Indeed, the frequency of CD4+ CD25+ T regulatory cells did 
not change (P ≥ 0.45) by feeding either the HNP51 or the VNP51 to HMAP- or VMAP-
infected mice (Figure 5B) regardless of the culture stimulant used.  
     CD8α+ immune cells. The frequency of CD8α+ immune cells increased (P = 0.04) in the 
non-stimulated in vitro splenocyte cultures of mice fed the VNP51 and infected with the 
HMAP (Figure 3C). Also, feeding the VNP51, not the HNP51 (P = 0.36), to control non-
infected mice increased (P = 0.01; Figure 5C) the frequency of CD8α+ immune cells on day 
135. On the contrary, no change (P ≥ 0.2) in the frequency of CD8α+ immune cells in other 
treatment groups was detected on day 135. Under ConA stimulation, however, only feeding 
the HNP51 to VMAP-infected mice tended to increase (P = 0.09) CD8α+ immune cells 
frequency on day 135 (Figure 5C). 
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     On the contrary, under MAP-antigen stimulation of the in vitro splenocyte cultures, 
feeding the HNP51 or VNP51 to HMAP- or VMAP-infected mice increased (P ≤ 0.03) the 
frequency of the CD8α+ immune cells to be higher than that of the infected control mice on 
day 135 (Figure 3C). Intriguingly, stimulation of splenocytes from non-infected mice fed 
either HNP51 or the VNP51 by MAP antigen raised (P = 0.03 and P = 0.005) the frequency 
of CD8α+ immune cells higher than that of the non-infected controls (Figure 5C) on day 135. 
     CD8α+CD25+ T reg cells. Frequency of CD8α+CD25+ T regulatory cells on day 135 was 
did not differ (P ≥ 0.48) among the various treatments in the non-stimulate splenocyte 
cultures (Figure 5D). Stimulation with ConA, nonetheless, tended to decrease (P = 0.06 and 
P = 0.07) frequency of CD8α+CD25+ T regulatory cells of in vitro cultures of mice fed the 
HNP51 and either infected with HMAP or VMAP, respectively (Figure 5D). Also, under 
ConA stimulation, feeding the VNP51 tended to decrease (P = 0.06) and decreased (P = 
0.007) CD8α+CD25+ T regulatory cells population in splenocyte cultures of HMAP- and 
VMAP-infected mice, respectively, to be significantly lower than that of the infected control 
mice on day 135 (Figure 5D). Of significance, under MAP antigen stimulation condition, 
CD8α+CD25+ T regulatory cells population decreased (P ≤ 0.05) in splenocyte cultures of 
mice fed the HNP51 or VNP51 and infected with the HMAP or the VMAP (Figure 5D).  
     Feeding the HNP51 or VNP51 per se to non-infected mice did not alter (P ≥ 0.55) 
CD8α+CD25+ T regulatory cells frequency under no stimulation or MAP antigen stimulation 
(Figure 3D). Yet, under ConA stimulation, frequency of CD8α+CD25+ T regulatory cells 
increased (P ≤ 0.05) to be greater than that of non-infected control on day 135 (Figure 5D). 
       IL-10 and IFN-γ. By day 135 of the study mice have been infected for 90 days. VNP51 
or HNP51 fed to VMAP- or HMAP-infected mice did not change (P ≥ 0.21; Figure 6A) IFN-
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γ concentrations in vitro. Concentration of IFN-γ, on the other hand, was elevated (P = 
0.0003) in splenocyte cultures from HMAP-infected control mice compared with that from 
VMAP-infected control mice (Figure 6A). Also, feeding the VNP51 (P = 0.008), not the 
HNP51 (P = 0.77), notably decreased secretion of IFN-γ by splenocytes in vitro compared 
with the control mice (Figure 6A).   
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Figure 5. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their in vitro 
splenic T cell subpopulations proliferation stimulated with ConA (open bars) or with  
MAP antigen (grey bars) or nonstimulated (dark bars) on day 135.  Panel A. CD4+ T 
helper cell proliferation. Panel B. CD4+CD25+ T reg cell. Panel C. CD8α+ immune cells.   
Panel D. CD8α+CD25+ T reg cell. Data are mean ± SEM. (*) indicates a significant 
difference at P ≤ 0.05; (#) indicates a tendency for a significant difference at 0.05 < P ≤ 
0.10. 
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     Of note worthy, VNP51 fed to HMAP- or VMAP-infected mice decreased significantly (P 
≤ 0.02; Figure 6B) IL-10 secretion in their in vitro splenocyte cultures. Conversely, VNP51 
raised IL-10 concentration (P = 0.002; Figure 6B) in vitro in splenocytes of mice infected 
with the HMAP on day 135.  
     Remarkably, feeding the HNP51 per se did not vary (P = 0.83) IL-10 concentrations 
(Figure 6B) nor did feeding the HNP51 alter significantly (P = 0.50; Figure 6B) their 
splenocyte secretion of IL-10 in comparison to control mice not fed the probiotic. Feeding 
the VNP51 to mice, however, decreased (P = 0.05) IL-10 secretion when their splenocytes 
were stimulated with the sonicated VMAP antigen in vitro (Figure 6B) when compared with 
that of the control mice. Also, feeding the HNP51 to mice tended to decrease (P = 0.08) IL-
10 secretion in their splenocyte culture when stimulated with MAP antigen compared with 
that of the control mice (Figure 6B).  
     Total and MAP-specific IgG isotypes. In addition, the immuneomodulating effects of 
HNP51 and VNP51 was mostly suppressive to CD4+ T helper cell responses (Th1 and Th2 
responses) on day 135. Feeding the HNP51 to mice infected with the VMAP or HMAP 
decreased substantially (P = 0.0001 and P = 0.05, respectively) serum total IgG1 and (P = 
0.0001 and P = 0.0001, respectively) total IgG2a concentrations (Figures 6C and E). 
     Also, feeding the VNP51 to VMAP-infected mice lowered significantly (P = 0.03 and P = 
0.0001, respectively) their serum total IgG1 and IgG2a concentrations (Figures 6C and E). On 
the contrary, feeding the VNP51 to mice infected with HMAP triggered a significant increase 
(P = 0.0001 and P = 0.02) in their total IgG1 and IgG2a concentrations, respectively, 
compared with HMAP-infected controls (Figures 6C and E). 
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     When HNP51 or VNP51 were fed to control non-infected mice, their total IgG1 and IgG2a 
decreased significantly (P ≤ 0.0003) when compared with the non-infected control mice 
(Figure 6C and E). On the other hand, infection with HMAP or VMAP caused total IgG1 and 
IgG2a to increase (P ≤ 0.008) on day 135 with VMAP effect being significantly greater (P ≤ 
0.01; Figure 6C and E) than that of HMAP-infected control mice.  
     Generally, feeding either the HNP51 or VNP51 appeared not in favor of triggering anti-
MAP adaptive immune response (Figures 3H and J). It was obvious that HNP51 or VNP51 
fed to VMAP-infected mice remarkably lowered (P ≤ 0.007) their MAP-specific IgG1 and 
IgG2a (Figures 6D and F) below that of the control mice infected with either the HMAP or 
VMAP. In contrast, feeding the HNP51 to HMAP-infected mice did not cause (P ≥ 0.54) 
their MAP-specific IgG1 and IgG2a to significantly change (Figures 6D and F). In contrast, 
feeding the VNP51 to HMAP-infected mice decreased (P = 0.002) their MAP-specific IgG2a, 
but not MAP-specific IgG1 (P = 0.30; Figures 6D and F). 
 
 
 
 
 
 
 
 
 
 
192 
 
 
 
0
10
20
30
40
50
60
**
* A
*
IF
N
-
g,
 
pg
/m
L
0
40
80
120
160
200
*
*
B
* *
*
IL
-
10
, 
pg
/m
L
 
0
100
200
300
400
500
600
700
800
900
*
C
*
*
*
*
*
Ig
G
1,
 
u
g/
m
L
0
5
10
15
20
25
30 D
 
*
*
* *
Ig
G
1,
 
u
g/
m
L
 
Cn
trl
HM
AP
VM
AP
HN
P5
1
HN
P5
1+
HM
AP
HN
P5
1+
VM
AP
VN
P5
1
VN
P5
1+
HM
AP
VN
P5
1+
VM
AP --
0
200
400
600
800
1000
1200
1400
1600
*
E
*
***
*
*
*
*
Ig
G
2a
, 
u
g/
m
L
Cn
trl
HM
AP
VM
AP
HN
P5
1
HN
P5
1+
HM
AP
HN
P5
1+
VM
AP
VN
P5
1
VN
P5
1+
HM
AP
VN
P5
1+
VM
AP --
0
10
20
30
40
50
60
*
*
*
*
F
Ig
G
2a
, 
u
g/
m
L
 
Figure 6. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their MAP-
specific interferon (IFN)-γ and interleukin (IL-) 10 and serum total and MAP-specific 
immunoglobulins (Ig) concentrations on day 135. Panel A. MAP-specific IFN-γ 
concentrations. Panel B. MAP-specific IL-10 concentrations. Panel C. Total IgG1 
concentrations. Panel D. MAP-specific IgG1 concentrations. Panel E. Total IgG2a 
concentrations. Panel F. MAP-specific IgG2a concentrations. Data are mean ± SEM. (*) 
indicates a significant difference at P ≤ 0.05 and (#) indicates a tendency for a significant 
difference at 0.05 < P ≤ 0.10. 
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Day 180 Results 
     CD4+ T helper cells.  On day 180, frequency of CD4+ T helper cells did not respond (P ≥ 
0.27) to stimulation with ConA mitogen or MAP antigen (Figure 7A). Also, in the non-
stimulated culture, frequency of CD4+ T helper cells was invariant (P ≥ 0.14) among 
different treatments and controls (Figure 7A).  
     CD4+CD25+ T reg cells.  Similarly, non-stimulation or stimulation of splenocyte cultures 
with MAP antigen did not change (P ≥ 0.34; Figure 7B) the frequency of CD4+CD25+ T 
regulatory cells in vitro. On the other hand, stimulation of the in vitro cultures with ConA, 
tended to decrease (P = 0.06) CD4+CD25+ T regulatory cells in splenocytes of HMAP-
infected mice fed the HNP51. In contrast, CD4+CD25+ T regulatory cells did not differ (P = 
0.39) in the VMAP-infected mice fed the HNP51. On the contrary, feeding the VNP51 to 
HMAP- or VMAP-infected mice decreased (P ≤ 0.04) CD4+CD25+ T regulatory cells 
population relative to the infected controls (Figure 7B).  
     CD8α+ immune cells. On day 180, non-stimulation of in vitro splenocyte cultures only 
tended (P = 0.06) to increase CD8α+ immune cells of splenocytes cultures of HMAP-infected 
mice fed the VNP51 (Figure 7C). But,  effects of feeding HNP51 to VMAP-infected mice or 
feeding the VNP51 to HMAP- or VMAP-infected mice on CD8α+ immune cells were not 
significant (P ≥ 0.16; Figure 7C).   
     Under ConA stimulation, however, feeding the HNP51 to VMAP-infected mice tended to 
increase (P = 0.1; Figure 4) CD8α+ immune cells frequency in vitro (Figure 7C). In contrast, 
feeding the HNP51 to HMAP-infected mice or feeding the VNP51 to HMAP- or VMAP-
infected mice did not modify (P ≥ 0.12) CD8α+ immune cells in vitro (Figure 7C). Of 
significance, when in the vitro cultures were stimulated with MAP antigen, feeding the 
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HNP51 or the VNP51 to HMAP- or VMAP-infected mice appreciably increased (P ≤ 0.0007; 
Figure 7C) CD8α+ immune cells population in vitro. At this point, feeding the HNP51 or the 
VNP51 to non-infected control mice did not cause significant change (P ≥ 0.11) in CD8α+ 
immune cells repertoire in vitro splenocyte cultures stimulated with MAP antigen (Figure 
7C). 
     CD8α+CD25+ T helper cells. Non-stimulation of in vitro splenocyte cultures indicated 
that feeding the HNP51 or VNP51 to mice infected with HMAP or VMAP did not alter (P ≥ 
0.59) CD8α+CD25+ T regulatory cells on day 180. On the other hand, ConA or MAP antigen 
stimulation coupled with feeding the HNP51 or the VNP51 to HMAP- or VMAP-infected 
mice decreased significantly (P ≤ 0.004; Figure 7D) CD8α+CD25+ T regulatory cells 
population to be lower than that of infected controls.  
     Again, feeding the HNP51 or VNP51 per se to non-infected mice did not alter (P ≥ 0.70) 
CD8α+CD25+ T regulatory cells frequency under no stimulation or MAP antigen stimulation 
(Figure 7D). Yet, under ConA or MAP stimulation, frequency of CD8α+CD25+ T regulatory 
cells increased (P ≤ 0.002) to be higher than that of non-infected control on day 180 (Figure 
7D). 
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Figure 7. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their in vitro 
splenic T cell subpopulations proliferation stimulated with ConA (open bars) or with  
MAP antigen (grey bars) or nonstimulated (dark bars) on day 180.  Panel A. CD4+ T 
helper cell proliferation. Panel B. CD4+CD25+ T reg cell. Panel C. CD8α+ immune cells.   
Panel D. CD8α+CD25+ T reg cell. Data are mean ± SEM. (*) indicates a significant 
difference at P ≤ 0.05; (#) indicates a tendency for a significant difference at 0.05 < P ≤ 
0.10. 
 
     IL-10 and IFN-γ. The modulating immune effect of NP51 was still pronounced by day 
180. The MAP-specific IFN-γ secretion in the in vitro splenocyte cultures of mice infected 
with the VMAP tended to increase (P = 0.07) and was increased significantly (P = 0.0004) 
by HNP51 or VNP51 feeding, respectively, relative to the HMAP- or VMAP-infected 
controls (Figure 8A).  
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Conversely, feeding the HNP51 or VNP51 to mice infected with HMAP did not significantly 
change (P ≥ 0.16; Figure 8A) the secretion of IFN-γ in splenocyte culture from mice 
inoculated with HMAP. On the whole, there was significant treatment (P = 0.0001) and 
gender (P = 0.02; Figure 8A) effects on MAP-specific IFN-γ in the in vitro splenocyte 
cultures.  
     Importantly, feeding the VNP51, not the HNP51 (P ≥ 0.57; Figure 8A), remarkably 
increased the production of MAP-specific IL-10 by the splenocytes from mice infected with 
either the HMAP (P = 0.0003) or VMAP (P = 0.0001; Figure 8A) when stimulated with the 
sonicated MAP in vitro.    
     Total and MAP-specific IgG isotypes. By day180, the immune-modulating effects of 
HNP51 and VNP51 changed dramatically (Figures 8C, 8D, 8E and F). Feeding the HNP51 to 
HMAP- or VMAP-infected mice did not change significantly (P ≥ 0.14; Figures 8C and E) 
their serum total IgG1 or IgG2a relative to those of the control mice.    
     But feeding the VNP51 to mice infected with the HMAP considerably decreased (P = 
0.03) their total IgG1 concentration and simultaneously maintained their total IgG2a 
concentration significantly greater (P = 0.0001) than that of the HMAP-infected control 
mice. In contrast, however, feeding the VNP51 to VMAP-infected mice did affect (P = 0.81; 
Figure 8C) their total IgG1 and maintained their total IgG2a concentration lower (P = 0.02) 
than that of the control similar to finding of day 135 (Figure 8E). 
     Similar to that of day 135, feeding VNP51 to non-infected mice significantly lowered 
their total IgG1 (P = 0.01) and IgG2a (P = 0.0001; Figures 8C and E). Also, HNP51 feeding to 
non-infected mice lowered (P = 0.002) their total IgG2a but did not significantly change (P = 
0.18) their total IgG1 relative to that of uninfected control mice (Figures 8C and E). Notably,  
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Figure 8. Effect of VNP51 and HNP51 probiotic feeding to Balb/c mice on their MAP-
specific interferon (IFN)-γ and interleukin (IL-) 10 and serum total and MAP-specific 
immunoglobulins (Ig) concentrations on day 180. Panel A. MAP-specific IFN-γ 
concentrations. Panel B. MAP-specific IL-10 concentrations. Panel C. Total IgG1 
concentrations. Panel D. MAP-specific IgG1 concentrations. Panel E. Total IgG2a 
concentrations. Panel F. MAP-specific IgG2a concentrations. Data are mean ± SEM. (*) 
indicates a significant difference at P ≤ 0.05 and (#) indicates a tendency for a significant 
difference at 0.05 < P ≤ 0.10. 
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whereas the effect of HNP51 and VNP51 on total IgG1 and IgG2a was identical (P = 0.21), 
feeding the VNP51 decreased (P = 0.0001) total IgG2a lower than that of the HNP51-fed 
mice (Figures 8C and E).  
     Examination of the MAP-specific immunoglobulins revealed a pattern that coincides with 
the total IgG1 and IgG2a (Figures 8C, D, E and F). Feeding the HNP51 to HMAP- or VMAP-
infected mice decreased dramatically (P ≤ 0.02) their MAP-specific IgG1 and IgG2a (Figures 
8D and F). Curiously enough, feeding the VNP51 to HMAP-infected animal raised 
significantly their MAP-specific IgG1 and IgG2a higher (P ≤ 0.002) than that of the HMAP- 
and VMAP-infected controls (Figures 8D and F).  
DISCUSSION 
          This paper describes novel findings outlining the efficacy of the probiotics NP51 to 
curtail progression of JD in a murine model. The most important finding of this work is the 
discovery that NP51 prevents progression of MAP infection through upregulation of the 
CD8α+ immune cell-mediated immunity. These findings provide substantial evidence that 
future MAP vaccines should be designed to mediate CD8α+ immune cell-mediated 
immunity, rather than Th1-mediated adaptive immunity.   
     Overall, feeding the VNP51 to HMAP-infected mice elicited a sustained secretion of 
MAP-specific IFN-γ and its counter-regulatory MAP-specific IL-10 (Figures 2A and B, 4A 
and B, 6A and B, and 8A and B). It also increased total and MAP specific IgG1, but mostly, 
decreased total and MAP specific IgG2a suggesting attenuation of the inflammatory response 
(Figures 2C, 2D, 2E, and 2F, 4C, 4D, 4E, and 4F, 6C, 6D, 6E, and 6F, 8C, 8D, 8E, and 8F).  
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     Nerstedt and colleagues (2007) has shown that feeding Lactobacillus acidophilus to mice 
upregulates genes involved in host defense against pathogens infection as well as genes that 
control energy homeostasis.  
       Feeding probiotics to mice orchestrates DC maturation and activation of NK cells 
(Fernandez et al., 1999; Guiton et al., 2009; Gad et al., 2011; Evrard et al., 2011). Activation 
of DC during intracellular pathogens, such as Toxoplasma gondii and Mycobacterium 
tuberculosis infections augmented CD8+ T cell-mediated immunity (Guiton et al., 2009; ) in 
mice. Report by Rauelt and colleagues (2003) clearly showed that NKG2D immunoreceptor 
mediate DC, NK cells, and CD8+ cytotoxic T cells mutual activation.  
     Also, infection with MAP decreases abrogate CD4+ Th1 responses during the incubation 
period that extend for 2-5 years (Noss et al. 2001; Pai et al., 2004; Weiss and Souza, 2008).   
Intriguingly, in CD4+ T helper cell deficient mice, NK cells activated CD8+- cytotoxic T cell-
mediated immunity against intracellular parasites (Combe et al., 2005).  
     In this study, no change, however, was detected in CD4+ T helper cells population (Figure 
1A, 3A, 5A, and 7A) suggesting that the source of the IFN-γ is not CD4+-mediated adaptive 
immunity. Following infection with intracellular pathogen, CD8+ T cells were the primary 
source of IFN-γ secretion (Bou-Bahnem et al., 2009). IFN-γ augments the ability of 
macrophages to express MHC class I and crosspresent exogenous antigen to CD8+ cytotoxic 
T cells (Trost et al., 2009). In contrast, signaling of the 19-kDa lipoprotein on the cell wall of 
MAP via TLR-2 on macrophage inhibits IFN-γ-induced upregulation of macrophage genes 
involved in the immune response against intracellular pathogens (Pai et al., 2004).  
     Of significant interest, is the finding that the CD8α+ immune cells (cytotoxic T cells, DC, 
NK cells, and NK T cells) have increased substantially (Figures 1C, 3C, 5C, and 7C, and 
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8C), but not the CD4+ T helper cells.  Works by Perez-Cano and colleagues (2010) showed 
that Lactobacillus salivarius CECT5713 and Lactobacillus fermentum CECT5716 
stimulation of PMNs did not seem to activate CD4+ T helper cells (Perez-Cano et al., 2010). 
In contrast, L. salivarius CECT5713 and L. fermentum CECT5716 induced the activation of 
the CD8+ immune cells.  
    Our data indicate that VNP51- and HNP51-orchestrated CD8α+ immune response is 
characterized by a Th1-like immunity. The data also point significant evidence that probiotic 
VNP51 and HNP51 do not mediate proliferation of CD4+ Th2 helper cell repertoire instead 
VNP51 and HNP51 modulate the activity of immunoglobulin-secreting plasma cells (Figures 
2C, 2D, 2E, and 2F, and 4C, 4D, 4E, and 4F, and 6C, 6D, 6E, and 6F,  and 8C, 8D, 8E, and 
8F).   
     CD8α+CD25+ T regulatory cell population decreased by HNP51 or VNP51 feeding 
(Figures 1D, 3D, 5D, and 7D) to VMAP- or HMAP-infected mice or VMAP-infected 
controls. Similar to CD4+CD25+ T reg cells, CD8α+CD25+ T reg cells inhibit proliferation of 
CD25+ T cells via cell-to-cell contact that requires expression of CTLA-4 and TGF-ß (Cosmi 
et al., 2003). Induction of CD8+CD25+ T reg cells during infection with pathogenic simian 
immunodeficiency virus (SIV) in cynomolgus macaques correlated negatively with SIV 
antigen-specific T cell proliferation but correlated positively with increased virus burden in 
cynomolgus macaques (Karlson et al., 2007) and in human (Nigam et al., 2010). 
     Curiously enough, when HNP51 or VNP51 was fed to VMAP-infected mice on day 90, 
not only secretion of MAP-specific IFN-γ was not stimulated, but also total and MAP 
specific IgG1 and IgG2a production was inhibited, suggesting that probiotic NP51, whether 
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heat-killed or viable, mediate its anti-VMAP immune responses through a pathway that does 
not involve Th1 and Th2 responses in murine model of JD.  
     It was established that up to 29 days postinfection with intracellular pathogens, the 
primary sources of IFN-γ in mice is chiefly the CD8+ immune cells, cytotoxic and NK T cells 
(Thale and Kiderlen, 2005; Bou Gahnem et al., 2009), not MHC-II-expressing CD4+ T helper 
cells. Thus, it is rational to suggest that the simultaneous increase of the antiinflammatory IL-
10 is the MAP-infected macrophages, not CD4+ Th-2 T cells whose frequency did not 
change under mitogen or MAP antigen stimulation (Figures 1A, 3A, 5A, and 7A). Also, 
infection with MAP is known to increase the production of IL-10 primarily from the 
macrophage lineage (Fiorentino et al., 1991). 
       The immunoglobulin profile indicates that HNP51 and VNP51 differentially modulate 
the immune system depending on viability of MAP. We observed that HNP51 did not 
increase MAP-specific IgG1 and decreased MAP-specific IgG2a in HMAP-infected mice. On 
the contrary, HNP51 sustained a robust IgG1 and IgG2a decrease in VMAP-infected mice 
(Figures 1C and E, 2C and E, 3C and E, 4C and E).  
     By day 135, the anti-VMAP immune response induced by either the HNP51 or VNP51 
became distinct than that triggered against HMAP. Remarkably, HNP51 or VNP51 
administration to VMAP-infected mice did not elevate IFN-γ concentration but decreased 
VMAP-specific IL-10 production in their in vitro splenocyte cultures when stimulated with 
the sonicated VMAP antigen on day 135 (Figures 6A and B). The decrease of IL-10 
production is associated with decreased infectivity and dissemination of MAP (Denis and 
Ghadirian, 1993).  
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On the contrary, stimulation of the in vitro splenocyte culture of HMAP-infected mice fed 
the VNP51 increased IL-10 production. It can be speculated that the immunologic goal of the 
increased IL-10 in the splenocytes culture of HMAP-infected mice is to alleviate the 
unnecessary IFN-γ produced against an already dead pathogen and to counter-regulate the 
tissue destructive effects of IFN-γ (Figure 6A and B). 
     To verify whether this immune response was associated with decreased infectivity of 
MAP, we cultured different tissues from VMAP-infected mice fed either the HNP51 or the 
VNP51 on Herrold’s egg yolk agar medium. Of significance, administration of the HNP51 or 
VNP51 remarkably decreased the VMAP burden in livers, MLNs, and spleens of mice 
infected with the VMAP on days 135 (Osman, et al. unpublished data).  
     The decreased VMAP burden in tissues on day 135, when the IFN-γ concentration was 
not elevated and IL-10 concentration was decreased, provided evidence that killing of VMAP 
has been accomplished by the HNP51- and VNP51-induced CD8α+ immune machineries 
(cytotoxic T cells and NK cells) that bypasses the need for high IFN-γ induction.  
      Abrogation of CD8+ T cells cytotoxicity and production of IFN-γ, not CD4+ T helper cell 
function, increased mortality of Mycobacterium tuberculosis-infected mice deficient in IL-15 
(Rausch et al., 2005). Impaired CD8+ T cell cytotoxicity and increased mortality because of      
M. tuberculosis infection were associated with down-regulation of NKG2D on CD8+ 
cytotoxic T cells (Rausch et al., 2005) suggesting a role for NK and DC in induction of CD8+ 
T cell-mediated immunity triggered against M. tuberculosis.  
     Depletion of endogenous IL-10 in Balb/c mice infected with the virulent Mycobacterium 
avium subspecies avium (MAA) diminished the bacterial growth in their spleens. Also, 
addition of anti-IL-10 antibodies to the supernatants of MAA-infected macrophages 
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remarkably enhanced their bactericidal activity (Denis and Ghadirian, 1993). Thus, it is 
possible that down regulation of IL-10 secretion to decrease pathogenicity of VMAP seems 
to be one immune mechanism that features NP51 immunologic action.  
     By day 180, histopathological examination of VMAP-infected mice demonstrated 
presence of paucibacillary granulomas suggesting significant killing of MAP. Also, the 
decreased spleen cellularity indicated a subsided immune response against VMAP infection 
(Osman et al., manuscript under review). The paucibacillary phenotype of granuloma 
observed was associated with an active production of VMAP-specific IFN-γ in the in vitro 
splenocyte cultures from VMAP-infected mice fed either the HNP51 or VNP51 (Figure 8A).  
     It seems more prudent for the proinflammatory IFN-γ to increase at this time in the 
VMAP-infected mice fed the VNP51. We are lured to speculate that an increase of IFN-γ at 
this stage is unlikely to exacerbate the already subsiding ileitis, especially when VMAP-
specific IL-10 is elevated (Figure 8A and B). We validated the histopathological evidence of 
MAP remission on day 180 by culturing tissues of VMAP-infected mice fed or not the 
HNP51 or VNP51 on Herrold’s egg yolk agar medium supplemented with Mycobactin J. Of 
interest, MAP burden was remarkably attenuated in livers, MLNs, and ceca of VMAP-
infected mice fed the HNP51 or the VNP51 (Osman et al., manuscript under review).  
     The most important finding of this work is the discovery that the VNP51- and HNP51-
induced immune response targeting MAP is accomplished through the CD8α+ immune cell-
mediated immunity.  
         Our data suggest that VNP51 and HNP51 caused DC maturation and activation of NK 
cells leading to induction of CD8α+ immune cell-mediated immunity. These findings lend 
support to Guiton et al (2009) that CD8+ cytotoxic T cells are the dominant effector cells 
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following DC activation and infection with intracellular pathogen. Also our findings are in 
agreement with observation of Rault and colleagues that NKG2D immunoreceptor 
orchestrate the interaction of DC, NK, and CD8+ T cell to activate CD8+ immune cell-
mediate immunity against intracellular pathogens. 
CONCLUSIONS 
     The data suggest that probiotic VNP51 and HNP51 induce CD8α+ immune cells 
upregulation that hinders MAP growth in vivo. The important finding that feeding the VNP51 
to HMAP-infected mice increases significantly their CD8α+ immune cell repertoire and 
serum MAP-specific IgG1 and IgG2a higher than that of the HMAP- and VMAP-infected 
control mice exquisitely reveal and persuasively advocate the efficacy of VNP51 as a potent 
adjuvant to second generation MAP vaccines. The data also provide considerable evidence 
that the second generation MAP vaccines should be designed to induce CD8+ T cell 
mediated, not Th1, immunity. 
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CHAPTER 6.  TRANSFORMATION OF LACTATING DAIRY COW 
DIGESTIVE SYSTEM MICROBIOME BY FEEDING BOVAMINE®: 
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INTERPRETIVE SUMMARY: Modification of immune responses and digestive system 
microbiota of lactating dairy cows by feeding Bovamine®. By Osman et al., page. Ruminal 
and digestive system microbiota is known to influence animal productivity. A novel direct-
fed microbial that positively modifies the digestive system microbiota to enhance the 
production efficiency of dairy animals was evaluated. Herein, we show that Bovamine® 
modifies the ruminal and digestive system microbiota to increase concentrations of ruminal 
volatile fatty acids that may lead to enhanced production efficiency. 
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ABSTRACT 
     We evaluated the effect of Bovamine®, Lactobacillus acidophilus strain NP51 and 
Probionibacterium freudenreichii strain NP24, feeding on the bacterial population 
composition of the digestive system microbiota of Jersey and Holstein dairy cattle during late 
lactation (average DIM = 202.44 days on time 0). To unveil the underlying mechanisms, we 
examined the Bovamine® immune modulative effects as well as effects on productivity. 
Dairy cows were randomized to treatment groups that were either fed the Bovamine® (1 ×109 
CFU of Lactobacillus acidophilus strain NP51 plus 2 × 109 CFU of Probionibacterium 
freudenreichii· cow-1·day-1) or the lactose carrier mixed with the total mixed ration (TMR) 
for six weeks.  Feeding Bovamine® favorably modified the digestive system microbial 
ecology as seen by the bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP) 
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compared with that of the control cows fed the lactose carrier only. Fecal Firmicutes : 
Bacteroides was decreased suggesting decreased shedding of potentially pathogenic bacteria. 
On the contrary, ruminal Firmicutes : Bacteroides was increased, which is indicative of 
increased energy harvest and improved ruminal digestibility. As a result, concentrations of 
the total volatile fatty acids were increased significantly in the rumen. These results suggest 
that feeding Bovamine® to lactating dairy cows during late lactation favorably alters their 
digestive system microbiota and improves the nutrient digestibility and energy availability 
with significant implication to transition and early lactation dairy cows.  
INTRODUCTION 
     The digestive system of dairy cattle is inhabited by a multitude of microorganisms that 
profoundly influence the whole dairy cow physiology, metabolism, and productivity 
(Ozutsumi et al., 2005; Dowd et al., 2008; MeGarvey et al., 2010). It is well established that 
dairy cattle serve as primary reservoir for E. coli O157:H7 (Chapman et al., 2001) and 
Salmonella (Steinmuller et al., 2006). Thus, transformation of dairy cattle digestive system 
microbiota to decrease prevlance of pathogenic bacterial species in their fecal matter is 
central to biosecurity, food safety, and production efficiency. Microbiota of the bovine 
digestive system can be transformed in a noteworthy manner, not only through the alterations 
of the diet chemical composition (Callaway, 2010), but also through feeding probiotics 
(Vamanu et al., 2008).  
      Bovamine® is a patented formulation of Lactobacillus acidophilus strain NP51, lactic 
acid-producing bacteria and Probionibacterium freudenreichii NP24, lactic acid-utilizing 
bacteria. These microbes are mixed with lactose as a carrier to make the commercially 
available Bovamine®.  
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     It has been shown that feeding Bovamine® to beef cattle appreciably decreases  E. coli 
O157:H7 shedding in feces (Younts-Dahl et al., 2006; Stephens et al., 2007). Also, E. coli 
O157:H7 population was decreased significantly on the hide of Bovamine®-fed cattle. In 
additon, feeding Bovamine® decreased shedding of Salmonella in feces of beef steers 
(Stephens et al., 2007). 
     Feeding Lactobacillus acidophilus strain NP51 alone decreased shedding of  
E. coli O157:H7. Also, feeding  Lactobacillus acidophilus strain NP51 to beef steers 
decreased the average thickness of the lamina properia (Elam et al., 2003) with excellent 
implication to inflammation reduction and digestive system diseases. Additionally, feeding 
the viable or heat-killed NP51 to murine model of Johne’s disease decreased shedding of 
Mycobacterium avium subspecies paratuberculosis, the causitive agent of Johne’s disease, in 
their fecal pellets (Osman et al., unpublished data). Also, supplemental Bovamine® feed to 
beef steers on steam-flacked corn diet increased their gain:feed by about 2% (Vasoconcelos 
et al., 2008). 
     The biological mechanisms that underly the effects of Bovamine® on the productivty and 
immunity of dairy cow are understood poorly and are yet to be unravelled. We hypothesize 
that feeding Bovamine® to dairy cattle differentially alter the relative abundance of the 
bacterial composition of their digestive system microbiota to inhibit growth of pathogenic 
bacteria, improve nutrient digestibility and energy homeostasis, and favorably modify the 
immune system responses. To test this hypothesis, we fed Bovamine® to late lactation dairy 
cattle and evaluated ruminal microbial population fermentation and immune responses. 
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MATERIALS AND METHODS 
Experimental Design 
     Dairy cows (24 Holsteins and 24 Jerseys) in late lactation (average DIM = 202.4 days) 
were assigned randomly to one of two treatment groups: Bovamine®-fed (n = 24) or control 
(n = 24).  Each treatment group contained 12 Holstein and 12 Jersey dairy cows housed 
separately in a pen at the Iowa State University Research Dairy Farm in Ames, IA. Cows 
were adapted to the pen and total mixed ration (TMR; Table 1) diet for two weeks prior to 
the administration of the treatment. 
     The Bovamine® group was fed 1.04 ×109 CFU of Lactobacillus acidophilus strain NP51 
plus 2.04 × 109 CFU of Probionibacterium freudenreichii mixed with lactose (Bovamine® 
commerical dairy formula; Nutrition Physiology Company, LLC, Guymon, OK) at a rate of 
1.04 g· cow-1·day-1 for six wk. Bovamine® was mixed with 471.7g per cow daily of ground 
corn and top-dressed onto the TMR that fed ad libitum. The control group was fed the lactose 
carrier (1.04 g per cow) mixed with 471.1 g of ground corn per cow daily for six wk. Cows 
were fed once a day at 9:00 h and milked twice a day at 18:00 h. All the experimental 
procedures were done in accordance with the guidelines of the Iowa State University 
Institutional Animal Care and Use Committee (IACUC). 
Sampling and Analysis. 
     Ruminal and Fecal Samples. At the end of the two-wk adaptation period (time 0) and at 
the end of wk 3, and wk 6 of the experiment, ruminal liquor (100 mL) was collected by using 
a stomach tube. Simultaneously, about 15 g of feces were collected directly from the rectum 
of each cow. Both ruminal and fecal samples were used for examining the relative abundance 
of major bacterial phyla and taxa within the ruminal and fecal microbiota. We used the 16S 
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rDNA bacterial tag-encoded FLX amplicon pyrosequencing (bTEFAP; Roche 454 
Pyresequencer; Dowd et al., 2008) to perform the diversity analyses. 
     Also, separate aliquots of the ruminal liquor and fecal samples were used to determine the 
pH by using the pH meter Accumet AR15 (Fisher Scientific, Pittsburg, PA) and the 
concentration of different VFAs by using the Varian 3900 GC Gas Chromatograph (Varian 
Analytical Instruments,  Walnut Creek, CA).  
     Blood Samples. Sixty milliliters of blood were collected from 16 cows (eight Holsteins 
and eight Jerseys) in each treatment group by jugular venipuncture on time 0, wk 3, and wk 
6. Blood samples were used to isolate the peripheral blood mononuclear cells (PMNs; 
Karcher et al., 2008). Briefly, 60 mL of blood were mixed with 6 mL of 2 × acid-citrate-
dextrose anticoagulant (ACD, 1:10) and diluted with sterile phosphate-buffered saline (PBS; 
0.14 M NaCl, 0.003 M KCl, 0.01 M Na2HPO4, and 0.0018 M KH2PO4; pH 7.4). After 
centrifugation at 4000 × g for 30 min, the PMN layer was collected and overlaid onto 5 mL 
of Ficoll-Hypaque (Sigma-Aldrich, Saint Louis, MO).  
     After centrifugation at 4000 × g for 30 min, PMNs were harvested into a 50 mL sterile 
graduated tube (Corning Inc, Corning, NY) and RBCs were lysed hypotonically. The PMNs 
were collected by centrifugation at 3000 × g for 10 min. PMNs then were washed twice using 
sterile PBS and counted by using the Z1 Coulter Counter Analyzer (Beckman Coulter, Brea, 
CA).    
     Subsequently, cells were diluted to 2 × 106 cells/ mL and cultured in vitro in RPMI-1640-
GlutMax (Invitrogen, Carlsbad, CA) plus 10% heat-inactivated fetal calf serum (Fisher 
Scientific, Hanover Park, IL) and 1% antibiotic/antimycotic solution (Invitrogen, Carlsbad, 
CA).  
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     In vitro cell cultures were either nonstimulated or stimulated with concanavalin A (Sigma-
Aldrich) at 10 µg/mL. The cell cultures were incubated at 370 C and 5% CO2: 95% O2 for 72 
h. Following incubation, the pelleted cells were washed twice with cold sterile PBS and 
stained for surface markers with primary antibodies CD4 IL-AII, IgG2a (ABD Serotec), CD8 
BAQIIIA, IgM (ABD Serotec), γδ TCR, 6B21A (ABD Serotec), CD25 LCTBA, IgG2b (ABD 
Serotec), and CD335 ACSI Igb1 (ABD Serotec, Raleigh, NC).  
     The cells in wells were incubated for 20 min at 4o C in the dark followed by brief 
centrifugation and decanting of the supernatant. Pelleted cells were suspended in a secondary 
antibodies cocktail (Alexa 350 IgM, FITC IgG2a, PE IgG1, Cy5 IgG2b, and APC Cy7 IgG3, 
ABD Serotec, Raleigh, NC) at 100 µL per well.   
     Subsequently, frequencies of cells were determined by using the fluorescence-activated 
cell sorter (BD FACSAria II; Becton Dickinson Biosciences, Franklin Lakes, NJ). Cell 
frequency data were analyzed by using FlowJo software (Tree Star, Inc., Ashland, OR).  
Statistical Analysis 
    
      For volatile fatty acids production and flow cytometric statistical analyses, we used the 
PROC MIXED of SAS version 9.2 with covariance structure variance component and 
containment method for determining the degrees of freedom. The Class Statement specified 
breed, treatment, cow ID, and time. Also, the Model Statement specified the fixed effect of 
interest equals breed, treatment, time, and all their possible interactions. Cow nested in 
treatment by bread interaction was considered a random effect. The least squared means of 
the response variable of interest at different time points for both the Jersey and Holstein 
breeds were computed using the LSMEANS statement in PROC MIXED. Subsequently, 
pairwise differences among least squared means were computed by using the PDIFF option 
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and adjusted by using the Tukey method. Probability (P-) values ≤ 0.05 indicate significant 
difference, and P values between 0.05 and 0.10 indicate tendency for the effect to be 
different or significant.  
          For the microbiome and metagenomics data analyses, treatment effects on the relative 
abundances of all phyla were evaluated by using a mixed-effects model. Relative abundances 
were transformed prior to analysis, and analyses were conducted separately for each of the 
sampling sites (rumen vs. fecal) and breeds (Jersey vs. Holstein). In addition, the ratio of 
Firmicutes to Bacteroidetes (log transformed) was determined. Treatment and week were 
considered fixed effects. Repeated measurements from the same individual was considered 
random effects. Given the study design (measurements at baseline time 0 and at wk 6), the 
designation of a treatment effect is based on a significant (i.e., P < 0.10) treatment by week 
interaction. Overall error rates were controlled using a false discovery rate of 5%.  
Uncontrolled P values were used to screen taxa, and α = 0.10 was used as a reference. 
RESULTS 
     Effect on ruminal total volatile fatty acid concentrations. At time 0 of the study, total 
volatile fatty acids (VAFs) concentrations did not differ (P = 0.50) between treatment groups 
of  Holstein and Jeresy dairy cows (Tabel 1). On wk 3, feeding Bovamine® to dairy cows 
substantially increased (P = 0.0001; Table 1) total VFAs by 34% compared with those of the 
control dairy cows. Feeding Bovamine® to dairy cows increased their total VFAs by 68.4 and 
14.5% on wk 3 and 6, respectively, compared with those of time 0 baseline (Table 1).  
     At the end of wk 6, most dairy cows approached the end of the 305-d lactation period. 
Considering each breed separately, feeding the Bovamine® at the end of the lactation period 
to Holstein dairy cows did not appreciably change (P = 0.93; Table 1) total VFAs 
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concentrations. On the contrary, Bovamine® fed to Jersey dairy cows increased substantially 
(P = 0.01) total VFAs in comparison with those of the Jersey control cows fed the lactose 
carrier only (Table 1). Regardless of the breed, feeding Bovamine® to the dairy cows tended 
to elevate (P = 0.06) total VFAs by 30% greater than that of the control dairy cows on wk 6 
of the study (Tabel 1).  
Table 1. Effects of Bovamine® feeding to dairy cattle on ruminal total VFAs production 
at time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data are mean ± SEM. (SEM = 
6.03-8.44). 
                                    
                Total VFAs, mM 
 
Statistical difference (P-value) 
                    Control Bovamine®-fed Breed Overall 
Time 
Time 0 
Wk 3 
Wk 6 
HC 
69.6±7.3 
81.0±6.03 
60.9±6.3 
JC 
69.8±6.6 
82.5±6.6 
51.1±6.6 
HB 
68.5±8.4 
114.1±6.3 
74.3±6.3 
JB 
61.05±6.6 
104.2±6 
74.1±6 
Holsteins 
0.93 
0.0003 
0.14 
Jerseys 
0.35 
0.02 
0.01 
 
0.50 
0.0001 
0.005 
VFAs, volatile fatty acids; HC, Holstein control cows; JC, Jersey control cows; HB, Holstein dairy cows fed 
Bovamine®; JB, Jersey dairy cows fed Bovamine®. 
 
     Acetate : propionate in the rumen.  At time 0 of the study, acetate : propionate was 
significanly (P = 0.0003) in the Bovamine®-fed Holstein cows as compred with that of the 
control Holstein cows.  As a result, the acetate:propionate in the Bovamine®-fed dairy cattle 
became significantly (P = 0.04) higher than that of the control (Table 2). On the other hand, 
the acetate : propionate ratio did not significantly differ (P = 0.80) between the control and 
Bovamine®-fed Jersey dairy cows at time 0 baseline (Table 2).  Bovamine® feeding, 
however, did not significantly (P ≥ 0.0.68) alter the acetate : propionate in rumens of 
Holstein and Jersey dairy cows on wk 3 or wk 6 (Tabel 2). 
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Table 2 . Effects of Bovamine® feeding to dairy cattle on ruminal acetate : propionate 
on time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data are mean ± SEM. (SEM 
= 0.67-0.73). 
                                    
        Acetate:propionate, mM 
 
Statistical difference (P value) 
Control Bovamine®-fed Breed Overall 
Time 
Time 0 
Wk 3 
Wk 6 
HC 
9.4±0.73 
2.14±0.67 
2.45±0.70 
JC 
2.84±0.73 
3.08±0.73 
2.83±0.73 
HB 
13.9±0.94 
2.94±0.8 
2.51±0.70 
JB 
3.10±0.73 
3.1±0.67 
3.08±0.67 
Holsteins 
0.0003 
0.68 
0.95 
Jerseys 
0.80 
0.95 
0.77 
 
0.04 
1.000 
1.000 
HC, Holstein control cows; JC, Jersey control cows; HB, Holstein dairy cows fed Bovamine®; JB, Jersey dairy 
cows fed Bovamine®. 
 
Effect on T lymphocyte subpopulations. 
     CD25+ T cells. At time 0, CD25+ T cells frequency in peripheral blood of dairy cows did 
not differ significantly (P = 0.61; Table 3) between the Bovamine®- fed and control groups. 
Stimulation of the in vitro T cell cultures with ConA expanded significantly (P = 0.001) the 
CD25+ T cells population relative to the nonstimulated cell cultures in both the control and 
Bovamine®-fed cows.  
Table 3. Effects of Bovamine® feeding to dairy cattle on proliferation of CD25+ T cell 
repertoire in PMNs at time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data are 
mean ± SEM. (SEM = 0.41-0.52). 
                                  CD25+ T cells repertoire frequency Statistics (P value) 
 Time        Stim                   Control Bovamine®-fed Breed Overall 
  HC JC HB JB Holsteins Jerseys  
Time 0 NS 8.8±0.44 10.13±0.39 9.2±0.52 9.4±0.52 0.52 0.24 0.73 
 ConA 15.3±0.44 15.8±0.39 15.3±0.52 16±0.52 0.93 0.76 0.88 
wk 3 NS 9.5±0.41 9.12±0.39 9.6±0.44 9.0±0.41 0.86 0.82 0.98 
 ConA 15.1±0.41 13.6±0.39 17.5±0.44 15.9±0.41 0.0002 0.0001 0.0001 
wk 6 NS 8.9±0.41 10.23±0.41 9.7±0.41 9.0±0.41 0.15 0.02 0.66 
 ConA 13.2±0.41 14.53±0.41 19.6±0.4 17.3±0.41 0.0001 0.0001 0.0001 
Stim, stimulation with concanvalin (ConA) or nonstimulation (NS); HC, Holstein control cows; JC, Jersey 
control cows; HB, Holstein dairy cows fed Bovamine®; JB, Jersey dairy cows fed Bovamine®. 
 
      
222 
 
 
 
      By wk 3 and 6, feeding the Bovamine® significantly increased (P = 0.001) the frequency 
of CD25+ T cells when stimulated with ConA relative to that of the control group (Tabel 3).   
     CD4+ T helper cells. CD4+ T helper cell ferequency did not differ (P = 0.20) on time 0 
between the Bovamine® feeding and control group (Tabel 4). Also, Bovamine® feeding did 
not significantly (P ≥ 0.26) change the frequency of CD4+ T helper cells population in the 
peripheral blood of dairy cows on wk 3 and wk 6 (Table 4). Note worthy, Bovamine® fed to 
Jersey, not Holstein (P = 0.68), dairy cattle increased (P = 0.05) CD4+ T helper cell 
repertoire under ConA stimulation (Table 4). 
Table 4. Effects of Bovamine® feeding to dairy cattle on proliferation of CD4+ T helper 
cell repertoire in PMNs on time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data 
are mean ± SEM. (SEM = 1.7-2.1). 
Time             Stim                CD4+ T helper cells repertoire frequency Statistics (P value) 
                                              Control Bovamine®-fed Breed Overall 
  HC JC HB JB Holsteins Jerseys  
Time 0 NS 50.1±1.8 51±1.6 46.8±2.1 51.6±2.1 0.23 0.83 0.47 
 ConA 69.1±1.8 70.1±1.6 73.2±2.1 71.5±2.1 0.13 0.77 0.20 
wk 3 NS 46.9±1.7 50.7±1.6 50.3±1.8 50.5±1.7 0.16 0.91 0.34 
 ConA 72±1.7 70.5±1.6 74.1±1.8 72.2±1.7 0.41 0.45 0.26 
wk 6 NS 49.1±1.7 48.2±1.7 50.1±1.7 48.02±1.7 0.66 0.95 0.79 
 ConA 78.8±1.7 69.3±1.7 71.8±1.7 74±1.7 0.68 0.05 0.27 
Stim, stimulation with concanvalin (ConA) or nostimulation (NS); HC, Holstein control cows; JC, Jersey 
control cows; HB, Holstein dairy cows fed Bovamine®; JB, Jersey dairy cows fed Bovamine®. 
 
     CD4+CD25+ T reg cells. T reg cell frequency was not significantly different (P ≥ 0.98) 
between the Bovamine® fed and the control groups when non-stimulated or stimulated with 
ConA on time 0 (Table 5). Bovamine® feeding, however, increased (P ≤ 0.02) the frequency 
of CD4+CD25+T reg cells by wk 3 and 6 (Table 5) under ConA stimulation relative to that of 
the control cows.  
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Table 5. Effects of Bovamine® feeding to dairy cattle on CD4+CD25+ T reg cell 
repertoire in PMNs at time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data are 
mean ± SEM. (SEM =0.94-1.20 ). 
                                   CD4+CD25+ T reg cells repertoire frequency           Statistics (P value) 
 Time         Stim                    Control  Bovamine®-fed Breed Overall 
  HC JC HB JB Holsteins Jerseys  
Time 0 NS 10.4±1.0 12.0±0.89 11.2±1.2 10.5±1.2 0.60 0.32 1 
 ConA 17.6±1.0 17.8±0.89 17.4±1.2 18.2±1.2 0.89 0.76 0.91 
wk 3 NS 10.0±0.94 10.2±0.89 10.4±1.0 9.9±0.94 0.79 0.83 0.96 
 ConA 13.5±0.94 13.7±0.89 16.8±1.0 16.3±1.0 0.02 0.05 0.002 
wk 6 NS 11.5±0.94 13.8±0.94 11.8±0.94 12.2±0.94 0.81 0.24 0.50 
 ConA 15.5±0.94 14.50±0.91 19.3±0.94 19.1±0.94 0.005 0.0008 0.0001 
Stim, stimulation with concanvalin (ConA) or nostimulation (NS); HC, Holstein control cows; JC, Jersey 
control cows; HB, Holstein dairy cows fed Bovamine®; JB, Jersey dairy cows fed Bovamine®. 
 
     CD8+ cytotoxic T cells. At time 0, when nonstimulated in vitro, frequency of CD8+ 
cytotoxic T cells reperoire did not significantly (P = 0.97) change between the control and 
Bovamine® fed group (Table 6). When stimulated with ConA, CD8+ cytotoxic T cells 
exapanded egually (P = 0.60) in the Bovamine® fed and control groups, but significantly 
higher (P = 0.0001)  than the expansion of the nonstimulated cultures from the two control 
groups (Table 6).  
     By wk 3 and 6, on the other hand, Bovamine® feeding per se substantially increased (P ≤ 
0.09) the CD8+ cytotoxic T cells population in the nonstimulated in vitro cell cultures to be 
greater than that of the control cows (Table 6). Expansion of CD8+ cytotoxic T cells of 
Bovamine®-fed cows under ConA stimulation was significantly higher (P ≤ 0.002) than that 
of cell culture from control cows (Tabel 6).  
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Table 6. Effects of Bovamine® feeding to dairy cattle on CD8+ cytotoxic T cell repertoire 
in PMNs on time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data are mean ± 
SEM. (SEM = 0.75–1.01). 
                                      CD8+ cytotoxic T cells repertoire frequency Statistics ( P value) 
Time           Stim                     Control Bovamine®-fed Breed Overall 
  HC JC HB JB Holsteins Jerseys  
Time 0 NS 22.9±0.9 21.5± 22.0±1.0 22.4±1.0 0.53 0.48 0.97 
 ConA 29.4±0.8 28.3±0.8 29.5±1.0 29.7±1.0 0.95 0.27 0.42 
wk 3 NS 24.4±0.8 23.6±0.8 28.7±0.9 29.2±0.8 0.0004 0.0001 0.0001 
 ConA 29.1±0.8 29.1±0.8 35.3±0.9 35.7±0.8 0.001 0.0001 0.0001 
wk 6 NS 24.6±0.8 24.9±0.8 28.8±0.8 26.8±0.8 0.0002 0.09 0.0002 
 ConA 32.4±0.8 34.7±0.8 39.5±0.8 38.2±0.8 0.0001 0.002 0.0001 
Stim, stimulation with concanvalin (ConA) or nostimulation (NS); HC, Holstein control cows; JC, Jersey 
control cows; HB, Holstein dairy cows fed Bovamine®; JB, Jersey dairy cows fed Bovamine®. 
 
     CD8+CD25+ T reg cells.  Following a pattern disimilar to that of the CD8+ cytotoxic T 
cells, CD8+CD25+ T reg cells did not differ (P ≥ 0.47) at time 0 and wk 3 and 6 between 
control and the Bovamine®-fed groups in the nonstimulated cultures (Tabel 7). Also, by time 
0 and wk 3, Bovamine® feeding  and stimulation with ConA did not significantly vary 
CD8+CD25+ T reg cells differently from that of the control (Tabel 7).  
Table 7. Effects of Bovamine® feeding to dairy cattel on CD8+CD25+ T reg cell 
repertoire in PMNs on time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data are 
mean ± SEM. (SEM = 1.10-1.39). 
                                     CD8CD25+ T reg cell repertoire frequency        Statistics (P value) 
Time          Stim                    Control Bovamine®-fed Breed Overall 
  HC JC HB JB Holsteins Jerseys  
Time 0 NS 13.8±1.2 14.3±1.0 14.7±1.4 14.3±1.4 0.62 0.99 0.73 
 ConA 23.9±1.2 22.9±1.0 23.2±1.4 23±1.4 0.69 0.94 0.82 
wk 3 NS 11.8±1.1 12.6±1.0 11.5±1.2 11.3±1.1 0.88 0.37 0.47 
 ConA 19.2±1.1 17.3±1.0 21.3±1.2 17.1±1.1 0.19 0.89 0.39 
wk 6 NS 15.2±1.1 14.7±1.1 15.6±1.1 14.4±1.1 0.83 0.86 0.98 
 ConA 23.1±1.1 21.2±1.1 30.7±1.1 25.1±1.1 0.0001 0.01 0.0001 
Stim, stimulation with concanvalin (ConA) or nostimulation (NS); HC, Holstein control cows; JC, Jersey 
control cows; HB, Holstein dairy cows fed Bovamine®; JB, Jersey dairy cows fed Bovamine®. 
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On wk 6, on the other hand, feeding Bovamine® and stimulation with ConA increased 
CD8+CD25+ T reg cells proliferation to be  significantly (P = 0.001) higher than that of the 
ConA-stimulated control (Table 7). 
      CD335+ NK cells. At time 0, nonstimulated NK cells expressing CD335+ of Bovamine®-
fed cows did not significanly (P ≥ 0.17 ) differ from that of the control cows on any wk 
tested (Tabel 8). Stimulation of CD335+ NK cells with ConA, however, nondiscriminately (P 
= 0.33 for the difference) and significanly (P = 0.0001) elevated CD335+ NK cells repertoir 
in the Bovamine®-fed and control cows to be higher than that of the nonstimualted cultures 
of both groups on time 0 (Tabel 8). 
     By wk 3 and 6, Bovamine® feeding and ConA stimulation appreciably (P = 0.0001) 
increased expansion of CD335+ NK cells population to be greater than that of CD335+ NK 
from control cow cell cultures (Table 8).  
Table 8. Effects of Bovamine® feeding to dairy cattle on CD335+ NK cell repertoire in 
PMNs on time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data are mean ± SEM. 
(SEM = 0.11-0.13). 
                                     CD335+ NK cells repertoire frequency       Statistics (P-value) 
Time          Stim                     Control Bovamine®-fed Breed Overall 
  HC JC HB JB Holsteins Jerseys  
Time 0 NS 1.6±0.11 1.8±0.10 1.8±0.11 1.6±0.13 0.19 0.17 0.99 
 ConA 2.5±0.11 2.4±0.10 2.6±0.13 2.6±0.13 0.81 0.24 0.33 
wk 3 NS 1.7±0.11 1.6±1.0 1.7±o.11 1.6±0.11 0.67 0.95 0.79 
 ConA 2.5±0.11 2.5±0.10 3.6±.11 3.4±0.11 0.0001 0.0001 0.0001 
wk 6 NS 1.7±0.11 2.1±0.11 1.8±0.11 1.9±0.11 0.67 0.36 0.73 
 ConA 2.7±0.11 2.6±0.11 4.1±0.11 3.6±0.11 0.0001 0.0001 0.0001 
Stim, stimulation with concanvalin (ConA) or nostimulation (NS); HC, Holstein control dairy cows; JC, Jersey 
control dairy cows; HB, Holstein dairy cows fed Bovamine®; JB, Jersey dairy cows fed Bovamine. 
 
     γδ T cells. The repertoire of γδ T cells did not significantly (P ≥ 0.19) differ between the 
nonstimulated in vitro cell cultures from Bovamine®-fed and control cows during time 0 and 
wk 3, and 6 (Table 9). Intriguingly, feeding Bovmaine and stimulation with ConA of γδ T 
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cells did not significantly (P ≥ 0.52) expand their repertoire relative to the nonstimulated 
cultures (Tabel 9). Bovamine® feeding, however, decreased (P = 0.03) γδ T cells in the 
nonstimulated splenocyte culutres of Jersey dairy cows, but not (P = 0.56) of Holstein dariy 
cows (Tabel 9). 
Table 9. Effects of Bovamine® feeding to dairy cattel on γδ T cell repertoire in PMNs on 
time 0, wk 3, and wk 6 relative to Bovamine® feeding. Data are mean ± SEM.  
(SEM = 0.21-0.26 ). 
                                     γδ T cells repertoire frequency          Statistics (P value) 
Time           Stim                    Control Bovamine®-fed Breed Overall 
  HC JC HB JB Holsteins Jerseys  
Time 0 NS 2.8±0.22 3.0±0.21 2.6±0.26 2.6±0.24 0.48 0.25 0.19 
 ConA 3.1±0.22 2.9±0.21 2.9±0.26 3.0±0.24 0.59 0.72 0.88 
wk 3 NS 3.6±0.21 3.7±0.20 3.7±0.22 3.3±0.21 0.71 0.22 0.57 
 ConA 3.5±0.21 3.5±0.2 3.7±0.22 3.6±0.21 0.52 0.71 0.47 
wk 6 NS 3.5±0.21 3.9±0.21 3.4±0.21 3.2±0.21 0.56 0.03 0.06 
 ConA 3.8±0.21 3.8±0.21 3.7±0.21 3.6±0.21 0.81 0.53 0.54 
Stim, stimulation with concanvalin (ConA) or nostimulation (NS); HC, Holstein control cows; JC, Jersey 
control cows; HB, Holstein dairy cows fed Bovamine®; JB, Jersey dairy cows fed Bovamine®. 
 
Effect on digestive system microbome. Feeding Bovamine® to late lactation Jersey and 
Holstein dairy cattle tended to maintain the relative abundance of Firmicutes (Bacilli and 
Clostridia) high (P = 0.06 and P = 0.07, respectively; figure 1) in comparison with the 
control cows on wk 6 (Figure 1).  
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Figure 1. Effects of Bovamine® feeding to dairy cattel on the ratio of the relative 
abundance of Firmicutes to Bacteroidetes in rumen. Points represent individual 
observations, and subjects are linked with a line. Average changes are denoted by the 
black lines.  
 
     In the rumens of the control group, relative abundance of Anaerofilm, Rhodomicrobium, 
Caldilinea, Desulfobulbus, Leptolyngbya, and Erysipelothrix genera correlated positively  
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(r ≥ 0.50; P ≤ 0.05) with production of all VFA at wk 6 (Figure 2). In rumens of Bovamine®-
fed cows, production of valerate and butyrate correlated positively with Succinovebrio, 
Bulleidia, Cattonella, Bacteroidaceae, and Verrucomicrobiales genera (r ≥ 0.5; P ≤ 0.05; 
Figure 2). Acetate production correlated positively with the relative abundance of 
Verrucomicrobiales, Mitsuokella, Burkholderia, and Roseomonas genera (r ≥ 0.5; P ≤ 0.05; 
Figure 2). Also, propionate production correlated positively with the relative abundance of 
the Caldilinea, Escherichia, Peptostreptococus, Clostridium, Mollicutes, Solirubrobacter, 
Proteus, Pseudmonas, Dorea, Staphylococcus, Massilia, Selenomonas, Paracoccus, and 
Roseomonas genera (r ≥ 0.5; P ≤ 0.05; Figure 2). Isobutyrate correlated positively with 
relative abundance of Anaerovibrio, Anaerofilm, Escherichia, Proteus, Pseudomonas, 
Staphylococcus, and Roseomonas genera (r ≥ 0.5; P ≤ 0.05; Figure 2). Valerate correlated 
positively with the relative abundance of Succinivibrio and Verrucomicrobiales genera in 
rumens of Bovamine®-fed cows (r ≥ 0.5; P ≤ 0.05; Figure 2).  
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Figure 2: Effects of Bovamine® feeding to dairy cattel on the Spearman Correlation 
among genera and individual VFAs in rumens of control and Bovamine®-fed Jersey 
and Holstein dairy cows on wk 6. 
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     In feces of Jersey dairy cows, feeding Bovamine® significantly decreased (P ≤ 0.04) 
shedding of Turicibacter and tended (P = 0.09) to decrease shedding of Streptococcus genera 
(Figure 3). Additionally, feeding Bovamine® increased shedding of Pyramidobacter, 
Thauera, Synergistetes (not shown) genera (Figure 3). Effect of the treatment by week 
interaction was significant (P ≥ 0.04) regarding the relative abundance of Veillonella and 
Microbacterium genera as they decreased in feces of Bovamine®-fed Jersey relative to that of 
the control cows (Figure 3).  
 
Figure 3. Effects of Bovamine® feeding to dairy cattel on the relative abundance of 
bacterial genera in the Jersey fecal samples. Points represent individual observations, 
and subjects are linked with a line. Changes in average relative abundance per 
treatment are denoted by the thick lines with a shaded 95% confidence region. 
 
     In feces of Holstein dairy cows, Bovamine® feeding significantly (P ≤ 0.04; Figure 4) 
decreased the relative abundance of Lactobacillus genus relative to that of the control cows 
on wk 6. The effect of treatment by week interaction was significant on the relative 
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abundance of the Ruminococcus, Pseudobutyrivibrio, Dorea, Moryella, and Gordonibacter 
as they decreased (P ≤ 0.05) in the feces of Bovamine®-fed Holsteins in comparison with that 
of the control cows (Figure 4). Also, Bovamine® feeding increased relative abundance of 
Paludibacter and maintained relative abundance of Paenibacillus, Comamonas, and 
Placentomycets (not shown) genera stable whereas they were decreased in the feces of the 
control Holstein cows on wk 6 of the study (Figure 4).  
 
Figure 4. Effects of Bovamine® feeding on the relative abundance of bacterial genera in 
the fecal matter of Holstein dairy cows. Points represent individual observations, and 
subjects are linked with a line. Changes in average relative abundance per treatment 
are denoted by the thick lines with a shaded 95% confidence region. 
 
     Feeding Bovamine® to Jersey dairy cows tended (P = 0.08; Figure 5) to decrease the 
relative abundance of Anaerofilm genus in their ruminal liquor and tended (P = 0.05 and P = 
0.10) to maintain the relative abundance of Citrobacter and TM7 (not shown) genera 
relatively stable in comparison with that of the control cows by wk 6. The effect of treatment 
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by week interaction was significant (P ≤ 0.03) on the relative abundance of the Treponema 
and Robinsonella genera,  which were increased in the ruminal liquor of Bovamine®-fed 
Jersey cows relative to that of the control cows (Figure 5). In contrast, the relative abundance 
of Brevibacillus genus was decreased (P = 0.03), whereas that of the Acidobacter genus was 
maintained relatively unchanged (P = 0.03) in comparison with those of the control (Figure 
5).    
 
 
Figure 5. Effects of Bovamine® feeding on the relative abundance of bacterial genera in 
the rumen liquor of Jersey dairy cows. Points represent individual observations, and 
subjects are linked with a line. Changes in average relative abundance per treatment 
are denoted by the thick lines with a shaded 95% confidence region. 
 
     In the rumen of Holstein dairy cows, feeding Bovamine® significantly (P = 0.001) 
increased the relative abundance of Sharpea and Synergistetes (not shown) genera and tended 
(P = 0.09 and P = 0.07, respectively) to increase the relative abundance of the Pedobacter 
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and Propionibacteria genera in their ruminal liquor (Figure 6). Also, Bovamine® feeding 
maintained the relative abundance of Lactobacillus genus relatively unchanged whereas 
abundance of Lactobacillus genus was significantly (P = 0.01) decreased in the ruminal 
liquor of the control Holstein cows (Figure 6). Also, Bovamine® feeding tended (P = 0.06) to 
decrease the relative abundance of TM7 genus in the ruminal liquor of Holstein dairy cows 
(data not shown). 
 
 
Figure 6. Effects of Bovamine® feeding on the relative abundance of bacterial genera in 
the rumen liquor of Holstein dairy cows. Points represent individual observations, and 
subjects are linked with a line. Changes in average relative abundance per treatment 
are denoted by the thick lines with a shaded 95% confidence region. 
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DISCUSSION 
     We verified whether Bovamine® feeding at the prescribed dose is efficacious at 
advantageously transforming the digestive system microbiome of lactating dairy cattle. We 
conducted a microbiome-wide metagenomic analyses to trace a Bovamine®-induced massive 
transformation in the ruminal and fecal microbiome to the genera level (Figures 1-6). The 
data exquisitely provided convincing evidence that feeding Bovamine® favorably alters the 
digestive system microbiome of dairy cattle (Figures 1-6). We also verified whether the 
Bovamine®-provoked transformation of the ruminal microbiome is coupled to increase 
energy harvest in the rumen (Tables 1 and 2). Chromatographic analyses of the ruminal 
liquor content of VFA indicated that Bovamine® feeding significantly increased the 
concentrations of VFA by wk 3 and 6 (Tables 1 and 2).  Overall, feeding Bovamine® tended 
(P = 0.06 and P = 0.07) to maintain the ratio of Firmicutes to Bacteroides in the rumens of 
Holstein and Jersey dairy cows to be higher than that of the control cows, suggesting that 
Bovamine® mediates greater energy capture and feed efficiency (Figure 1).  
      In obese human subjects, the Firmicutes to Bacteroides ratio is significantly greater than 
that of lean subjects (Armougom and Raoult, 2008). Of significance, the energy capture by 
human subjects was increased by 150 kcal when the relative abundance of the genus 
Firmicutes were increased by 20% and that of Bacteroides genus was decreased by the same 
percentage in the intestine (Jumpertz et al., 2011). In this study, feeding Bovamine® to dairy 
cows significantly increased ruminal Firmicutes relative abundance and simultaneously 
increased the production of VFAs concentration by 68.4 and 14.5% on wk 3 and wk 6, 
respectively (Figure 1; Table 1). In support of our findings, feeding microbial constituents of 
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Bovamine® to feedlot cattle fed steam-flaked corn-based diets increased their gain : feed by 
about 2% (Vasoconcelos et al., 2008).  
     The acetate : propionate inversely correlates with methanogenesis in rumens of cows 
(Russell et al., 1998). Because Bovamine® did not alter the acetate : propionate it is likely 
that Bovamine® doesn’t increase methane emission (Table 2).  This finding indicates that 
feeding Bovamine® to dairy cattle does not adversely impact global warming.  
     Dominance of particular bacteria species and their metabolism in the rumen contributes to 
differences in cattle feed efficiency (Hernandez-Sanabria et al., 2010). We verified whether 
the increase of VFAs concentration is associated with Bovamine®-induced alteration of the 
microbiome. In rumens of dairy cattle those fed Bovamine®, Spearman rank correlation 
coefficient for the association of individual genera with individual VFA indicated that 
individual VFAs correlated with different genera in the ruminal microbiome of the 
Bovamine®-fed cows (Figure 2). Probiotics feeding causes significant modification of the 
host gut microbiome leading to significant changes in metabolism of amino acids, VFAs, bile 
acids, and also accelerates glycolysis (Martin et al., 2008). Metagenomic analyses conducted 
to correlate the ruminal microbiome composition with feed efficiency phenotype in cattle 
illustrated that microbiota of feed-efficient steers cluster together differently than that of feed 
inefficient steers (Guan et al., 2008). Also, feed efficiency correlated positively with 
increased concentrations of butyrate and valerate in the rumen of feed-efficient cattle (Guan 
et al., 2008).  
     In feces of Jersey and Holstein cows, feeding Bovamine® significantly (P = 0.04) 
decreased Turicibacter genus shedding. Turicibacter has been linked to digestive system 
inflammation (Bosshard et al., 2002). Also, Bovamine® feeding tended to decrease (P = 0.10, 
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P = 0.09, P = 0.06, respectively) relative abundance of Citrobacter, an opportunistic 
pathogen in humans (Whalen et al., 2007), Streptococcus, and Comamonas and increased (P 
= 0.05) Thauera (Figures 3 and 4). It has been shown that T. selenatis decreases selenate to 
form selenium nanospheres that is secreted into the microenvironment (Charles et al., 2011). 
In addition, feeding Bovamine® to dairy cows increased (P = 0.01) the relative abundance of 
Lactobacillus and tended to increase the relative abundance of Propionibacterium in their 
rumen liquor, which is indicative of the ability of Bovamine® microbial constituents to 
transiently colonize the rumen (Figures 5 and 6). 
    The Bovamine®-induced microbiome shift seemed to be accompanied with modification of 
the immune responses. Feeding Bovamine® to dairy cattle significantly increased expression 
of CD25+ T cells by wk 3 and wk 6 (Table 2), CD4+ T cells, and CD4+CD25+ T reg cells in 
PMNs of Jersey dairy cow by wk 6 under ConA stimulation (Table 3). In agreement, 
stimulation of PMNs with probiotic mixture in vitro increased expression of CD4, CD25, 
CD69, and CD11b (Hua et al., 2010) and increased CD4+CD25+ T reg cell repertoire (Baroja 
et al., 2007).  
     The increase of CD8+ T cells by Bovamine® feeding agrees with findings of Hua et al 
(2010) that probiotic stimulation of PMNs increases expression of CD11b. It is well 
established that expression of CD11b is upregulated on effector CD8+ T cells (Christensen et 
al., 2001). It is possible that probiotics mediate differential activation of T cell 
subpopulations via modifying DC phenotype and function (Hart et al., 2004).  
     Bovamine®-triggered expansion of CD335+ repertoire of NK cells in peripheral blood of 
dairy cattle lends support to findings of Gill and coworkers (2001) who fed Lactobacillus 
rhamnosus HN001 or Bifidobacterium lactis HN019 to elderly and observed expansion of 
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CD56+ NK cells in their peripheral blood and increased tumoricidal activity. Cattle fed 
Bovamine® demonstrated increased serum IgA and increased granulocytes and monocytes in 
peripheral blood (Guillen et al., 2009).       
     We did not detect a Bovamine®-caused expansion of resting nonstimulated γδ T cells cells 
in in vitro cultures, nor did ConA stimulation expand their repertoire (Table 8). It is likely 
that the extreme sensitivity of γδ T cells to mitogen-induced apoptosis (Guo et al., 2001) has 
confounded their stimulation with Bovamine®. Unlike activated αß T cells that continue to 
divide after activation (Nobholz and Macdonald, 1983), activated γδ T cells, however, 
proliferate instantly and then die by apoptosis (Spaner et al., 1993). The short proliferation 
and rapid death of γδ T cells probably did not allow us to detect their proliferation under 
effect of Bovamine® and ConA stimulation (Table 8). 
CONCLUSIONS 
     In conclusion, Bovamine® feeding to dairy cows significantly transformed their digestive 
system microbiota, and increased the energy capture via increasing the Firmicutes to 
Bacteroides ratio. The increase energy capture resulted in increased production of VFAs in 
the rumen, suggesting the efficacy of Bovamine® to increase feed efficiency in dairy cows. 
These findings have far-reaching implications to fresh and transition dairy cattle as well as 
finishing beef cattle. 
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CHAPTER 7. GENERAL CONCLUSIONS 
General Discussion 
     Mycobacterium avium subspecies paratuberculosis (MAP) is the causative agent of 
paratuberculosis, also known as Johne’s disease (JD) in ruminant animals. JD is a chronic 
wasting ileitis that is characterized by a prolonged incubation period that lasts two to five 
years followed by a profuse, watery, intermittent diarrhea that concludes with the remise of 
the affected animal.   
     Once described in 1885 by John and Forthingham, JD was a sporadic disease that posed 
unimportant economical loss to dairy and beef industries. Adoption of the modern animal 
farming technology has enabled increasing the animal density in farms, resulting in increased 
JD incidence and increased economic losses to dairy farmers in particular. In addition, the 
ability of MAP to form biofilm makes MAP highly ubiquitous in the environment.     
       Currently, 68% of US dairy herds are infected with JD, and economic losses because of 
JD have been estimated by the USDA National Animal Health Monitoring System to 
approach US$ 250 million annually.  
     Up to date, vaccines are designed against JD to trigger Th1 responses that are 
characterized by induction of the proinflammatory cytokines IFN-γ and TNF-α. In our 
laboratory, we are concerned that induction of proinflammatory response in an ileum of a JD-
infected cow could exacerbate symptoms of JD by causing further mucosal tissue damage 
that impairs nutrient absorption and hasten death of subclinically infected animals. 
     Our experiments have grown out of the curiosity that NP51 has completely inhibited MAP 
growth in in vitro co-culture. To examine the efficacy of NP51 to inhibit MAP growth in 
vivo, we recruited 360 specific pathogen-free Balb/c mice and randomly assigned them to 
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consume sterile standard mouse chow supplemented with or without the probiotic HNP51 or 
VNP51 and either noninfected or infected with HMAP or VMAP 45 days after the onset of 
NP51 feeding . The study exquisitely illustrated that VNP51 and HNP51 probiotic feeding 
decreased MAP burden in various tissues of infected Balb/c mice including livers, spleens, 
mesenteric lymph node, and ceca.  This result was further confirmed by sufficiently revealing 
that VNP51 and HNP51 also decreased shedding of MAP IS900 genomic DNA in fecal 
pellets of VMAP-infected mice.  
     We also elucidated the immune mechanism whereby NP51 targets MAP growth in vivo. 
By using flow cytometric analyses, we provided persuasive evidence that NP51 potently 
links the innate immunity to the CD8α+ cytotoxic T cell adaptive immunity via activating the 
CD8α+ immune cell repertoire that includes dendritic cells (DC), natural killer cells (NK), 
natural killer T cells (NK T cells), and cytotoxic T cells. Intriguingly, VNP51- and HNP51-
caused immune response bypassed the Th1 immune responses and the potential local 
mucosal damage it might induce.  
     Whereas the NK cells kills MAP-infected cells that do not express MHC class 1 
molecules on the surface (MAP suppresses expression of MHC molecules on macrophages), 
cytotoxic T cells kills cells that express peptide antigen on MHC class I molecules. 
Additionally, because MAP infects and suppresses activation of macrophages, antigen-
presenting cells, it is pivotal that DC has to be activated to switch the innate immunity to a 
CD8+ T cell-mediated immunity through cross presentation of MAP-derived antigenic 
peptide on MHC class I. Additionally, activation of NK T cells is required to secrete IL-12 
and IFN-γ to induce maturation of DC. 
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     Thus, the VNP51- and HNP51-orchestrated anti-MAP immune response elegantly unveils 
the “economy” and “wisdom” of the immune system by inducing the NK and cytotoxic T 
cells that kill MAP-infected cells only and spare adjacent healthy cells in a very precise  
“immunological microsurgery”. This VNP51- and HNP51-induced “immunological 
microsurgery” preserves the healthy ileal intestinal epithelial cells to ensure adequate nutrient 
absorption and survival of the JD-infected mouse while concurrently ridding the ileum of its 
MAP-infected cells. 
    The exquisite observation that VNP51 fed to HMAP-inoculated mice activate both the 
CD8α+ cell-mediated immunity and MAP-specific humoral immunity provided influential 
evidence that VNP51 has considerable adjuvant efficacy to potentiate potency of next 
generation MAP vaccines.  
Recommendations for Future Research 
     In these experiments, we have presented persuasive evidence that VNP51 and HNP51 
adequately inhibited MAP growth in vivo and prevented progression of JD in Balb/c mice. 
Because the VNP51- and HNP51-induced anti-MAP immune responses are independent of 
the viability of MAP, it is cost-effective to use HNP51 to treat mice infected with MAP.  
     I propose that a treatment study be conducted to further elucidate whether co-
administration of probiotic NP51 and VMAP to specific pathogenic-free Balb/c mice would 
inhibit VMAP infection. The study would also provide an opportunity to elucidate the 
molecular interaction that underlies the VNP51- and HNP51-orchestrated inhibition of MAP 
growth in vivo. To achieve these goals, the following research can be conducted: 
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Experimental Design   
     Mice. Two hundred and twenty-four 6-week-old Balb/c mice (112 MHC class 1a-/- and 
112 wild type mice) will be randomized to two main treatment groups: viable MAP-infected 
controls (VMAP; n = 112, 56 MHC class 1a-/- and 56 wild type) and VMAP-infected mice 
fed the heat-killed probiotic NP51 (VMAP+HNP51, n = 112, 56 MHC class 1a-/- and 56 
wild type). Mice will be housed in a BSL-2 rodent room. The environment within the room 
will be maintained to provide a temperature of 22.2O C, a relative humidity of 35-45%, and 
12 h light/dark cycle. Four female or male mice will be housed in each autoclaved standard 
mice cage fitted with raised-wire floors and High Efficiency Particulate Air (HEPA) filters.  
     Infection with VMAP. Mice in the VMAP control group and the VMAP+HNP51 will be 
inoculated with 108 CFU of VMAP suspended in 100 µL of sterile PBS (Stabel, USDA, 
ARS, NADC) intraperitonealy on day 1 of the study.  
     Diet. Mice in the VMAP control will be fed the sterile mouse chow meal mixed with 
maltodextrin (MDX) carrier at 3% of their chow diet starting on day 1 of the study. On the 
other hand, mice in the VMAP+HNP51 will be fed the HNP51 at 1× 106 CFU·mouse-1·day-1 
contained in 3.0 g of the sterile mouse chow meal for the first 15 days. The offering of chow 
meal will be increased by 0.5 g·mouse-1 every 15 days until it reaches a maximum of 5.0 
g·mouse-1·day-1 by day 91 of the study but continues to provide 1× 106 CFU of 
HNP51·mouse-1·day-1. 
Following inoculation with MAP, 14 mice (7 MHC class 1a-/- and 7 wild type) from each 
treatment group will be euthanized on days 1, 15, 30, 45, 90, 135, 180, and 225 relative to 
inoculation with MAP and HNP51 feeding.  
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Sample collection and intended analyses.  
     Blood. About 0.9 mL of blood will be withdrawn by cardiac puncture and allowed to clot 
at 4o C over night before serum is separated by centrifugation at 10,000 × g for 15 min. To 
quantify total immunoglobulin (Ig) G1 and IgG2a, 100 uL of appropriately diluted sera will be 
used according to the manufacturer’s instruction (Kamiya Biomedical Company, Seattle, 
WA).  
     To quantify MAP specific IgG1 and IgG2a, 96-well plates will be coated with 100 µL/well 
of HMAP suspended in coating buffer (Bethyl Laboratories, Inc., TX, USA) at 2000 ng/mL. 
Plates will be incubated while covered at 4o C overnight. After the incubation, the coating 
buffer will be decanted inside a biosafety cabinet and the plates will be washed four times by 
filling the wells with 300 µL of the wash buffer (Bethy Laboratories, Inc., TX, USA). To 
block the nonspecific binding, 200 µL of block buffer (Bethyl Laboratories, Inc) will be 
pipetted in each well and the plates shall be incubated for 30 min at RT. Subsequently, the 
blocking buffer will be decanted and the plates will be dried in the hood and stored at 4o C 
until the IgG1 and IgG2a were determined as previously mentioned by using reagents from 
Kamiya Biomedical Company.     
     Tissues. Mesenteric lymph nodes (MLN), livers, and ilea will be dissected and used to 
quantify tissue MAP burden on Herrold’s yolk agar media. Part of the livers will be used to 
quantify acid-fast bacilli.  
     Spleens will be dissected and used to prepare splenocyte single-cell suspension. 
Splenocytes will be cultured in vitro in 48-well plate at 2 × 106 cells per mL RPMI 1640 
(Invitrogen, Carlsbad, CA) plus 10% heat-inactivated FCS (Fisher Scientific, Hanover Park, 
IL) and 1% Antibiotic/antimycotic (Invitrogen Carlsbad; NM). 
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     Splenocyte in vitro cultures will be either nonstimulated (negative control) or stimulated 
with concanavalin A (Sigma-Aldrich, St. Louis, MO) at 3 µg/mL (positive control), with 
sonicated MAP antigen at 10 µg/mL, or with HNP51 at 10 µg/mL and then incubated at 370 
C and 5% CO2/95/O2 for 72 hours. Following incubation, the cell-free supernatant will be 
collected and stored at -700 C for later analysis for interferon (IFN)-γ and interleukin (IL)-10, 
IL-12, and tumor necrosis factor (TNF)-α concentrations.  
     Splenocytes will be washed twice with cold sterile PBS and stained for the surface CD8α 
(anti-mouse CD8α APC, eBioscience, San Diego, CA), CD25 (anti-mouse CD 25 
phycoerytherin; PE, eBioscience, San Diego, CA), CD11b, CD11c, DC-SIGN, CD56, CD3. 
Subsequently, cells will be fixed, permeabilized, and stained for the intracellular transcription 
factors Tbet1, RORγ-2, and, GATA-3, and Foxp1. 
     Frequencies of T cell subpopulations and expression of the intracellular transcription 
factors will be determined by using the fluorescence-activated cell sorter (BD FACSAria II; 
Becton Dickson Biosciences, Franklin Lakes, NJ). Data will be analyzed by using FlowJo 
software (Tree Star, Inc., Ashland, OR). For IL-10, IL-12, IL-17, IFN-γ, and TNF- 
concentrations, commercially available ELISA kits from R&D Systems (McKinley Place, 
MN) will be used to determine their concentrations.  
Statistical Analyses  
 
     A linear mixed-effects model will be invoked to analyze the response variable by using 
the PROC MIXED procedure of the Statistical Analysis System (SAS; SAS Institute Inc., 
Cary, North Carolina, USA) version 9.2. The model will account for the fixed effects of 
diets, infection status, day of euthanization, and their interactions. Differences among 
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treatment means will be deemed significant when the probability (P) value ≤ 0.05. Tendency 
for a difference will be declared at 0.05 ≤ P ≤ 0.1.  
Expected results: 
1. VMAP-infected MHC class 1a-/-: we expect from this group to: 
-  Succumb to severe MAP infection characterized by progressive emaciation and 
increased fatalities.  
- Exhibit increased IL-10 and decreased IFN-γ and TNF-α secretion in their in vitro 
splenocyte cultures. 
- Have extremely decreased frequency of CD3+CD8α+ cytotoxic T cells, CD25+ T 
cells, and CD11b, but increased frequency of CD3+Foxp3+ T cells. 
- Have normal CD56 and CD11c, but decreased CD3, and CD25. 
- Have increased MAP burden in tissues and acid-fast bacilli in liver higher than 
that of other groups. 
- Have the highest increase of MAP IS900 genomic DNA in fecal pellets relative to 
other groups 
2. VMAP-infected wild type: We expect from this group to: 
- Succumb to a protracted chronic MAP infection. Fatalities are expected by day 
260 but less severe than that of the HMC class 1a-/- group. 
- Exhibit increased IL-10 and moderately decreased IFN-γ and TNF-α secretion in 
their in vitro splenocyte cultures relative to that of the VMAP-infected MHC-
class 1-/- mice. 
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- Have normal frequency of CD8α+CD3+ T cells, but elevated frequency of 
CD3+Foxp3+ T cell will be as high as that of the VMAP-infected MHC-class 1-/- 
mice. 
- Have normal CD3-CD56+, CD3+CD56+ and CD11c+, but moderately decreased 
CD3+CD25+ cells compared with that of the VMAP-infected MHC class 1-/-. 
- Have increased MAP IS900 genomic DNA in fecal pellets but less than that of the 
VMAP-infected MHC class 1-/- group.    
3. HNP51+VMAP-infected MHC-class 1a-/-: We expect from this group to: 
- Succumb to severe MAP infection characterized by progressive emaciation and 
increased fatalities.  
- Exhibit increased IL-10 and decreased IFN-γ and TNF-α secretion in their in vitro 
splenocyte cultures. 
- Have extremely decreased frequency of CD3+CD8α+ cytotoxic T cells and 
CD11b, but increased frequency of CD3+Foxp3+ T cells  
- Have normal CD3-CD56+, CD3+CD56+ and CD11c+, but decreased CD3+CD25+ 
cells. 
- Have increased MAP burden in tissues and increased acid-fast bacilli in liver 
similar to that of the VMAP-infected MHC-class 1-/-. 
- Have increased MAP IS900 genomic DNA in fecal pellets comparable to that of 
the VMAP-infected MHC class 1-/- group.    
4. HNP51+VMAP-infected wild type:  We expect from this group to: 
-  Have milder MAP infection that does not induce emaciation or cause fatalities.  
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- Exhibit increased IL-10, IFN-γ, and TNF-α secretion in their in vitro splenocyte 
cultures. 
- Have the highest frequency of activated CD3+CD8α+ cytotoxic T cells and 
CDb11+ cells, but decreased frequency of CD3+Foxp3+ T cells. 
- Have normal CD3-CD56+, CD3+CD56+ and CD11c+, but the highest frequency of 
CD3+CD25+ cells. 
- Have significantly decreased MAP burden in tissues and decreased acid-fast 
bacilli in liver in comparison to that of all other groups. 
- Decreased MAP IS900 genomic DNA in fecal pellets.   
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